Official Protocol Title:  
NCT number:  [STUDY_ID_REMOVED] 
Document Date:  02-Apr-2019A Phase 3, Randomized, Double-blind, Active Comparator-
controlled, Multicenter Clinical Study to Evaluate the Safety, 
Tolerability, and Immunogenicity of V114 in Recipi[INVESTIGATOR_778716] (PNEU-STEM)
PRODUCT: V114 1
PROTOCOL/AMENDMENT N O.:022-04
V114 -022-04FINAL PROTOCOL 02-APR -2019
Title Page
THIS PROTOCOL AMENDMENT AND ALL OF THE INFORMATION RELATING 
TO IT ARE CONFIDENTIAL AND PROPRIETARY PROPERTY OF MERCK 
SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC., NJ, U.S.A. 
(MSD).
Protocol Title: A Phase 3, Randomized, Double -blind, Active Comparator -controlled, 
Multicenter Clinical Study to Evaluate the Safety , Tolerability , and Immunogenicity  of V114 
in Recipi[INVESTIGATOR_778717] (PNEU -STEM)
Protocol Number: 022-04
Compound Number: V114
Sponsor Name:
[CONTACT_19519] & Dohme Corp., a subsidiary  of [COMPANY_006] & Co., Inc.
(hereafter referred to as the Sponsor or MSD)
Legal Registered Address:
One [COMPANY_006] Drive
[PO_BOX]
Whitehouse Station, New Jersey , [ZIP_CODE] -0100, U.S.A.
Regulatory Agency Identifying Number(s):
IND [ADDRESS_1070001] 2018- 000066- 11
Approval Date: 02-April -[ADDRESS_1070002]: V114 2
PROTOCOL/AMENDMENT N O.:022-04
V114 -022-04FINAL PROTOCOL 02-APR -2019
Sponsor Signatory
Typed Name:
[CONTACT_1641]:Date
Protocol -specific Sponsor c ontact information can be found in the Investigator Study
File Binder (or equivalent).
Investigator Signatory
I agree to conduct this clinical study in accordance with the design outlined in this protocol 
and to abide b y all provisions of this protocol.
Typed Name:
[CONTACT_1641]:Date
07X67T
PRODUCT: V114 3
PROTOCOL/AMENDMENT N O.:022-[ADDRESS_1070003].
Amendment 3 14-NOV- 2018 The primary  purpose of this amendment is 
to add a pediatric cohort ( ≥3years of age) 
to the existing study .
Amendment [ADDRESS_1070004]: V114 4
PROTOCOL/AMENDMENT N O.:022-04
V114 -022-04FINAL PROTOCOL 02-APR -2019
PROTOCOL AMENDMENT S UMMARY OF CHANGES
Amendment: 04
Overall Rationale for the Amendments:
The primary  purpose of this amendment is toadjust the stratification factor for steroid use and clarify  the definition and reporting time
frame forspecific events of i nterest . Other clarifications and editorial revisions were also made as shown in the Summary  of Changes 
Table below.
Summary of Changes Table:
Section # and Name [CONTACT_11029]  
1.3 Schedule of Activities ( AE 
monitoring )
8.4.[ADDRESS_1070005] be reported throughout the 
duration of the individual’s participation in 
the study .Revisions made for clarity .
4.1 Overall Design
6.3.2 Stratification
9.1 Statistical Analy sis Plan Summary
9.10 Subgroup anal ysisUpdated stratificatio n factor for 
corticosteroid use as follows:
Original : Use of sy stemic steroids below a 
prednisone equivalent dosage of 
≤0.5 mg/kg/day  (including no steroid use) 
within 14 days before Day 1.
Revised : Use of s ystemic steroids within 
14days before randomization ( Day 1).The steroid stratification factor was 
adjusted to align with the clinical use of 
steroid medication and steroid tapers in 
hematopoietic stem cell transplant (HSCT) 
recipi[INVESTIGATOR_693545], or who are at high 
risk for, graft -versus -host disease (GVHD).
07X67T
PRODUCT: V114 5
PROTOCOL/AMENDMENT N O.:022-04
V114 -022-04FINAL PROTOCOL 02-APR -2019
Section # and Name [CONTACT_11029]  
5.2 Exc lusion Criteria Updated exclusion criterion 21 as follows 
(newtext in bold , deleted text in 
strikethough):
Prior or scheduled to receive receipt of
immunoglobulins or plasma products within 
30days of administration of study vaccine.Revision made for cla rity.
6.1 Study  Intervention(s) Administered Updated the sourcing for Prevnar 13™ from 
“Central” to “Central or local.”Revision made to accommodate country  
requirements.
8.1.[ADDRESS_1070006] Updated text as follows:
•Throughout a participant’s participation 
in the study , new onset and/or change
worsening of GVHD status since Day 1 
as well as relapse and progression of 
underly ing disease (ie, the disease for 
which allo -HSCT was performed [see 
inclusion criterion 2 in Section 5.1]) will 
berecorded as specific events of interest. 
Specific events of interest are to be 
reported as non- serious or serious 
AEs as defined in Appendix 3.
Standard reporting time frames for non -
serious and serious AEs (serious and Revision made for clarity and accuracy .
07X67T
PRODUCT: V114 6
PROTOCOL/AMENDMENT N O.:022-04
V114 -022-04FINAL PROTOCOL 02-APR -2019
Section # and Name [CONTACT_778753]-serious) will appl y (see Table 4in 
Section 8.4.1) .
9.6.2 Statistical Methods for Safet y 
Analy ses•Updated to include the evaluation of 
specific events of interest at each 
analysis timepoint.
•Revised the description of the special 
events of interest anal ysis as follows :
In addition, the proportion of 
participants who develop have new 
onset and/or worsening of GVHD 
during stud y participation as well as 
relapse and progression of underl ying 
disease (ie, the disease for which the 
allo-HSCT was performed [see inclusion 
criterion 2in Section 5.1]) during study 
participation will be summari zed 
descriptively .Revision made for clarity
07X67T
PRODUCT: V114 7
PROTOCOL/AMENDMENT N O.:022-04
V114 -022-04FINAL PROTOCOL 02-APR -2019
Section # and Name [CONTACT_11029]  
10.3.4 Recording AE and SAE Updated the time period during which 
injection -site redness/erythema or swelling 
will be evaluated as follows:
Original : Injection -site redness/ery thema 
from the day  of vaccination t hrough Day 5 
postvaccination will be evaluated by  
[CONTACT_75367].
Revised : Injection -site redness/ery thema 
from the day  of vaccination through Day 5 
(for adult participants) or Day 14 (for 
pediatric participants) postvaccination will 
be evaluated b y maximum size.Revision made for accuracy .
07X67T
PRODUCT: V114 8
PROTOCOL/AMENDMENT N O.:022-04
V114 -022-04FINAL PROTOCOL 02-APR -2019
Table of Contents
DOCUMENT HISTORY ........................................................................................................ 3
PROTOCOL AMENDMENT S UMMARY OF CHANGES ............................................... 4
1 PROTOCOL SUMMARY ............................................................................................ 15
1.1 Synopsis ................................................................................................................. 15
1.2 Schema .................................................................................................................. 22
1.3 Schedule of Activities (SoA) ................................................................................ 23
2 INTRODUCTION .......................................................................................................... 34
2.1 Study Rationale ....................................................................................................34
2.2 Background .......................................................................................................... 35
2.2.1 V114 and Pneumococcal Disease ................................................................ 35
2.2.2 Preclinical and Clinical Studies ...................................................................36
2.2.3 Information on Other Study -related Therap y.............................................. 36
[IP_ADDRESS] Prevnar 13™ ...................................................................................... 36
[IP_ADDRESS] PNEUMOVAX™23 .......................................................................... 37
2.3 Benefit/Risk Assessment ...................................................................................... 37
3 HYPOTHESIS, OBJECTIV ES, AND ENDPOINTS ................................................. 38
4 STUDY DESIGN ............................................................................................................ 41
4.1 Overall Design ......................................................................................................41
4.2 Scientific Rationale for Study Design ................................................................ .43
4.2.1 Rationale for Endpoints ............................................................................... 43
[IP_ADDRESS] Immunogenicit y Endpoints ................................................................ 43
[IP_ADDRESS] Safety  Endpoints ................................................................................ 44
[IP_ADDRESS] Future Biomedical Research .............................................................. 44
4.2.2 Rationale for the Use of Comparator/Placebo ............................................. 44
4.3 Justification for Dose ........................................................................................... 45
4.4 Beginning and End of Study Definition ............................................................. 45
4.4.1 Clinical Criteria for Early Study Termination ............................................. 45
5 STUDY POPULATION ................................................................................................ 45
5.1 Inclusion Criteria ................................................................................................ .45
5.2 Exclusion Criteria ................................................................................................ 46
5.3 Lifestyle Considerations ...................................................................................... 49
5.4 Screen Failures .....................................................................................................49
5.5 Participant Replacement Strategy ......................................................................49
6 STUDY INTERVENTION ............................................................................................ 49
6.1 Study Intervention(s) Administered ...................................................................[ADDRESS_1070007]: V114 9
PROTOCOL/AMENDMENT N O.:022-04
V114 -022-04FINAL PROTOCOL 02-APR -2019
6.2 Preparation/Handling/Storage/Accountability ................................................. 51
6.2.1 Dose Preparation .......................................................................................... 51
6.2.2 Handling, Storage, and Accountability ........................................................ 51
6.3 Measures to Minimize Bias: Randomization and Blinding .............................. 51
6.3.1 Intervention Assignment.............................................................................. 51
6.3.2 Stratification ................................................................................................ .52
6.3.3 Blinding........................................................................................................52
6.4 Study Intervention Compliance .......................................................................... 52
6.5 Concomitant Therapy .......................................................................................... 53
6.5.1 Rescue Medications and Supportive Care ................................................... 53
6.6 Dose Modification (Escalation/Titration/Other) ............................................... [ADDRESS_1070008] to Follow -up................................................................................................ .55
8 STUDY ASSESSMENTS AND PROCEDURES ........................................................ 55
8.1 Administrative and General Procedures ........................................................... 57
8.1.1 Informed Consent/Assent ............................................................................. 57
[IP_ADDRESS] General Informed Consent/Assent ..................................................... 58
[IP_ADDRESS] Consent/Assent and Collection of Specimens for Future
Biomedical Research .........................................................................58
8.1.2 Inclusion/Exclusion Criteria ........................................................................[ADDRESS_1070009] .....................................................................59
8.1.4 Medical History ........................................................................................... 59
8.1.5 Prior and Concomitant Medications Review ............................................... 59
[IP_ADDRESS] Prior Medications ............................................................................... 59
[IP_ADDRESS] Concomitant Medic ations ..................................................................59
8.1.6 Assignment of Screening Number ............................................................... 59
8.1.7 Assignment of Treatment/Randomization Number .....................................60
8.1.8 Study  Intervention Administration .............................................................. 60
[IP_ADDRESS] Timing of Dose Administration ......................................................... [ADDRESS_1070010]: V114 10
PROTOCOL/AMENDMENT N O.:022-04
V114 -022-04FINAL PROTOCOL 02-APR -2019
[IP_ADDRESS] Withdrawal From Future Biomedical Research ................................ 62
8.1.12 Participant Blinding/Unblinding ..................................................................63
8.1.13 Calibration of Equipment ............................................................................. 64
8.2 Immunogenicity Assessments ............................................................................. 64
8.2.1 Electrochemiluminescence (ECL) ............................................................... 64
8.2.2 Multiplex Opsonophagocytic Assay (MOPA) ............................................. [ADDRESS_1070011] ............................................................................................. 65
8.3.3 Body Temperature Measurement ................................................................ .66
8.3.4 Safety  Assessments and Use of the eVRC ................................................... 66
8.3.5 Clinical L aboratory  Assessments ................................................................ .67
8.4 Adverse Events (AEs), Serious Adverse Events (SAEs), and Ot her 
Reportable Safety Events .................................................................................... 68
8.4.1 Time Period and Frequency  for Collecting AE, SAE, and Other 
Reportable Safet y Event Information .......................................................... 68
8.4.2 Method of Detecting AEs, SAEs, and Other Reportable Safet y Events ......70
8.4.3 Follow -up of AE, SAE, and Other Reportable Safety  Event Information ...70
8.4.4 Regulatory  Reporting Requirements for SAE ............................................. 70
8.4.5 Pregnancy  and Exposure During Breastfeeding .......................................... 70
8.4.6 Disease -related Events and/or Disease -related Outcomes Not Qualifying 
as AEs or SAEs ............................................................................................ [ADDRESS_1070012] (ECI s)................................................................ [ADDRESS_1070013] ........................................................................... 71
8.5 Treatment of Overdose ........................................................................................ 71
8.6 Pharmacokinetics................................................................................................ .71
8.7 Pharmacodynamics .............................................................................................. 71
8.8 Future Biomedical Research Sample Collection ............................................... 71
8.9 Planned Genetic Analysis Sample Collection .................................................... 72
8.10 Biomarkers ........................................................................................................... 72
8.11 Medical Resource Utilization and Health Economics .......................................72
8.12 Visit Requirements ............................................................................................... 72
8.12.1 Screening......................................................................................................72
8.12.2 Treatment Period/Vaccination Visit ............................................................ 72
8.12.3 Discontinued Participants Continuing to be Monitored in the Study .......... 72
9 STATISTICAL ANALYSIS PLAN ............................................................................. 73
9.1 Statistical Analysis Plan Summary .....................................................................73
9.2 Responsibility for Analyses/In -house Blinding ................................................. [ADDRESS_1070014]: V114 11
PROTOCOL/AMENDMENT N O.:022-04
V114 -022-04FINAL PROTOCOL 02-APR -2019
9.3 Hypothese s/Estimation ........................................................................................ 75
9.4 Analysis Endpoints ............................................................................................... 76
9.4.1 Immunogenicit y Endpoints .......................................................................... 76
9.4.2 Safety  Endpoints .......................................................................................... 76
9.5 Analysis Populations ............................................................................................ 77
9.5.1 Immunogenicit y Analysis Populations ........................................................ 77
9.5.2 Safety Anal ysis Populations ........................................................................78
9.6 Statistical Methods ............................................................................................... 79
9.6.1 Statistical Methods for Immunogenicit y Anal yses......................................79
9.6.2 Statistical Methods for Safety Anal yses...................................................... 80
9.6.3 Demographic and Baseline Characteristics ................................................. 82
9.7 Interim Analyses ..................................................................................................83
9.8 Multiplicity ........................................................................................................... 83
9.9 Sample Size and Power Calculations ................................................................ .83
9.9.1 Sample Size and Power for I mmunogenicity  Analy ses............................... 83
9.9.2 Sample Size and Power for Safet y Anal yses............................................... 84
9.10 Subgroup Analyses ............................................................................................... 85
9.11 Compliance (Medication Adherence) ................................................................ .85
9.12 Extent of Exposure ............................................................................................... 85
10 SUPPORTING DOCUMENTATION AND OPERATIONAL
CONSIDERATIONS .....................................................................................................86
10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations ........[ADDRESS_1070015] for Clinical Trials ............................................................. 86
10.1.2 Financial Disclosure ..................................................................................... 88
10.1.3 Data Protection ............................................................................................. 88
[IP_ADDRESS] Confidentiality  of Data ......................................................................89
[IP_ADDRESS] Confidentiality  of Participant R ecords ............................................... 89
[IP_ADDRESS] Confidentiality  of IRB/IEC I nformation ............................................ 89
10.1.4 Committees Structure ................................................................................... 89
[IP_ADDRESS] Scientific Advisory  Committee .......................................................... 89
[IP_ADDRESS] Executive Oversight Committee ........................................................ 89
[IP_ADDRESS] External Data Monitoring Committee ............................................... [ADDRESS_1070016]: V114 12
PROTOCOL/AMENDMENT N O.:022-04
V114 -022-04FINAL PROTOCOL 02-APR -2019
10.1.10 Study  and Site Closure ................................................................................. 92
10.2 Appendix 2: Clinical Laboratory Tests .............................................................. 93
10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting ............................................................... 94
10.3.1 Definition of AE .......................................................................................... 94
10.3.2 Definition of SAE ........................................................................................ 95
10.3.3 Addi tional Events Reported .........................................................................96
10.3.4 Recording AE and SAE ............................................................................... 96
10.3.5 Reporting of AE, SAE, and Other Reportable Safety  Events to the 
Sponsor ......................................................................................................101
10.4 Appendix 4: Medical Device Incidents: Definition and Procedures for 
Recording, Evaluating, Follow -up, and Reporting ......................................... 103
10.5 Appendix 5: Contraceptive Guidance and Pregnancy Testi ng...................... 104
10.5.1 Definitions ..................................................................................................104
10.5.2 Contraception Requirements ......................................................................104
10.5.3 Pregnancy  Testing ...................................................................................... 105
10.6 Appendix 6: Collection and Management of Specimens for Future 
Biomedical Research .......................................................................................... 106
10.7 Appendix 7: Country -specific Requirements .................................................. [ADDRESS_1070017] from Swedish Health Authority ....................... 111
[IP_ADDRESS] Benefit/Risk Assessment ................................................................ .111
[IP_ADDRESS] Ethics Committee Review [I nstitutional Review Board 
(IRB)/Independent Ethics Committee (I EC)] ..................................113
10.8 Appendix 8: Abbreviations ............................................................................... [ADDRESS_1070018]: V114 13
PROTOCOL/AMENDMENT N O.:022-[ADDRESS_1070019] OF TABLES
Table 1 Study  Interventions .......................................................................................... 50
Table 2 Approximate Blood Volumes Drawn b y Stud y Visit and by 
[CONTACT_778736] (Adult Cohort) ........................................................................... 57
Table 3 Approximate Blood Volumes Drawn b y Stud y Visit and by 
[CONTACT_778736] (Pediatric Cohort) ......................................................................57
Table 4 Reporting Time Periods and Time Frames for Adverse Events and 
Other Reportable Safet y Events .......................................................................69
Table 5 Analy sis Strategy  for Immunogenicit y Variables ............................................ 80
Table 6 Analy sis Strategy for Safety  Parameters .......................................................... 82
Table 7 Within -Group 95% CI s for Vary ing Hy pothetical IgG GMCs and 
Vary ing Standard Deviations with [ADDRESS_1070020]: V114 14
PROTOCOL/AMENDMENT N O.:022-[ADDRESS_1070021]: V114 15
PROTOCOL/AMENDMENT N O.:022-04
V114 -022-04FINAL PROTOCOL 02-APR -2019
1 PROTOCOL SUMMARY
1.1 Syno psis
Protocol Title: A Phase 3, Randomized, Double -blind, Active Comparator -controlled, 
Multicenter Clinical Study to Evaluate the Safety , Tolerability , and Immunogenicity of V114 
in Recipi[INVESTIGATOR_778717] (PNEU -STEM)
Short Title: Safet y and Immunogenicit y of V114 in Recipi[INVESTIGATOR_778718]-HSCT
Acronym: PNEUmococcal Conjugate Vaccine Trials : V114- 022(PNEU -STEM )
07X67T
PRODUCT: V114 16
PROTOCOL/AMENDMENT N O.:022-04
V114 -022-04FINAL PROTOCOL 02-APR -2019
Hypotheses, Objectives ,and Endpoints :     
The following objectives and endpoints will be evaluated in adult and pediatric recipi[INVESTIGATOR_778719] (allo-HSCT ).
Primary  Objectives Primary  Endpoints
-Objective: To evaluate the safet y and 
tolerability  of 3 doses of V114 and 3 doses of 
Prevnar 13™ with respect to the proportion 
of participants with adverse events (AEs) 
within each vaccination group.Following an y of the 3 doses of V114 or 
Prevnar 13™ for adults ≥18 y ears of age:
-Solicited injection -site AEs from Day  1 
through Day  5 postvaccination 
-Solicited sy stemic AEs from Day  1 through 
Day 14 postvaccination 
-Vaccine -related serious adverse events 
(SAEs) from Day  [ADDRESS_1070022]
Following an yof the 3 doses of V114 or 
Prevnar 13™ for pediatrics (3 to <18 y ears of 
age):
-Solicited injection -site AEs from Day  1 
through Day  14 postvaccination
-Solicited sy stemic AEs from Day  1 through 
Day 14 postvaccination
-Vaccine -related serious adverse eve nts 
(SAEs) from Day  [ADDRESS_1070023]
-Objective: To evaluate the serot ype-specific 
immunoglobulin G (IgG) Geometric Mean 
Concentrations (GMCs) at [ADDRESS_1070024] 
dose of Prevnar 13 ™ within each vaccination 
group.-Seroty pe-specific IgG responses for the [ADDRESS_1070025]: V114 17
PROTOCOL/AMENDMENT N O.:022-04
V114 -022-04FINAL PROTOCOL 02-APR -2019
Secondary  Objectives Secondary  Endpoints
-Objective: To evaluate the safet y and 
tolerability  of PNEUMOVAX™23 
(administered [ADDRESS_1070026] in 
participants who do not develop GVHD) 
with respect to the proportion of participants 
with AEs within each vaccination group.Following vaccination with 
PNEUMOVAX™23 for adults ≥18 y ears of 
age:
-Solicited injection -site AEs from Day  1 
through Day  5 postvaccination 
-Solicited sy stemic AEs from Day  1 through 
Day 14 postvaccination 
-Vaccine -related SAEs from Month 12 after 
allo- HSCTto 1 month after vaccination or 
the completion of the study .
Following vaccination with 
PNEUMOVAX™23 for pediatrics (3 to <18 
years of age):
-Solicited injection -site AEs from Day  [ADDRESS_1070027] to 1 month after vaccination 
or the completion of the study .
-Objective: To evaluate the safet y and 
tolerability  of a 4th dose of V114 and a 4th 
dose of Prevnar 13™ (both administered [ADDRESS_1070028] in participants who 
deve lop GVHD) with respect to the 
proportion of participants with AEs within 
each vaccination group.Following vaccination with a 4th dose of 
V114 or Prevnar 13™ for adults ≥18 y ears of 
age:
-Solicited injection -site AEs from Day  1 
through Day  5 postvaccinati on 
-Solicited sy stemic AEs from Day  1 through 
Day 14 postvaccination 
-Vaccine -related SAEs Day  1 through 6 
months after 4th vaccination of V114 and 
Prevnar 13™ or completion of the study.
07X67T
PRODUCT: V114 18
PROTOCOL/AMENDMENT N O.:022-04
V114 -022-04FINAL PROTOCOL 02-APR -2019
Following vaccination with a 4th dose of 
V114 or Prevnar 13™ for pediatrics (3 to 
<18 y ears of age):
-Solicited injection -site AEs from Day  1 
through Day  14 postvaccination
-Solicited sy stemic AEs from Day  1 through 
Day 14 postvaccination
-Vaccine -related SAEs from  Day  1 through 
6 months after 4th vaccination of V114 and 
Prevnar 13™ or completion of the study.
-Objective: To evaluate the serot ype-specific 
opsonophagocy tic activity (OPA) Geometric 
Mean Titers (GMTs) at [ADDRESS_1070029] 
dose of Prevnar 13™ within each va ccination 
group.-Seroty pe-specific OPA responses for the 15 
seroty pes in V114 at Day 90
-Objective: To evaluate the serot ype-specific 
(1) OPA GMTs and IgG GMCs at baseline 
(prevaccination with V114 or Prevnar 13™) 
and (2) Geometric Mean Fold Rises 
(GMF Rs) and proportions of participants 
with a ≥[ADDRESS_1070030] dose 
of Prevnar 13™ separately for both IgG and 
OPA responses within each vaccination 
group. -Seroty pe-specific OPA and IgG responses 
for the [ADDRESS_1070031]: V114 19
PROTOCOL/AMENDMENT N O.:022-04
V114 -022-04FINAL PROTOCOL 02-APR -2019
Overall Desig n:
Study  Phase Phase [ADDRESS_1070032] participant’s last 
study -related telephone call or visit.
For purposes of analy sis and reporting, the overall study  
ends when the Sponsor receives the last serology  assay  
result.
Number of Participant s:
Approximately  250adult participants and approximately  50 pediatric participants (≥3 years 
of age )will be randomized, with approximately  [ADDRESS_1070033]: V114 20
PROTOCOL/AMENDMENT N O.:022-04
V114 -022-04FINAL PROTOCOL 02-APR -2019
Intervention Groups and Du ration :
Intervention 
Group sIntervention 
Group Name [CONTACT_63562] .Vaccination Regimen Use
V114
V114Refer to 
IBOnce per 
Month for 3 
Doses TotalIM3 Dose s:Visit
2(Day 1), 
Visit 3 (Day 30) , and 
Visit 4 (Day 60)Experimental
PNEUMOVAX™23a
ORRefer to 
product 
labelingSingle 
DoseIMSingle Dose at 
Visit 6 ([ADDRESS_1070034] )Experimental
V114 
(4thDose)bRefer to 
IB4thDose IMSingle Dose at 
Visit 6 ([ADDRESS_1070035] )Experimental
Prevnar 13™
Prevnar 13™Refer to 
product 
labelingOnce per 
Month for 3 
Doses TotalIM3 Doses :Visit
2(Day 1), 
Visit 3 (Day 30) , and 
Visit 4 (Day 60)Experimental
PNEUMOVAX ™23a
ORRefer to 
product 
labelingSingle 
DoseIMSingle Dose at 
Visit 6 ([ADDRESS_1070036] )Experimental
Prevnar 13™ (4thDose)bRefer to 
product 
labeling4thDose IMSingle Dose at 
Visit 6 ([ADDRESS_1070037] )Experimental
aPNEUMOVAX™[ADDRESS_1070038] disease, a 4thdose of V114 or Prevnar 13™ ( double -
blind; same as was administered for the first 3 doses) administered at Visit 6 ([ADDRESS_1070039]) 
instead of PNEUMOVAX™23. 
allo-HSCT = allogeneic hematopoietic stem cell transplant ; IB = Investigator ’sBrochure; 
IM=intramuscular
Total 
Number2 intervention groups
Duration of 
ParticipationEach participant will participate in the study  for approximately  11months from 
the time the participant or the participant’s legally acceptable representative signs 
the Informed Consent Form (I CF)through the final contact.
07X67T
PRODUCT: V114 21
PROTOCOL/AMENDMENT N O.:022-04
V114 -022-04FINAL PROTOCOL 02-APR -2019
Study Governance Committees:
Steering Committee No
Executive Oversight Committee Yes
Data Monitoring Committee Yes
Clinical Adjudication Committee No
Study  governance considerations are outlined in Appendix 1.
Study Accepts Healthy Volunteers :No
A list of abbreviations used in this document can be found in Appendix 8.
07X67T
PRODUCT: V114 22
PROTOCOL/AMENDMENT N O.:022-[ADDRESS_1070040]: V114 23
PROTOCOL/AMENDMENT N O.:022-04
V114 -022-04FINAL PROTOCOL 02-APR -2019
1.3 Schedule of Activities (SoA)
Study Period Screening Intervention Follow -up
Comments Visit Number: [ADDRESS_1070041] 7Phone 
Contactd
Scheduled Time: Day [ADDRESS_1070042] be 
available before 
randomization into the 
study at Visit 2 
(Day 1), which must 
occur ≤30 days after 
Visit 1. Visit Window:Within [ADDRESS_1070043] be 
obtained before any 
study procedures.
Informed Consent 
for 
Future Biomedical 
Research (Optional) 
XConsent for future 
biomedical research 
samples must be 
obtained before the 
blood sample for ≥18 
years of age and saliva 
for <18 years of age 
(DNA sample) is 
collected.
Assignment of 
Screening Number X
Inclusion/Exclusion 
CriteriaX X
Medical History
X XThe participant’s 
medical history for the 
[ADDRESS_1070044]: V114 24
PROTOCOL/AMENDMENT N O.:022-04
V114 -022-04FINAL PROTOCOL 02-APR -2019
Study Period Screening Intervention Follow -up
Comments Visit Number: [ADDRESS_1070045] 7Phone 
Contactd
Scheduled Time: Day [ADDRESS_1070046] be 
available before 
randomization into the 
study at Visit 2 
(Day 1), which must 
occur ≤30 days after 
Visit 1. Visit Window:Within 30 
days 
before 
Visit 290 to180 
days after 
Allo-
HSCTDay 15 
to Day 
19 after 
Visit 2aDay 30 
to Day 
44 after 
Visit 2aDay 15 
to Day 
19 after 
Visit 3bDay 30 
to Day 
44 after 
Visit 3bDay 15 
to Day 
19 after 
Visit 4cDay 30 
to Day 
44 after 
Visit 4cDay 256 to 
Day 284 
after Allo -
HSCTDay 335 to 
Day 395 
after Allo -
HSCTDay 15 to 
Day 19 
after 
Visit 6Day 30 
to Day 
44 after 
Visit 6Day 166
to Day 
194after 
Visit 6d
Screening 
Laboratory TestsXComplete blood count 
with differential, blood 
chemistry (including 
renal function).
Assignment of
Randomization 
Number X
Participant 
Identification CardX
Prior/Concomitant 
Medication and 
Non-Study 
Vaccination ReviewX X X X X X X X X X
V114 or 
Prevnar 13™ 
Administration 
(Blinded) X X XAt each of the 
identified visits, 
participants will 
receive either a single 
dose of V114 or a 
single dose of
Prevnar 13™ .
07X67T
PRODUCT: V114 25
PROTOCOL/AMENDMENT N O.:022-04
V114 -022-04FINAL PROTOCOL 02-APR -2019
Study Period Screening Intervention Follow -up
Comments Visit Number: [ADDRESS_1070047] 7Phone 
Contactd
Scheduled Time: Day [ADDRESS_1070048] be 
available before 
randomization into the 
study at Visit 2 
(Day 1), which must 
occur ≤30 days after 
Visit 1. Visit Window:Within 30 
days 
before 
Visit 290 to180 
days after 
Allo-
HSCTDay 15 
to Day 
19 after 
Visit 2aDay 30 
to Day 
44 after 
Visit 2aDay 15 
to Day 
19 after 
Visit 3bDay 30 
to Day 
44 after 
Visit 3bDay 15 
to Day 
19 after 
Visit 4cDay 30 
to Day 
44 after 
Visit 4cDay 256 to 
Day 284 
after Allo -
HSCTDay 335 to 
Day 395 
after Allo -
HSCTDay 15 to 
Day 19 
after 
Visit 6Day 30 
to Day 
44 after 
Visit 6Day 166
to Day 
194after 
Visit 6d
PNEUMOVAX™23
Administration
or
V114 or 
Prevnar 13™ 
Administration 
(Blinded) XAt Visit 6 ([ADDRESS_1070049]), 
eligible participants 
will receive a single 
dose of 
PNEUMOVAX™[ADDRESS_1070050] disease (GVHD) 
will receive a 4thdose 
of V114 or Prevnar 
13™ (blinded) instead 
of 
PNEUMOVAX™[ADDRESS_1070051]: V114 26
PROTOCOL/AMENDMENT N O.:022-04
V114 -022-04FINAL PROTOCOL 02-APR -2019
Study Period Screening Intervention Follow -up
Comments Visit Number: [ADDRESS_1070052] 7Phone 
Contactd
Scheduled Time: Day [ADDRESS_1070053] be 
available before 
randomization into the 
study at Visit 2 
(Day 1), which must 
occur ≤30 days after 
Visit 1. Visit Window:Within [ADDRESS_1070054] (eVRC) 
X XAll p articipants will be 
provided an eVRC at 
Visit 2 (Day 1) and 
Visit 6 ([ADDRESS_1070055]) to 
record adverse events 
(AEs) and body 
temperature 
measurements. 
Instructions for using 
the eVRC will be 
reviewed with the 
participant or 
participant’s legally 
acceptable 
representative . 
Review eVRC Data 
with Participant or 
Participant’s Legally 
Acceptable 
RepresentativeX X X X X X X X
Collect eVRC 
Device from 
Participant or 
Participant’s Legally 
Acceptable 
RepresentativeX X
07X67T
PRODUCT: V114 27
PROTOCOL/AMENDMENT N O.:022-04
V114 -022-04FINAL PROTOCOL 02-APR -2019
Study Period Screening Intervention Follow -up
Comments Visit Number: [ADDRESS_1070056] 7Phone 
Contactd
Scheduled Time: Day [ADDRESS_1070057] be 
available before 
randomization into the 
study at Visit 2 
(Day 1), which must 
occur ≤30 days after 
Visit 1. Visit Window:Within [ADDRESS_1070058] Questionnaire 
provided by [CONTACT_429]. Data to be 
reported from this 
discussion will include 
serious adverse events 
(SAEs) and/or any 
updates to p reviously 
reported safety 
information. The 
planned Phone Contact 
[INVESTIGATOR_136] 9 months after 
allogeneic 
hematopoietic stem 
cell transplant (allo -
HSCT) should occur 
after Visit 5. If a study 
site visit occurs within 
[ADDRESS_1070059]: V114 28
PROTOCOL/AMENDMENT N O.:022-04
V114 -022-04FINAL PROTOCOL 02-APR -2019
Study Period Screening Intervention Follow -up
Comments Visit Number: [ADDRESS_1070060] 7Phone 
Contactd
Scheduled Time: Day [ADDRESS_1070061] be 
available before 
randomization into the 
study at Visit 2 
(Day 1), which must 
occur ≤30 days after 
Visit 1. Visit Window:Within [ADDRESS_1070062]: V114 29
PROTOCOL/AMENDMENT N O.:022-04
V114 -022-04FINAL PROTOCOL 02-APR -2019
Study Period Screening Intervention Follow -up
Comments Visit Number: [ADDRESS_1070063] 7Phone 
Contactd
Scheduled Time: Day [ADDRESS_1070064] be 
available before 
randomization into the 
study at Visit 2 
(Day 1), which must 
occur ≤30 days after 
Visit 1. Visit Window:Within [ADDRESS_1070065] –If 
Applicable
X X X XA pregnancy test 
consistent with local 
requirements (sensitive 
to at least 25 IU beta 
human chorionic 
gonadotropin [β -hCG]) 
must be performed 
before administration 
of study vaccine in 
females who are of 
reproductive potential. 
Urine or serum tests 
can b e used, and 
results must be 
negative before 
vaccination can occur.
Pregnancy tests can be 
repeated as needed 
based on local 
requirements.
07X67T
PRODUCT: V114 30
PROTOCOL/AMENDMENT N O.:022-04
V114 -022-04FINAL PROTOCOL 02-APR -2019
Study Period Screening Intervention Follow -up
Comments Visit Number: [ADDRESS_1070066] 7Phone 
Contactd
Scheduled Time: Day [ADDRESS_1070067] be 
available before 
randomization into the 
study at Visit 2 
(Day 1), which must 
occur ≤30 days after 
Visit 1. Visit Window:Within 30 
days 
before 
Visit 290 to180 
days after 
Allo-
HSCTDay 15 
to Day 
19 after 
Visit 2aDay 30 
to Day 
44 after 
Visit 2aDay 15 
to Day 
19 after 
Visit 3bDay 30 
to Day 
44 after 
Visit 3bDay 15 
to Day 
19 after 
Visit 4cDay 30 
to Day 
44 after 
Visit 4cDay 256 to 
Day 284 
after Allo -
HSCTDay 335 to 
Day 395 
after Allo -
HSCTDay 15 to 
Day 19 
after 
Visit 6Day 30 
to Day 
44 after 
Visit 6Day 166
to Day 
194after 
Visit 6d
Body Temperature 
Measurement Before 
Vaccination
X X X XEach participant's 
body temperature must 
be taken before 
vaccination. 
Participants who 
present with fever 
(oral or tympanic 
temperature ≥100.4°F 
[≥38.0°C] ;axillary or 
temporal temperature 
≥99.4°F [≥37.4°C]; or 
rectal temperature 
≥101.4°F [≥38.6 °C]) 
will have the 
vaccination delayed 
until fever is resolve d 
for [ADDRESS_1070068]: V114 31
PROTOCOL/AMENDMENT N O.:022-04
V114 -022-04FINAL PROTOCOL 02-APR -2019
Study Period Screening Intervention Follow -up
Comments Visit Number: [ADDRESS_1070069] 7Phone 
Contactd
Scheduled Time: Day [ADDRESS_1070070] be 
available before 
randomization into the 
study at Visit 2 
(Day 1), which must 
occur ≤30 days after 
Visit 1. Visit Window:Within 30 
days 
before 
Visit 290 to180 
days after 
Allo-
HSCTDay 15 
to Day 
19 after 
Visit 2aDay 30 
to Day 
44 after 
Visit 2aDay 15 
to Day 
19 after 
Visit 3bDay 30 
to Day 
44 after 
Visit 3bDay 15 
to Day 
19 after 
Visit 4cDay 30 
to Day 
44 after 
Visit 4cDay 256 to 
Day 284 
after Allo -
HSCTDay 335 to 
Day 395 
after Allo -
HSCTDay 15 to 
Day 19 
after 
Visit 6Day 30 
to Day 
44 after 
Visit 6Day 166
to Day 
194after 
Visit 6d
AE Monitoring
X X X X X X X X X X X X XdAEs (serious and 
nonserious) are to be 
reported from Days [ADDRESS_1070071], and deaths 
are to be reported 
throughout the 
duration of an 
individual’s study 
participation.
AEs (serious and 
nonserious) that occur 
after the consent is 
signed but before 
allocation/
randomization are also 
to be reported 
(Section 8.4.1).
07X67T
PRODUCT: V114 32
PROTOCOL/AMENDMENT N O.:022-04
V114 -022-04FINAL PROTOCOL 02-APR -2019
Study Period Screening Intervention Follow -up
Comments Visit Number: [ADDRESS_1070072] 7Phone 
Contactd
Scheduled Time: Day [ADDRESS_1070073] be 
available before 
randomization into the 
study at Visit 2 
(Day 1), which must 
occur ≤30 days after 
Visit 1. Visit Window:Within 30 
days 
before 
Visit 290 to180 
days after 
Allo-
HSCTDay 15 
to Day 
19 after 
Visit 2aDay 30 
to Day 
44 after 
Visit 2aDay 15 
to Day 
19 after 
Visit 3bDay 30 
to Day 
44 after 
Visit 3bDay 15 
to Day 
19 after 
Visit 4cDay 30 
to Day 
44 after 
Visit 4cDay 256 to 
Day 284 
after Allo -
HSCTDay 335 to 
Day 395 
after Allo -
HSCTDay 15 to 
Day 19 
after 
Visit 6Day 30 
to Day 
44 after 
Visit 6Day 166
to Day 
194after 
Visit 6d
Immunogenicity Procedures
Serum for 
Immunogenicity 
Assays (including 
Retention Serum)
X X X XBlood samples must be 
collected before study 
vaccination when 
applicable.
After completion of 
electrochemiluminesce
nce (ECL) and 
opsonophagocytic 
(OPA) testing, serum 
samples will be stored 
to conduct any 
additional study -
related testing as 
required by [CONTACT_778737] f or the 
development and/or 
validation of 
pneumococcal assays 
after completion of all 
study -related 
immunogenicity 
07X67T
PRODUCT: V114 33
PROTOCOL/AMENDMENT N O.:022-04
V114 -022-04FINAL PROTOCOL 02-APR -2019
Study Period Screening Intervention Follow -up
Comments Visit Number: [ADDRESS_1070074] 7Phone 
Contactd
Scheduled Time: Day [ADDRESS_1070075] be 
available before 
randomization into the 
study at Visit 2 
(Day 1), which must 
occur ≤30 days after 
Visit 1. Visit Window:Within 30 
days 
before 
Visit 290 to180 
days after 
Allo-
HSCTDay 15 
to Day 
19 after 
Visit 2aDay 30 
to Day 
44 after 
Visit 2aDay 15 
to Day 
19 after 
Visit 3bDay 30 
to Day 
44 after 
Visit 3bDay 15 
to Day 
19 after 
Visit 4cDay 30 
to Day 
44 after 
Visit 4cDay 256 to 
Day 284 
after Allo -
HSCTDay 335 to 
Day 395 
after Allo -
HSCTDay 15 to 
Day 19 
after 
Visit 6Day 30 
to Day 
44 after 
Visit 6Day 166
to Day 
194after 
Visit 6d
testing; this applies 
only to sera received 
from randomized study 
participants who 
provided consent for 
future biomedical 
research.
Future Biomedical Research
Blood (DNA) for 
Future Biomedical 
Research (Optional)
for adult participants 
≥18 years of age.XCollected from 
randomized 
participants who 
provided consent for 
future biomedical 
research (Section 8.8)
Saliva (DNA) for 
Future Biomedical 
Research for 
pediatric participants 
<18 years of age.XCollected from 
randomized 
participants who 
provided 
consent/assent for 
Future Biomedical 
Research (See 
Section 8.8).
aWhen scheduling the Phone Contact (Day 15) and Visit 3 (Day 30), “Day 1” is the date of Visit [ADDRESS_1070076] (Day 45) and Visit 4 (Day 60), “Day 1” is the date of Visit [ADDRESS_1070077] (Day 75) and Visit 5 (Day 90), “Day 1” is the date of Visit [ADDRESS_1070078] (6 m onths after Visit 6) will only be conducted in recipi[INVESTIGATOR_22880] V114 or Prevnar13 ™at Visit 6.
07X67T
PRODUCT: V114 34
PROTOCOL/AMENDMENT N O.:022-04
V114 -022-04FINAL PROTOCOL 02-APR -2019
2 INTRODUCTION
[COMPANY_006] Sharp & Dohme Corp. (MSD) is developi[INVESTIGATOR_63464] 15 -valent 
pneumococcal conjugate vaccine (PCV) (referred to as V114) for the prevention of 
pneumococcal disease caused by  [CONTACT_63504]. V114 contains the 13 serot ypes 
(1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 1 9A, 19F, 23F) present in the licensed vaccine 
Prevnar 13™ (pneumococcal 13 -valent conjugate vaccine [diphtheria CRM 197protein], 
Wyeth Pharmaceuticals, a subsidiary  of [COMPANY_007], Inc., Philadelphia, PA), plus 2 additional 
seroty pes (22F, 33F).
2.1 Study Rationale
Allogeneic h ematopoietic stem cell transplant (allo -HSCT) recipi[INVESTIGATOR_778720] a high risk for invasive pneumococcal disease (I PD) 
[Engelhard, D., et al 2002] [Giebink, G. S., et al 1986] [Youssef, S., et al 2007] . IPD is 
associated with high morbidity  and mortality  in allo -HSCT recipi[INVESTIGATOR_840], with rates of disease 
being 20 -to 30- fold higher than the general population . Pneumococcal disease can occur 
early (<[ADDRESS_1070079] -transplantation), but the majority  of IPD cases are reported ≥[ADDRESS_1070080] transplantation 
[Engelhard, D., et al 2002]. 
Immunization is the main preventative strategy  against pneumococcal disease [Rubin, L . G., 
et al 2014] . The majority  of pneumococcal disease cases are observed >[ADDRESS_1070081]
[Engelhard, D., et al 2002] [Cordonnier, C., et al 2009] . The vaccination series is 
recommended to be initiated at [ADDRESS_1070082] Streptococcus pneumoniae [Rubin, L . G., et al 2014] .Several clinical studies in both 
adult and pediatric populations have demonstrated the acceptable safet y and immunogenicit y 
profiles of 3 to 4 doses of PCV given 1 month apart followed by a dose of 
PNEUMOVAX™23 [Cordonnier, C., et al 2015] . Current international guidelines 
recommend the administration of 3 doses of PCV (eg, Prevnar 13™), at 1 -month intervals, to 
be started from 3 to 6 months after transplant, followed at 12 months after transplant b y a
dose of PNEUMOVAX™23 (pneumococcal vaccine, poly valent [23 -valent]) [Tombly n, 
Marcie, et al 2009] [Rubin, L . G., et al 2014] . In patients with chronic graft -versus -host 
disease (GVHD), an additional dose of PCV can be administered at [ADDRESS_1070083] 
[Rubin, L . G., et al 2014] , instead of PNEUMOVAX™ 23. 
This clinical study  is designed to describe the safety , tolerability , and immunogenicity  of 
V114 compared with Prevnar 13™ in allo -HSCT recipi[INVESTIGATOR_840] (≥3 years of age )who have not 
received a pneumococcal vaccine (vaccine -naïve) after the transplant. This study  will also 
describe the safet y and tolerability  of PNEUMOVAX™[ADDRESS_1070084]. I mmune responses to the 15 serot ypes contained in V114 following 
PNEUMOVAX™23 administration will also be described. Consistent with current 
guidelines, participants with chronic GVHD will receive a 4thdose of either V114 or 
Prevnar 13™ at [ADDRESS_1070085]-transplant instead of PNEUMOVAX™23. Chronic GVHD 
should be assessed in accordance with NIH consensus criteria [Jagasia, M. H., et al 2015] .
Recommendation for minimum platelet count is based on the Clinical Practice Guideline 
from the AABB [Kaufman, R. M., et al 2015] .Safety ,tolerability , and immunogenicit y
07X67T
PRODUCT: V114 35
PROTOCOL/AMENDMENT N O.:022-04
V114 -022-04FINAL PROTOCOL 02-APR -2019
following administration of the 4thdose of either V114 or Prevnar 13™ will be described. 
The data from this study  will contribute to the overall safet y database and immunogenicit y 
profile of V114 in individuals ≥3 years of age and older .
2.2 Background
2.2.1 V114 and Pneumococcal Disease
Refer to the Investigator’s Brochure (IB) for V114 for more detailed background, including 
information on pneumococcal disease burden.
S.pneumoniae is a significant cause of disease worldwide, with clinical manifestations 
including pneumonia, meningitis, otitis media, sinusitis, and sepsis. Adults with comorbid 
conditions, in particul ar immunocompromised individuals, have a higher incidence of 
invasive pneumococcal disease ( IPD)morbidity  and mortality  in all age groups compared to 
adults without the comorbid conditions [Lexau, C. A., et al 2005] . 
Currently  licensed pneumococcal conjugate vaccines (eg, Prevnar™, Sy nflorix™, and 
Prevnar 13™) were first implemented in infant immunization programs in many countries 
worldwide. Prevnar™ was first licensed in 2000 and later replaced b y Prevnar 13™ in 2009 
for the European Union and in 2010 for the [LOCATION_002] . Although Prevnar 13™ is 
indicated for children and adults, Sy nflorix™ is only  indicated for children up to 5 y ears of 
age. Widespread use of PCVs ha sreduced the burden of pneumococcal dise ase caused b ythe 
seroty pes contained in the vaccines in children who were targeted b y the vaccination 
programs and unvaccinated individuals from other age groups (herd protection) [Centers for 
Disease Control 
and Prevention 2008] [Ruckinger, S., et al 2009] [Farrell, D. J, et al 2007] 
[Pi[INVESTIGATOR_63466], Tamara, et al 2010] [L exau, C. A., et al 2005] [Metlay, J. P., et al 2006] [Whitney , 
Cynthia G., et al 2003] [Moore, M. R., et al 2015] [L epoutre, A., et al 2015] [We iss, S., et al 
2015] [Martinelli, D., et al 2014] [Guevara, M., et al 2016] [Waight, P. A., et al 2015] 
[Jokinen, J., et al 2015] [Palmu, A. A., et al 2015] [Wagenvoort, G. H., et al 2016] . Prevnar 
13™ was also shown to be efficacious against vaccine -type nonbacteremic pneumococcal 
pneumonia and IPD in adults ≥65 y ears of age [Bonten, M. J., et al 2015] . These study  results 
were the basis of the recommendation from the ACI P for the sequential administration of 
Prevnar 13™ followed at least 12 months later by  [CONTACT_63506]™23 in adults ≥65 y ears of 
age [Tomczy k, S., et al 2014] [Kobay ashi, M., et al 2015] . 
Although cases of IPD have decreased following implementation of PCVs, an increase in 
IPD caused b y serotypes not covered b y currently  available vaccines has been observed. 
V114 contains 2 additional serot ypes (22 F, 33F) compared with Prevnar 13™. The selection 
of 22F and 33F was primarily based on epi[INVESTIGATOR_63467] [ADDRESS_1070086] common seroty pe 
not included in Prevnar 13™ i n adults ≥18 y ears of age, causing 13% of I PD cases. Seroty pe 
33F is associated with an additional 5% of I PD cases [Moore, M. R., et al 2015] . Data from 
the [LOCATION_008] also showed that ,in 2013/2014, 22F and 33Fare frequent serot ypes in 
adults ≥65 years of age, accounting for approximately  10% and 4% of I PD cases in that age 
group , respectively  [Waight, P. A., et al 2015] . Data from [ADDRESS_1070087]: V114 36
PROTOCOL/AMENDMENT N O.:022-[ADDRESS_1070088] common seroty pes causing IPD 
[European Centre for Disease Prevention and Control 2016] .In pediatrics, approximately  4 
years after inclusion of Prevnar™ in the [LOCATION_002] infant immunization schedule, 
seroty pes 22F and 33F accounted for approximately  13% of IPD cases in children <5 y ears 
of age (incidence rate of IPD due to 22F and 33F combined of 3.1 cases per 100,000 person -
years [PY]), in contrast to 1.3% of IPD cases in the pre -PCV7 era (incidence rate of 22F and 
33F IPD of 1.2 cases per 100,000 PY) [Hicks, L . A., et al 2007] . By 2013, both 22F and 33F 
were among the leading seroty pes causing I PD bey ond those already  included in 
Prevnar 13™, accounting for approximately 21% of all I PD in children <5 y ears of age in the 
[LOCATION_002] [Moore, M. R., et al 2015]
The serot ypes included in V114 will provide broad coverage of the leading serotypes 
associated with pneumococcal disease worldwide. V114 is designed to meet continuing 
medical and public health needs for PCVs globally, as well as to address the emergence of 
pneumococcal disease caused by  [CONTACT_63508]. V114 is 
designed to offer broader seroty pe coverage than Prevnar 13™ against pneumococcal disease 
in both pediatric and adult populations.
2.2.2 Preclinical and Clinical Studies
Refer to the IB for information on completed preclinical and clinical studies conducted with 
V114 . 
2.2.3 Information on Other Study -related Therapy
[IP_ADDRESS] Prevnar 13™
Refer to approved labeling for detailed background information on Prevnar 13™.
Prevnar 13™ contains all of the pneumococcal seroty pes included in Prevnar™ (4, 6B, 9V, 
14, 18C, 19F, and 23F) plus 6 additional seroty pes (1, 3, 5, 6A, 7F, and 19A). The adult 
indication was approved based on immune responses elicited b y Prevnar 13™ in comparison 
with PNEUMOVAX™23. A placebo -controlled clinical efficacy  study (Community  
Acquired Pneumonia Immunization Trial in Adults [CAPi[INVESTIGATOR_34172] ]) evaluated the efficacy of 
Prevnar 13™ against pneumococcal pneumonia and I PD in immunocompetent ad ults 
≥65years of age. Results from CAPi[INVESTIGATOR_63468] 13™ was 45.6% 
(95% confidence interval [ CI]:21.8% to 62.5%) efficacious against vaccine -type 
nonbacteremic pneum ococcal pneumonia and 75.0% ( 95% CI: 41.4% to 90.8%) efficacious 
against vaccine -type IPD in adults ≥65 years of age [Bonten, M. J., et al 2015] .
In man y countries, Prevnar 13™ is given as a part of routine immunization schedules for all 
infants and children 2 to 59 months of age and for children 60 to 71 months of age with 
immunocompromising conditions. Children without a history of immunization with 
Prevnar 13™ are recommended to receive catch up immunization with Prevnar 13™, 
regardless of previous immunization with other PCVs containing fewer PnPs seroty pes. The 
Advisory  Committee on Immunization Practices (ACI P) also recommends children [ADDRESS_1070089]: V114 37
PROTOCOL/AMENDMENT N O.:022-04
V114 -022-04FINAL PROTOCOL 02-APR -2019
18years of age with immunocompromising conditions, functional or anatomic asplenia, CSF 
leaks, or cochlear implants, also receive Prevnar 13™. Children and adults who have 
undergone stem cell transplantation receive 3 dose series of Prevnar 13™  after 
transplantation[Centers for Disease Control and Prevention (CDC) 2013] .
Prevnar™ and Prevnar 13™ are also known as Prevenar™ and Prevenar 13™ in many 
countries outside of the [LOCATION_002]; these vaccines arereferred to as Prevnar™ and 
Prevnar 13™ throughout this document.
[IP_ADDRESS] PNEUMOVAX™23
Refer to approved labeling for detailed background information on PNEUMOVAX™23.
PNEUMOVAX™[ADDRESS_1070090] important 
seroty pes causing disease in adults (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 
17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F). The formulation is not adjuvanted and no 
carrier protein is used. 
In the [LOCATION_002], PNEUMOVAX™23 is recommended by  [CONTACT_63509] P for routine use in 
immunocompetent adults ≥[ADDRESS_1070091] 1year after 
Prevnar 13™ [Kobay ashi, M., et al 2015] . It is also recommended for use in adults aged 19 to 
64 years of age with underly ing medical conditions that increase the risk for serious 
pneumococcal infection. These conditions include but are not limited to chronic heart 
disease, chronic lung disease (including chronic obstructive pulmonary disease, emph ysema, 
and asthma), diabetes mellitus, alcoholism, chronic liver disease (including cirrhosis), and 
cigarette smoking [Centers for Disease Control and Prevention 2010] . 
PNEUMOVAX™23 is also recommended in immunocompromised adults ≥19 years of age ; 
in this population, a dose of PNEUMOVAX™23 is recommended ≥8 weeks following a 
dose of Prevnar 13™ [Kobay ashi, M., et al 2015] . Vaccination with PNEUMOVAX™23 is 
also recommended for children 2 to 18 y ears of age with underl ying medical conditions after 
completing all recommended Prevnar 13™ doses [Centers for Disease Control and 
Prevention (CDC) 2013] .Many  countries follow similar age -based and/or risk- based 
recommendations for the use of PNEUMOVAX™23 [Castiglia P. 2014] .  
2.3 Benefit/Risk Asse ssment
It cannot be guaranteed that participants in clinical studies will directly  benefit from 
intervention during participation, as clinical studies are designed to provide information 
about the safet y and effectiveness of an investigational vaccine.
Approximately  50% of participants will receive Prevnar 13™, the standard of care, as the 
active comparator in this study . Based on the available data, V114 is expected to provide 
comparable immune responses to Prevnar 13™ for the s hared serot ypes while providing 
additional coverage for the 2 serot ypes (22F ,33F) unique to V114 . However, it is unknown if 
the investigational V114 will have the same benefit as Prevnar 13™ in the recipi[INVESTIGATOR_778721]-HSCT.
07X67T
PRODUCT: V114 38
PROTOCOL/AMENDMENT N O.:022-04
V114 -022-04FINAL PROTOCOL 02-APR -2019
As per current guidelines, eligible participants will also receive PNEUMOVAX™[ADDRESS_1070092] 
additional seroty pes [Rubin, L . G., et al 2014] . However, participants who develop chronic 
GVHD during their first y ear after allo -HSCT will be considered ineligible to receive 
PNEUMOVAX™23. Instead of PNEUMOVAX™23, participants with chronic GVHD will 
receive a 4thdose of blinded study  vaccine (ie , V114 or Prevnar 13™) at [ADDRESS_1070093]. 
Additional details regarding specific benefits and risks for participants participating in this 
clinical study  may  be found in the accompanyi ng IB and Informed Consent Form (ICF) .See 
Appendix 10.7.1 fo r Country -specific 
requirements for Sweden.
3 HYPOTHESIS, O BJECTIVES ,AND ENDPOINTS
The following objectives and endpoints will be evaluated in adult and pediatric recipi[INVESTIGATOR_778719] (allo-HSCT ).
Objectives Endpoints
Primary
•Objective: To evaluate the safet y and 
tolerability  of 3 doses of V114 and 3doses 
of Prevnar 13™ with respect to the 
proportion of participants with adverse 
events (AEs) within each vaccination group.Following an y of the 3 doses of V114 or 
Prevnar 13™ for adults ≥18 y ears of age :
•Solicited injection -site AEs from Day  
1 through Day  5 postvaccination 
•Solicited sy stemic AEs from Day  1 
through Day  14 postvaccination 
•Vaccine -related serious adverse events 
(SAEs) from Day  [ADDRESS_1070094]
Following an y of the 3 doses of V114 or 
Prevnar 13™ for pediatrics ( 3to <18
years of age):
•Solicited injection -site AEs from Day  
1 through Day  14 postvaccination
•Solicited sy stemic AEs from Day  1 
through Day  14 postvaccination
•Vacci ne-related serious adverse events 
(SAEs) from Day  [ADDRESS_1070095]: V114 39
PROTOCOL/AMENDMENT N O.:022-04
V114 -022-04FINAL PROTOCOL 02-APR -2019
•Objective: To evaluate the serot ype-specific 
immunoglobulin G (IgG) Geometric Mean 
Concentrations (GMCs) at [ADDRESS_1070096] dose of Prevnar 13™ 
within each vaccination group.•Seroty pe-specific IgG responses for 
the 15 serot ypes in V114 at Day 90
Secondary
•Objective: To evaluate the safet y and 
tolerability  of PNEUMOVAX™23
(administered [ADDRESS_1070097] in 
participants who do not develop GVHD )
with respect to the proportion of participants 
with AEs within each vaccination group.Following vaccination with 
PNEUMOVAX™23 for adults ≥18 y ears 
of age :
•Solicited injection -site AEs from Day  
1 through Day  5 postvaccination 
•Solicited sy stemic AEs from Day  1 
through Day  14 postvaccination 
•Vaccine -related SAEs from Month [ADDRESS_1070098] to1 month after
vaccination or the completion of the 
study .
Following vaccination with 
PNEUMOVAX™23 for pediatrics ( 3to 
<18years of age) :
•Solicited injection -site AEs from Day  
1 through Day  14 postvaccination
•Solicited sy stemic AEs from Day  1 
through Day  14 postvaccination
•Vaccine -related SAEs from Month [ADDRESS_1070099]: V114 40
PROTOCOL/AMENDMENT N O.:022-04
V114 -022-04FINAL PROTOCOL 02-APR -2019
•Objective: To evaluate the safet y and 
tolerability  of a 4th dose of V114 and a 4th 
dose of Prevnar 13™ (both administered [ADDRESS_1070100] in participants who 
develop GVHD ) with respect to the 
proportion of participants with AEs wi thin 
each vaccination group .Following vaccination with a 4thdose of 
V114 or Prevnar 13™ for adults ≥18 y ears 
of age :
•Solicited injection -site AEs from Day  
1 through Day  5 postvaccination 
•Solicited sy stemic AEs from Day  1 
through Day  14 postvaccination 
•Vaccine -related SAEs Day 1 through 6 
months after 4thvaccination of V114 
and Prevnar 13™ or completion of the 
study .
Following vaccination with a 4thdose of 
V114 or Prevnar 13™ for pediatrics ( 3to 
<18years of age) :
•Solicited injection -site AEs from Day
1 through Day  14 postvaccination
•Solicited sy stemic AEs from Day  1 
through Day  14 postvaccination
•Vaccine -related SAEs from Day  1 
through 6 months after 4thvaccination 
of V114 and Prevnar 13™ or 
completion of the study .
•Objective: To evaluate the serot ype-specific 
opsonophagocy tic activity (OPA) Geometric 
Mean Titers (GMTs) at [ADDRESS_1070101] 
dose of Prevnar 13™ within each 
vaccination group.•Seroty pe-specific OPA responses for 
the 15 serot ypes in V114 at Day 90
•Objective: To evaluate the serot ype-specific 
(1) OPA GMTs and IgG GMCs at baseline 
(prevaccination with V114 or Prevnar 13™ ) 
and (2) Geometric Mean Fold Rises 
(GMFRs) and proportions of participants 
with a ≥[ADDRESS_1070102] 
dose of Prevnar 13™ separately for both 
IgG and OPA responses within each 
vaccination group . •Seroty pe-specific OPA and IgG 
responses for the [ADDRESS_1070103]: V114 41
PROTOCOL/AMENDMENT N O.:022-04
V114 -022-04FINAL PROTOCOL 02-APR -2019
Exploratory
•Objective: To evaluate the serot ype-specific 
(1) IgG GMCs and OPA GMTs at 30 day s 
postvaccination with either 
PNEUMOVAX™23 (participants without 
chronic GVHD) ora 4th dose of V114 or 
Prevnar 13™ (participants with chronic 
GVHD) administered at Month [ADDRESS_1070104] within each vaccination group;
(2) GMFRs and proportions of participants 
with a 
≥4-fold rise from prevaccination 
(Month [ADDRESS_1070105]) to 30 days 
following either PNEUMOVAX™23 ora 
4th dose of V114 or Prevnar 13™ (Month 
[ADDRESS_1070106]) for both IgG and OPA 
responses within each vaccination group.•Seroty pe-specific IgG and OPA 
responses for the [ADDRESS_1070107]
•Objective: To evaluate the serot ype-specific 
IgG GMCs at 30 day s postvaccinati on for 
participants administered 3 doses of V114 
compared to participants administered 3 
doses of Prevnar 13™ .•Seroty pe-specific IgG responses for 
the 15 serot ypes in V114 at Day 90
4 S TUDY DESIGN
4.1 Overall Design
This is a Phase 3, randomized, double -blind, active comparator -controlled, parallel- group, 
multicenter, clinical study to describe the safet y, tolerability, and immunogenicity of V114 
and Prevnar 13™ when administered as a 3- dose regimen in recipi[INVESTIGATOR_778722] -HSCT.
Prospective participants will be s creened for enrollment at Visit 1, which must occur w ithin 
30 day s before Visit 2 (Day 1). At Visit 2 (Day  1), which must occur [ADDRESS_1070108], eligible participants will be randomly assigned in a 1:1 ratio to 1 of the 
2blinded study  vaccines ( V114 or Prevnar 13™ ). 
Atotal of a pproximately  250 adult and 50 pediatric participants will be random ized so that 
approximately  150 participant s will receive V114 and approximately  150participants will 
receive Prevnar 13™ .The randomization process will be performed using stratification 
techniques to ensure a reasonable balance between the [ADDRESS_1070109] to 
the following factors: useof systemic steroids within 14 day
s before randomization ( Day 1), 
07X67T
PRODUCT: V114 42
PROTOCOL/AMENDMENT N O.:022-04
V114 -022-04FINAL PROTOCOL 02-APR -2019
age category  (3 to <18yearsand18 to 49 y ears or ≥50 y ears), and haploidentical donor status
(yes or no) .
Blinded study  vaccine (V114 or Prevnar 13™ )will be administered to each eligible 
participant a t each of the following 3 time points: Visit 2 (Day  1), Visit 3 (Day 30), and 
Visit 4 (Day  60). 
Eligible participants will also receive a single dose of PNEUMOVAX™23 at Visit 6 
(12months after allo- HSCT) . However, participants who develop chronic GVHD during the 
first y ear after allo -HSCT will be considered ineligible to receive PNEUMOVAX™23 and 
will instead receive a 4thdose of blinded study  vaccine (V114 or Prevnar 13™) at Visit 6.
Participants will be followed for local and s ystemic AEs from Day  1 through Day 14 
following each vaccination. I nformation for SAEs and deat hs, regardless of whether the 
events are considered to be vaccine -related b y the investigator, will be collected from the 
time consent is signed through completion of participation in the study . An external Data 
Monitoring Committee (DMC) will conduct a pe riodic review of safet y and tolerability  data 
for the adult V114 Phase 3 program . A description of the structure, function, and guidelines 
for decision- making by  [CONTACT_1363], along with the timing and content of the safet y reviews 
will be outlined in the DMC c harter. Information regarding the composition of the DMC is 
provided in Appendix 1.
Throughout a participant’s participation in the study, new onset and/or change inGVHD as 
well as relapse and progression of underl ying disease (ie, the disease for which allo- HSCT 
was performed) will be recorded as specific events of interest.
Blood samples for immunogenicity  assay s will be obtained at the following time points:
Immediately  before V114 or Prevnar 13™ vaccination at Visit 2 (Day  1)
30 day s after the 3rdvaccination with V114 or Prevnar 13™ 
Visit 5 (Day  90)
Immediately  before vaccination with PNEUMOVAX™23, or 4thdose of either V114 
or Prevnar 13™, administered [ADDRESS_1070110] (Visit 6)
30 day s after vaccination with PNEUMOVAX™23, or 4thdose of eit her V114 or 
Prevnar 13™ (Visit 7)
After completion of electrochemiluminescence (ECL )and OPA testing, serum samples will 
be stored to conduct an y additional study -related testing as required by [CONTACT_63510]. Leftover sera from the stu dy may  be used for the development and/or validation 
of pneumococcal assay s after completion of all study -related immunogenicity  testing; this 
applies only  to sera received from randomized study  participants who provided consent for 
future b iomedical research.
07X67T
PRODUCT: V114 43
PROTOCOL/AMENDMENT N O.:022-[ADDRESS_1070111] recipi[INVESTIGATOR_778723]. The proposed dosing regimen and vaccination 
strategy  ([ADDRESS_1070112], PNEUMOVAX™23 or 
a 4thdose of either V114 or Prevnar 13™ in participants with chronic GVHD) is consistent 
with current guidelines for pneumococcal vaccination in recipi[INVESTIGATOR_778722] -HSCT . The 
immunogenicit y and safety endpoints, including the duration of the safet y follow -up period, 
are consistent with previous studies evaluating the safet y of PCVs in recipi[INVESTIGATOR_778721]-HSCT .
4.2.1 Rationale for Endpoints
[IP_ADDRESS] Immunogenicity Endpoints
Previous studi es have demonstrated the need for the administration of at least [ADDRESS_1070113] 3 doses of PCV and generall y remained 
stable after PNEUMOVAX™23 [Cordonnier, C., et al 2015] .
Sera from participants will be used to measure vaccine -induced serot ype-specific IgG and 
OPA responses for all 15 seroty pes (1, 3, 4, 5, 6A, 6B, 7 F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 
and 33F) included in V114 using the pneumococcal electrochemiluminescence (PnECL) 
assay  and Multiplexed Opsonophagocy tic Assay  (MOPA) assay . 
Several studies have shown a positive correlation between serot ype-specific Ig G antibod y 
concentrations and OPA titers in children and adults [Centers for Disease Cont rol and 
Prevention 2010] [Anttila, M., et al 1999] [Romero -Steiner, S., et al 1997] . OPA assesses 
levels of 
functional antibodies capable of opsonizing pneumococcal capsular poly saccharides 
for presentation to phagocy tic cells for engulfment and subsequent killing, and therefore is 
considered an important immunologic surrogate for protection against I PD in adult s. Note 
that no antibody  concentration or titer for either assay  has been defined as the threshold value 
that correlates with protection in adults.
In this stud y, IgG responses are considered primary because prophy lacticantibiotic therapy  
may interfere wi th the OPA assay .
Details on the immunogenicity  endpoints evaluated in thi s study  can be found in 
Section 9.4.1.
07X67T
PRODUCT: V114 44
PROTOCOL/AMENDMENT N O.:022-04
V114 -022-04FINAL PROTOCOL 02-APR -2019
[IP_ADDRESS] Safety Endpoints
The safet y endpoints evaluated in this study  were selected based on the product’s safet y 
profile demonstrated in previous studies, published data from marketed PCVs, and feedback 
received from regulatory  agencies during product development. The electronic Vaccination 
Report Card (eVRC), used to record AEs during the postvaccination periods defined in 
Section 8.1.9, was structure d as recommended in the final Food and Drug Administration 
Patient Reported Outcome Guidance [U.S. Food and Drug Administration 2009] . 
Details on the safet y endpoints evaluated in this study  can be found in Sec tion 8.3.4 and 
Section 9.4.2.
Details on AEs, including definitions and reporting requirements, can be found in 
Appendix 4.
[IP_ADDRESS] Future Biomedical Research
The Sponsor will conduct future biomedical r esearch on specimens for which consent was 
provided during this study . This research may  include genetic anal yses (DNA), gene 
expression profiling ( ribonucleic acid [ RNA ]), proteomics, metabolomics (serum, plasma), 
and/or the measurement of other analy tes, depending on whi ch specimens are consented for 
future bio medical r esearch.
Such research is for biomarker testing to address emergent questions not described elsewhere 
in the protocol (as part of the main study ) and will only  be conducted on specimens from 
appropriatel y consented participants. The objective of collecting/retaining specimens for 
future biomedical r esearch is to explore and identify  biomarkers that inform the scientific 
understanding of diseases and/or their therapeutic treatments. The overarching goal is to use 
such information to develop safer, more effective drugs/vaccines, and/or to ensure that 
participants receive the correct dose of the correct drug/vaccine at the cor rect time. The 
details of this future biomedical r esearch substudy  are presented in Appendix 6.
4.2.2 Rationale for t he Use of Compar ator/Placebo
This study  utilizes Prevnar 13™ as the active comparator as this is the only PCV licensed in 
many  developed countries. 
Prevnar 13™ is approved in children for,among other indications, the prevention of invasive 
disease ,and in adults 18 y ears of age and older for the prevention of pneumococcal 
pneumonia and invasive disease caused b y 13 S.pneumoniae serot ypes (1, 3, 4, 5, 6A, 6B, 
7F, 9V, 14, 18C, 19A, 19F, and 23F).
Refer to approved labeling for detailed background information on Prevnar 13 ™.
The standard of care in recipi[INVESTIGATOR_778722]
-HSCT includes 3 doses of Prevnar 13™, 
administered at [ADDRESS_1070114] by a dose of PNEUMOVAX™23 (or a 4thdose of Prevnar 13™ 
07X67T
PRODUCT: V114 45
PROTOCOL/AMENDMENT N O.:022-[ADDRESS_1070115] chronic GVHD) [Tombly n, M., et al 2009] . The active 
comparator that is the current standard of care is expected to provide meaningful safet y and 
immunogenicit y data against which sa fety and immunogenicit y of V114 may be evaluated in
recipi[INVESTIGATOR_778722]- HSCT .
4.3 Justification for Dose
Each dose of V114 used in this study  is similar to that used in previous V114 adult and 
pediatric clinical studies (refer to the V114 IB for more detailed i nformation on dose 
selection) . However, while most previous adult clinical studies included a single dose onl y of 
V114, t he current study includes 3 doses of V114 ( with an additional 4thdose in participants 
with chronic GVHD ) that are administered in accordance with current guidance for 
allo-HSCT recipi[INVESTIGATOR_840].
The doses of Prevnar 13™ and PNEUMOVAX™[ADDRESS_1070116] participant signs the 
informed consent/assent form . 
The overall study  ends when the last participant completes the last study -related telephone -
call or visit, withdraws from the study, or is lost to follow -up (ie, the participant is unable to 
be contact[INVESTIGATOR_530] b y the investigator).
For purposes of analy sis and reporting, the overall study  ends when the Sponsor receives the 
last serology  assay  result.
4.4.1 Clinical Criteria f orEarly Study Termination
There are no prespecified c riteria for terminating the study  early.
5 STUDY POPULATION
Male/Female participants at least [ADDRESS_1070117] will be 
enrolled in this study .
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, is not permitted.
5.1 Inclusion Criteria
Participants are eligible to be included in the study onl y if all o f the following criteria apply:
1.Received a human leukocy te antigen (HLA) compatible donor including haploidentical 
and mismatched (related or unrelated) first allo- HSCT (ie, bone marrow or peripheral 
blood stem cell) 90 to 180 daysprior to randomization (Visit 2 ).
07X67T
PRODUCT: V114 46
PROTOCOL/AMENDMENT N O.:022-[ADDRESS_1070118] for acute ly mphoblastic leukemia (ALL) in first or second 
remission, acute m yeloid leukemia (AML) in first or second remission, chronic my eloid 
leukemia (CML) in first chronic or accelerated phase, Hodgkin’s lymphoma , 
non-Hodgkin's l ymphoma , myelodysplastic s yndrome (MDS), my elofibrosis ,
myeloproliferative diseases, and non -malignant disease such as aplastic anemia, or 
sickle cell disease inparticipants ≥18 years of age and an y non -malignant disease for
participants 3to <18 y ears of age .
3.Life expectancy  >[ADDRESS_1070119], according to investigator judgement.
4.Clinically  stable engraftment according to investigator judgment.
Demographics
5.Participant is Male or Female ≥3 yearsof age.
Female Participants
6.A female participant is eligible to participate if she is not pregnant (Appendix 5 ), not 
breastfeeding, and at least 1 of the following conditions applies:
a.Not a woman of childbearing potential (WOCBP) as defined in Appendix [ADDRESS_1070120] dose of 
study  intervention.
Informed Consent
7.The participant or legall y acceptable representative (exclusively  used for subject s who 
are < 18years of age )understands the study  procedures, alternate treatments available, 
and risks involved with the study  and voluntarily  agrees to participate b y giving written 
informed consent or assent ( provided b y a legally acceptable representative for subjects 
<18years of age ). Participant smay also provide consent for future biomedical research. 
However, these participants may participate in the main study  without participating in 
future biomedical r esearch. 
5.2 Exclusion Criteria
Participants are excluded from the study if an y of the following criteria apply:
Medical Conditions
1.Receipt of a previous a llo-HSCT.
Note : recipi[INVESTIGATOR_22880] a previous autologous HSCT are eligible .
07X67T
PRODUCT: V114 47
PROTOCOL/AMENDMENT N O.:022-[ADDRESS_1070121] with ex -vivo graft manipulation (e.g. CD34 selection, TCR alpha 
beta depletion, etc .), in vivo T cell depletion with alemtuzumab, or haploidentical 
allo-HSCT with hi gh dose anti -thymocy te globulin .
3.Received allo- HSCT for :
Multiple my eloma
In participants ≥18 y ears of age only, any nonmalignant diseases except sickle 
cell disease and aplastic anemia.
4.Persistent or relapsed primary  disease (diagnosed as per the invest igator’s institution’s 
morphologic criteria for refractory  or relapse of disease) after a llo-HSCT .
5.History  of severe GVHD (Grade 3 or 4 GVHD) after allo -HSCT
Note : Overall GVHD status is determined as per GVHD grading scale used by  
[CONTACT_778738].
6.Planned organ transplantation after allo -HSCT.
7.History  of culture -positive pneumococcal disease occurring after allo -HSCT 
(eg,positive blood culture, positive cerebrospi[INVESTIGATOR_778724], or positive culture at 
another sterile site).
8.Known hy persensitivity  to any  component of pneumococcal pol ysaccharide vaccine, 
pneumococcal conjugate vaccine, or an y diphtheria toxoid -containing vaccine.
9.History  of acquired immunodeficiency  such as doc umented HIV infection, or anatomic 
asplenia.
10.Coagulation disorder contraindicating intramuscular vaccinations.
11.*Recent febrile illness (defined as oral or t ympanic temperature ≥100.4°F [≥38.0°C]; 
axillary  or temporal temperature ≥99.4°F [≥37.4°C]; or recta l temperature ≥101.4°F 
[≥38.6°C]) or received antibiotic therapy for an y acute illness occurring within 72 hours 
before receipt of study  vaccine.
12.Severe hepatic impairment (defined as Child -Pugh Class C) at Screening (Visit 1) .
13.*Serum aspartate transaminas e (AST) or alanine transaminase (ALT) > 6 ×upper limit of 
normal (ULN) or serum total bilirubin >2.5 × ULN at Screening (Visit 1 ).
14.*Grade ≥4 renal impairment (estimated glomerular filtration rate <30ml/min/1.73m2or 
dialy sis) at Screening (Visit 1) .
15.*Platelet count < 30,000/µL at Screening (Visit 1) .
07X67T
PRODUCT: V114 48
PROTOCOL/AMENDMENT N O.:022-04
V114 -022-04FINAL PROTOCOL 02-APR -2019
16.*Absolute neutrophil count < 1,000/µL  at Screening (Visit 1) .
17.A WOCBP who has a positive urine or serum pregnancy  test before the 1stvaccination 
at Visit 2.
Prior/Concomitant Therapy
18.Received chimeric antigen receptor T- cell (CAR -T) therap y or checkpoint inhibitor 
directed therap y(ie, anti PD -1)after allo
-HSCT .
19.Received or planned to receive anti-CD20 B- cell targeted therap y (eg, rituximab) after 
allo- HSCT .
20.*Received s ystemic steroids at a prednisone equiv alent dose >0.5 mg/kg/day (steroids at 
a prednisone equivalent dose ≤0.5 mg/kg/day  are allowed) for ≥[ADDRESS_1070122] 30 day s before administration of any study  vaccine.
21.*Prior or s cheduled receipt of immunoglobulins or plasma products within [ADDRESS_1070123], or is expected to 
receive non -study  pneumococcal vaccine during participation in the study .
23.*Received an y licensed, non- live vaccine within 14 day s before receipt of any  study  
vaccine, or is scheduled to receive an y licensed, non -live vaccine within 14days after 
receipt of any study vaccine.
Exception: inactivated influenza vaccine and h aemophilus influenzae type B(Hib)
vaccine may  be administered, but onl y if it is administered at least 7 day s before receipt 
of an y study vaccine and/or at least 7days after receipt of an y stud y vaccine.
24.*Received an y live vaccine within 30 days before receipt of an y study vacc ine or is 
scheduled to receive an y live vaccine within 30 days after receipt of an y study  vaccine.
Prior/Concurrent Clinical Study Experience
25.Is currently  participating or has participated in an interventional clinical study  with an 
investigational compou nd/agent or device within 2 weeks of participating in this current 
study ,or plans to receive any  investigational compound/agent or device (in addition to 
existing therap y) within 2 weeks of an y vaccination , that in the opi[INVESTIGATOR_778725].
Other Exclusions 
26.Is, at the time of signing informed consent /assent , a user of recreational or illicit drugs or 
has had a recent history  (within the last y ear) of drug or alcohol abuse or dependence as 
assessed b y the stud y investigator.
07X67T
PRODUCT: V114 49
PROTOCOL/AMENDMENT N O.:022-[ADDRESS_1070124] udy, or interfere with the 
participant’s participation for the full duration of the study.
28.Is or has an immediate family  member (eg, spouse, parent/legal guardian, sibling, or 
child) who is investigational site or Sponsor staff directly involved with t his study .
For items with an asterisk (*), if the participant meets these exclusion criteria, the 
Day [ADDRESS_1070125].
5.3 Lifestyl e Considerations
No lifesty le restrictions are required .
5.4 Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study, but 
are not subsequently randomized in the study ]. A minimal set of screen failure information is 
required to ensure transparent reporting of screen failure participants to meet the 
Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to 
respond to queries from regulatory  authorities . Minimal information inclu des demograph y, 
screen failure details, eligibility criteria, and any AEs or SAEs meeting reporting 
requirements as outlined in the data entry guidelines.
5.5 Participant Replacement Strategy
A participant who withdraws from the stud ywill not be replaced.
6 STUDY INTERVENTION
Study  intervention is defined as an y investigational intervention(s), marketed product(s), 
placebo, or me dical device(s) intended to be administered to a study  participant according to 
the study  protocol.
Clinical supplies [V114, Prevnar 13™, PNEUMOVAX™23 ] will be packaged to support 
enrollment . Clinical supplies will be affixed with a clinical label in accordance with 
regulatory  requirements.
6.1 Study Intervention(s) Administered
The study  interventions to be used in this study  are outline dinTable 1.
07X67T
PRODUCT: V114 50
PROTOCOL/AMENDMENT N O.:022-04
V114 -022-04FINAL PROTOCOL 02-APR -2019
Table 1 Study  Interventions
Arm 
Name [CONTACT_778754]/
NIMP Sourcing
V114 Experimental V114 Biological/
VaccineSterile suspension Refer to IB 0.5 mL IM 3 Doses:
Visit 2 (Day 1)
Visit 3 (Day 30)
Visit 4 (Day 60)Experi
mentalIMP Central
PNEUMOVAX™2
3a
ORBiological/
VaccineSterile suspension Refer to 
product 
labeling0.5 mL IM Single Dose at 
Visit 6 ([ADDRESS_1070126] )Experi
mentalIMP Central
V114 
(4thDose)bBiological/
VaccineSterile suspension Refer to IB 0.5 mL IM 4th Dose at 
Visit 6 ([ADDRESS_1070127])Experi
mentalIMP Central
Prevnar 
13™Active 
ComparatorPrevnar 13™ Biological/
VaccineSterile suspension Refer to 
product 
labeling0.5 mL IM 3 Doses: 
Visit 2 (Day 1)
Visit 3 (Day 30)
Visit 4 (Day 60)Experi
mentalIMP Central or 
local
PNEUMOVAX™2
3a
ORBiological/
VaccineSterile suspension Refer to 
product 
labeling0.5 mL IM Single Dose at 
Visit 6 ([ADDRESS_1070128])Experi
mentalIMP Central
Prevnar 13™ 
(4thDose)bBiological/
VaccineSterile suspension Refer to 
product 
labeling0.5 mL IM 4th Dose at 
Visit 6 ([ADDRESS_1070129])Experi
mentalIMP Central
aPNEUMOVAX™[ADDRESS_1070130] disease, a 4thdose of V114 or Prevnar 13™ (blinded; same as first 3 doses) is administered instead of PNEUMOV AX™23. 
Admin = administration; IB = Investigator’s Brochure; IM = intramuscular; IMP = investigational medicinal product; NIMP = non -
investigational medicinal product .
The definition of IMP and NIMP is based on guidance issued by [CONTACT_63512]. Regional and/or country differences of the definition of IMP/NIMP may exist. In these 
circumstances, local legislation is followed.
All supplies indicated in Table 1will be provided per the "Sourcing" column depending upon local country  operational requirements. 
Every  attempt should be made to source these supplies from a single lot/batch number. The study  site is responsible for recor ding the 
lot number, manufacturer, and expi[INVESTIGATOR_171531] y locally  purchased product per local guidelines unless otherwise instructed by  [CONTACT_429].
Refer to Section 8.1.[ADDRESS_1070131]: V114 51
PROTOCOL/AMENDMENT N O.: 022 -04 
V114 -022-04FINAL PROTOCOL 02-APR -2019
6.2 Preparation/Handling/Storage/Accountability
6.2.[ADDRESS_1070132] be stored 
in a secure, environmentally  controlled, and monitored (manual or automated) area in 
accordance with the labeled storage conditions with access limited to the investigator and 
authorized site staff.
The investigator, institution, or the head of the medical institution (where applicable) is 
responsible for stud y intervention accountability , reconciliation, and record maintenance (ie, 
receipt, reconciliation, and final disposition r ecords).
For all stud y sites, the local country Sponsor personnel or designee will provide appropriate 
documentation that must be completed for drug accountability  and return, or local discard 
and destruction if appropriate. Where local discard and destruc tion is appropriate, the 
investigator is responsible for ensuring that a local discard/destruction procedure is 
documented.
The study  site is responsible for recording the lot number, manufacturer, and expi[INVESTIGATOR_63470] y purchased product (if appl icable) as per local guidelines unless otherwise 
instructed by  [CONTACT_1034].
The investigator shall take responsibility  for and shall take all steps to maintain appropriate 
records and ensure appropriate supply, storage, handling, distribution, and usage of stud y 
interventions in accordance with the protocol and any applicable laws and regulations.
6.3 Measures to Minimize Bias: Randomization and Blinding
6.3.1 Intervention Assignment
Treatment allocation/randomization will occur centrally using an interactive response 
technology  (IRT) s ystem. There are 2study  intervention arms. Participants will be assigned 
randomly  in a 1:
1ratio to V114 and Prevnar 13™ , respectivel y.
07X67T
PRODUCT: V114 52
PROTOCOL/AMENDMENT N O.: 022 -04 
V114 -022-04FINAL PROTOCOL 02-APR -2019
6.3.2 Stratification
Treatment allocation/randomization will be stratified according to the following factors:
1.Use of s ystemic steroids within 14days before randomization ( Day 1)(yes or no)
2.Age category  (3 to<18 years ,18to49 years, or ≥50 years)
3.Haploidentical donor status (yes or no)
6.3.3 Blinding
A double -blinding technique will be used. V114 and Prevnar 13™ will be prepared and/or 
dispensed by  [CONTACT_63513]. The 
participant and the investigator who is involved in the clinical evaluation of the participants 
will remain blinded to the group assignments .
Because the V114 and Prevnar 13™ have a different appearance, a member of the study site 
staff will be unblinded for the purposes of receiving, maintaining, preparing and/or 
dispensing, and administering these stud y vaccines. PNEUMOVAX™23 will also be 
prepare d and/or dispensed and administered b y unblinded study  site staff for consistency  of 
study  vaccine administration across all visits and to protect the stud y blind in the participants 
receiving a 4thdose of V114 or Prevnar 13™ due to chronic GVHD . In order to avoid bias, 
the unblinded study  personnel will have no further contact [CONTACT_778739] y participants for an y 
study -related procedures/assessments after administration of study  vaccines, which includes 
all safet y follow up procedures. Additionally, blinded si te personnel will not be present in the 
exam room when study  vaccines are administered. Contact [CONTACT_778740].
Blinded site personnel will be responsible for all safet y and immunogenicity follow -up 
procedures after vaccine administration.
An unblinded Clinical Research Associate will monitor vaccine accountability  at the study  
site. All other Sponsor personnel or delegate(s) and [COMPANY_006] Research Laboratories ( MRL) 
employ ees directly  involved with the conduct of this study  will remain blinded to the 
participant- level intervention assignment.
See Section 8.1.1
2for a description of the method of unblinding a participant during the 
study  should such action be warranted .
6.4 Study Intervention Compliance
Interruptions from the protocol specified plan for V114 or Prevnar 13™ vaccination at 
Visit 2 (Day  1), Visit 3 (Day  30), and Visit 4 (Day  60), and PNEUMOVAX™23 or 4thdose 
of V114 or Prevnar 13™ at Visit 6 ([ADDRESS_1070133] ),require consultation 
between the investigator and the Sponsor and written documentation of the collaborative 
decision on participant management.
07X67T
PRODUCT: V114 53
PROTOCOL/AMENDMENT N O.: 022 -04 
V114 -022-04FINAL PROTOCOL 02-APR -2019
6.5 Concomitant Therapy
Medications or vaccinations specificall y prohibited in the exclusion criteria are not allowed
during the ongoing stud y. If there is a clinical indication for an y medication or vaccination 
specificall y prohibited, di scontinuation from study intervention may be required. The 
investigator should discuss any  questions regarding this wit h the Sponsor Clinical Director. 
The final decision on any supportive therap y or vaccination rests with the investigator and/or 
the participant’ s primary  physician. However, the decision to continue the participant on 
study  intervention requires the mutual agreement of the investigator, the Sponsor, and the 
participant.
Listed below are specific restrictions for concomitant therap y or vaccination:
1.Any administration of a non -study pneumococcal vaccine is prohibited during the 
study .
2.Administration of any  non-live vaccine within the 14 days before or 14days after 
receipt of an y study vaccine is prohibited.
Exception : Inactivated influenza vaccine and haemophilus influenzae t ype B (Hib
)
vaccine may be administered but must be given at least [ADDRESS_1070134] 
7days after receipt of any  study  vaccine.
3.Administration of any  live vaccine within 30 day s before or 30 day s after receipt of 
any study  vaccine is prohibited.
4.Administration of immunoglobulins orplasma products is prohibited within 30 days 
of administration of any study  vaccine.
Any deviation from the above requires consultation between the investigator and the Sponsor 
and written documentation of the collaborative decision on participant management.
6.5.1 Rescue Medications and Supportive Care
No rescue or supportive medications are specified to be used in this study.
6.6 Dose Modification (Escalation/Titration/Other)
No dose modification is allowed in this study .
6.7 Intervention After the End of the Study
There is no stud y-specified intervention following the end of the stud y.
6.8 Clinical Supplies Disclosure
This study  is blinded but supplies are provided open label; therefore, an unblinded 
pharmacist or qualified study  site personnel will be used to blind sup plies. Study  intervention
07X67T
PRODUCT: V114 54
PROTOCOL/AMENDMENT N O.: 022 -04 
V114 -022-04FINAL PROTOCOL 02-APR -2019
identity  (name, strength, or potency ) is included in the label text; random code/disclosure 
envelopes or lists are not provided.
The emergency  unblinding call center will use the intervention/randomization schedule for 
the study  to unblind participants and to unmask study  intervention identity . The emergency  
unblinding call center should only  be used in cases of emergency  (see Section 8.1.12). In the 
event that the emergency unblinding call center is not available for a given site in this study , 
the central electronic intervention allocation/randomization sy stem (IRT) should be used to 
unblind participants and to unmask study  intervention identity . The Sponsor will not provide 
random code/disclosure envelopes or lists with the clini cal supplies.
SeeSection 8.1.[ADDRESS_1070135] be collected through the participant’s last scheduled follow -
up, even if the participant has discontinued study intervention. Therefore, all participants 
who discontinue study  intervention prior to completion of the protocol -specified vaccinations
will still continue to participate in the study as specified inSection 1.3 and Section 8.12.3, 
unless the participant withdraws consent (Section 7.2) .
Participants may  discontinue study  intervention at any  time for any  reason or be d iscontinued 
from the study  intervention at the discretion of the investigator shoul d any untoward effect 
occur. In addition, a participant may  be discontinued from study  intervention by  [CONTACT_19419], the stud y plan is violated, or 
for administrative and/or other safet y reasons. Sp ecific details regarding procedures to be 
performed at study  intervention discontinuation are provided in Section 8.1. 11.
A participant must be discontinued from study intervention but continue to be monitored in 
the study  for an y of the following reasons:
•The participant requests to discontinue study  intervention.
•The participant has a medical condition or personal circumstance which, in the opi[INVESTIGATOR_19348]/or Sponsor, placed the participant at unnecessary risk from continued 
administration of study  intervention.
•The participant has a confirmed positive urine or serum pregnancy  test before any stud y 
vaccination visit.
07X67T
PRODUCT: V114 55
PROTOCOL/AMENDMENT N O.: 022 -04 
V114 -022-04FINAL PROTOCOL 02-APR -2019
For participants who are discontinued from study  intervention but continue to be monitored 
in the study , see Section 1.3 and Section 8.12.3 for those procedures to be completed at each 
specified visit.
Discontinuation from study  intervention is “permanent.” Once a participant is discontinued, 
he/she shall not be allowed to restart stud y intervention .
7.[ADDRESS_1070136] be withdrawn from the study  if the participant or the participant’s legall y 
acceptable representative withdraws consent from the study .
If a participant withdraws from the study, they will no longer receive stud y treatment or b e 
followed at scheduled protocol visits.
Specific details regarding procedures to be performed at the time of withdrawal from the 
study ,as well as specific det
ails regarding withdrawal from future biomedical r esearch, are 
outlined in Section 8.1.11. The procedures to be performed should a participant repeatedl y 
fail to return for scheduled visits and/or if the study site is unable to contact [CONTACT_63517] 7.3.
7.[ADDRESS_1070137] t o Follow -up
If a participant fails to return to the clinic for a required study  visit and/or if the site is unable 
to contact [CONTACT_2299], the following procedures are to be performed:
•The site must attempt to contact [CONTACT_19423]. I f the 
participant is contact[INVESTIGATOR_530], the participant should be counseled on the importance of 
maintaining the protocol -specified visit schedule.
•The investigator or designee must make every  effort to regain contact [CONTACT_19424] (eg, telephone calls and/or a certified letter to th e participant’s last 
known mailing address or locally  equivalent methods). These contact [CONTACT_19425]’s medical record.
•Note: A participant is not considered lost to follow -up until the last scheduled visit for the 
indiv idual participant. The missing data for the participant will be managed via the 
prespecified statistical data handling and anal ysis guidelines.
8 STUDY ASSESSMENTS AND PROCEDURES
•Study  procedures and their timing are summarized in the SoA.
•Adherence to the study  design requirements, including those specified in the SoA, is 
essential and required for study  conduct.
07X67T
PRODUCT: V114 56
PROTOCOL/AMENDMENT N O.: 022 -04 
V114 -022-04FINAL PROTOCOL 02-APR -2019
•The investigator is responsible for ensuring that procedures are conducted by 
[CONTACT_11399] y qualified or trained staff. Delegation of study site p ersonnel responsibilities 
will be documented in the Investigator Trial File Binder (or equivalent).
•All study -related medica l decisions must be made by  [CONTACT_19427] a qualified 
physician .
•All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility  criteria. The investigator will maintain a screening log to 
record details of all participants screened and to confirm eligibility or record reasons for 
screening failure, as applicable.
•Addition al evaluations/testing may  be deemed necessary  by [CONTACT_63519] y. In some cases, such evaluation/testing 
may be potentially  sensitive in nature (eg, HIV, Hepatitis C), and thus local regulation s 
may require that additional informed consent be obtained from the participant. I n these 
cases, such evaluations/testing will be performed in accordance with those regulations.
Table 2shows the approximate blood volumes drawn by  [CONTACT_778741] t ypefor 
the adult cohort . The maximum amount of blood collected from each participant at each 
study  visit will not exce ed 30mL and the total amount of blood for the entire study  will not 
exceed 89 mL. For those adult participants ≥ [ADDRESS_1070138]: V114 57
PROTOCOL/AMENDMENT N O.: 022 -04 
V114 -022-04FINAL PROTOCOL 02-APR -2019
Table 2 Approximate Blood Volumes Drawn b y Stud y Visit and by [CONTACT_703035]
(Adult Cohort)
Study VisitVisit 1
(Screen -
ing)Visit 2
(Day 1)Visit 3
(Day 30)Visit 4
(Day 60 )Visit 5
(Day 90 )Visit 6
([ADDRESS_1070139] )Visit 7
(30 Days 
after 
Visit 6 )
Blood parameterApproximate Blood Volume (mL)
Com plete blood count
2mL N/A N/A N/A N/A N/A N/A
Chemistry panel
6mL N/A N/A N/A N/A N/A N/A
Serum for immunogenicity assays 
(including retention serum ) N/A 20 mL N/A N/A 20 mL 20mL 20mL
Blood (DNA) for future biomedical 
researchN/A 8.5 mL N/A N/A N/A N/A N/A
Expected Total (mL)8 mL 28.5 mL N/A N/A [ADDRESS_1070140] = allogeneic hematopoietic stem cell transplant ; DNA = deoxyribonucleic acid; allo -HSCT = 
allogeneic hematopoietic stem cell transplant ; N/A = not applicable
Table 3 Approximate Blood Volumes Drawn b y Stud y Visit and by [CONTACT_703035]
(Pediatric Cohort)
Study VisitVisit 1
(Screen -
ing)Visit 2
(Day 1)Visit 3
(Day 30)Visit 4
(Day 60 )Visit 5
(Day 90 )Visit 6
([ADDRESS_1070141] )Visit 7
(30 Days 
after 
Visit 6 )
Blood parameterApproximate Blood Volume (mL)
Com plete blood count
2mL N/A N/A N/A N/A N/A N/A
Chemistry panel
3.5mL N/A N/A N/A N/A N/A N/A
Serum for immunogenicity assays 
(including retention serum) N/A 10mL N/A N/A 10mL 10mL 10mL
Blood (DNA) for future biomedical 
researchN/A N/A N/A N/A N/A N/A N/A
Expected Total (mL)5.5 mL 10mL N/A N/A 10mL 10mL 10mL
8.1 Administrative and General Procedures
8.1.1 Informed Consent /Assent
The investigator or medically  qualified designee (consistent with local requirements) must 
obtain documented consent , and assent if applicable, from each potential participant prior to 
07X67T
PRODUCT: V114 58
PROTOCOL/AMENDMENT N O.: 022 -04 
V114 -022-04FINAL PROTOCOL 02-APR -2019
participating in a clinical study or future biomedical r esearch . If the re are changes to the 
participant’s status during the stud y (eg, health or age of majority requirements), the 
investigator or medicall y qualified designee must ensure the appropriate consent /assent is in 
place.
[IP_ADDRESS] General Informed Consent/Assent
Consent /assent must be documented b y the participant’s dated signature [INVESTIGATOR_2394] a consent /assent
form along with the dated signature [CONTACT_63564].
A cop y of the signed and dated consent/assent form should be given to the participant before 
participation in the study .
The initial informed consent/assent form, any subsequent revised written informed 
consent/assent form , and any  written information provided to the participant must receive the 
Institutional Review Board/I ndependent Ethics Commit tee’s ( IRB/IEC’s )approval/favorable 
opi[INVESTIGATOR_19349]. The participant should be informed in a timel y manner if new 
information becomes available that may  be relevant to the participant’s willingness to 
continue participation in the study . The communication of thi s information will be provided 
and documented via a revised consent /assent form or addendum to the original consent /assent
form that captures the participant’s dated signature.
Specifics about a stud y and the study population will be added to the consent /assent form 
template at the protocol level.
The informed consent will adhere to IRB/IEC requirements, applicable laws and regulations, 
and Sponsor requirements .The assent, as applicable will adhere to IRB/IEC requirements, 
applicable laws and regulations a nd Sponsor requirements.
[IP_ADDRESS] Consent /Assent and Collection of Specimens for Future Biomedical 
Research
The investigator or medically  qualified designee will explain the future biomedical r esearch 
consent /assent to the participant, answer all of his/her questions, and obtain written informed 
consent /assent before performing an y procedure related to the future biomedical research 
substudy . A cop y of the informed consent /assent will be given to the participant.
8.1.2 Inclusion/Exclusion Criteria
All inclusion and exclus ion criteria will be reviewed by [CONTACT_63522] a qualified 
physician to ensure that the participant qualifies for the study .
If the participant meets any  of the e xclusion criteria with an asterisk (*), Visit 2(Day  1) may  
be rescheduled for a ti me when these criteria are not met and the Day  [ADDRESS_1070142]: V114 59
PROTOCOL/AMENDMENT N O.: [ADDRESS_1070143] information (including direct 
telephone numbers) to be used in the event of an emergency . The in vestigator or qualified 
designee will provide the participant with a participant identification card immediately after 
the participant provides written informed consent. At the time of intervention
allocation/randomization, site personnel will add the intervention/randomization number to 
the participant identification card.
The participant identification card also contains contact [CONTACT_19430] a healthcare provider can obtain information about study 
interventi on in emergency  situations where the investigator is not available.
8.1.4 Medical History
A medical history  will be obtained by  [CONTACT_778742] 1 
(Screening visit) and will be confirmed before vaccination at Visit 2 (Day  1). The 
participant’s medical history  for the 5 y ears prior to Visit 2 (Day  1) will be obtained to 
ensure that the participant satisfies the inclusion and exclusion criteria of the study . 
History  
of tobacco use will also be collected for all participants.
8.1.5 Prior and Concomitant Medications Revi ew
[IP_ADDRESS] Prior Medications
The investigator or qualified designee will review and record prior vaccinations and 
medications taken b y the participant within 30 days before the 1stdose of study  vaccin eat 
Visit 2 (Day  1).
[IP_ADDRESS] Concomitant Medications
The investigator or qualified designee will record medication, if an y, taken by [CONTACT_63525] y.
New and/or concomitant medications taken after the 1stdose of study vaccination at Visit 2 
(Day  1) and non -study  vaccines received since Visit [ADDRESS_1070144]: V114 60
PROTOCOL/AMENDMENT N O.: 022 -04 
V114 -022-04FINAL PROTOCOL 02-APR -2019
Any participant who is screened multiple times will retain the original screening number 
assigned at the initial screening visit. Specific details on the screening/rescreening visit 
requirements are provided in Section 8.12.1.
8.1.7 Assignment of Treatment/Randomization Numb er
All eligible participants will be randomly allocated and will receive a 
treatment /random ization number. The treatment/randomization number identifies the 
participant for all procedures occurring after treatment allocation/randomization. Once a 
treatment /randomization number is assigned to a participant, it can never be re -assigned to 
another participant.
A single participant cannot be assigned more than 1 treatment /randomization number.
8.1.8 Study Intervention Administrati on
V114 or Prevnar 13™ will be administered at Visit 2(Day 1), Visit 3 (Day  30), and Visit 4 
(Day  60). PNEUMOVAX™23 ,oralterna tively  V114 or Prevnar 13™ for participants with 
chronic GVHD, will be administered at Visit 6(12months after allo- HSCT ).
Unblinded study  personnel not otherwise involved in the conduct of the study  will prepare 
and administer the study  vaccine. Study  vaccines should be prepared and administered by  
[CONTACT_11399] y qualified members of the study personnel (eg, ph ysician, nurse, physician’s 
assistant, nurse practitioner, pharmacist or medical assistant) as allowed b y local/state, 
country  and institutional gu idance. Procedures for handling, preparing, and administering the 
unblinded vaccines are provided in the Investigator Trial File Binder. Unblinded study 
personnel should follow the preparation and administration instructions for Prevnar 13™ as 
specified in the product labels.
Study  vaccines should be removed from the refrigerator no more than 1 hour before 
vaccination. The time of removal and time of vaccination should be documented in the 
participant’s chart.
If the V114 is provided as a sy ringe : Prior to administration of study  vaccine, the unblinded 
pharmacist should shake vigorousl y to obtain a homogenous white suspension. If 
white -colored insoluble particle appears, the unblinded pharmacist should use rapid, 
horizontal hand- shaking for 5 to 1 0 seconds while holding the s yringe in be tween the thumb 
and index finger until complete resuspension. This action should be repeated, as necessary. If 
appearance is otherwise, the vaccine should not be administered. 
If V114 is provided as a vial : Prior to administration of study vaccine, the unblinded 
pharmacist should use rapid, horizontal hand -shaking for up to [ADDRESS_1070145]: V114 61
PROTOCOL/AMENDMENT N O.: 022 -04 
V114 -022-04FINAL PROTOCOL 02-APR -2019
The vaccine should not be used if the vaccine cannot be resuspended. Study  personnel should 
follow the preparation and administration instructions for Prevnar 13™ and 
PNEUMOVAX™[ADDRESS_1070146] labels.  Prevnar 13™ and 
PNEUMOVAX™23 will be supplied as a pre -filled sy ringe .
V114, Prevnar 13™ and PNEUMOVAX™23 will be administered to adult and pediatric 
participants as a single 0.5- mL intramuscular injection in th e deltoid region of the 
participant’s arm. Adequate treatment provision, including epi[INVESTIGATOR_778726] ,should be available for immediate use should an anaphy lactic or 
anaph ylactoid reaction occur [Centers for Disease Control and Prevention 2015] .  
Unblinded study  personnel should not have contact [CONTACT_624757] y-related 
procedures/assessments after administration of study  vaccines, which includes all safet y 
follow -up procedures. All safet y and immunogenicity assessments will be condu cted b y 
blinded personnel, and the participant and/or participant’s parent/guardian will be blinded to 
the study  vaccine received by  [CONTACT_2299]. Vaccination information, such as Component 
Identification Number and time of vaccination, must be recorded on the appropriate eCRF as 
per the Data Entry Guidelines .
[IP_ADDRESS] Timing of Dose Administration
Vaccinations may  be administered at any  time of day , and without regard to timing of meals. 
Each participant's body  temperature must be taken before each vaccine administration . 
Individuals who present with fever ( oral or t ympanic temperature ≥100.4°F [≥38.0°C]; 
axillary  or temporal temperature ≥99.4°F [≥37.4°C]; or rectal temperature ≥101.4°F 
[≥38.6°C]) will have the vaccination delayed until fever is resolved for at least 72 hours .
The collection of blood samples and administration of pregnancy tests (if applicable) must be 
done before each vaccine administration.
All participants will be observed for [ADDRESS_1070147] be performed b y blinded site personnel for all study  
vaccines (Section 1.3 and Section 6.3.3
).
8.1.[ADDRESS_1070148]
The eVRC was developed to be administered electronically  via a hand -held device. This item 
was structur ed as recommended in the final Food and Drug Administration Patient Reported 
Outcome Guidance [U.S. Food and Drug Administration 2009] . The investigator or delegate 
will train the participant or participant ’s legally  acceptable representative in the use of the 
eVRC at Visit 2 (Day 1) and Visit 6(12months after allo- HSCT).
Temperatures, injection- site reactions, vaccine -specific complaints, other complaints or 
illnesses, and concomitant medications or vaccinations will be recorded on the eVRC as 
described in Section 1.[ADDRESS_1070149]: V114 62
PROTOCOL/AMENDMENT N O.: 022 -04 
V114 -022-04FINAL PROTOCOL 02-APR -2019
The investigator or delegate will review the data captured on the eVRC with the 
participant or the participant’s legall y acceptable representative at Phone Contact 
(Day15), Visit 3 (Day 30), Phone Contact ( Day 45), Visit 4 (Day 60), Phone Contact 
(Day 75),and Visit 5 (Day 90), as well as at Phone Contact ( 15 day s after Visit 6) and 
Visit 7 (the Follow -up visit, 30 day s after Visit 6) .
Any differences between eVRC da ta and the clinical database must be clearly  
explained in the participant’s source documentation with an indication of where the 
information was obtained (eg, from the Day [ADDRESS_1070150] with the 
participant or participant’s legall y acceptab le representative ).
For the AEs outlined above, the investigator will use the information provided by [CONTACT_678818]’s legall y acceptable representative both on the eVRC, and 
verball y at the time of eVRC review, to appl y the appropriate assessment of intensity  and 
toxicity  as described in Appendix 3.  
8.1.[ADDRESS_1070151] study  participants or the participant’s legally  acceptable 
representative at approximately  [ADDRESS_1070152], and/or
any updates to previously  reported safet y information . 
If a stud y site visit occurs within [ADDRESS_1070153] will n eed to be conducted only forthose
participants receiving a 4thdose of V114 or Prevnar 13™ at 6 months after Visit 6.
8.1.11 Discontinuation and Withdrawal
Participants who discontinue study  intervention prior to completion of the protocol -specified 
vaccinations should be encouraged to continue to be followed for all remaining stud y visits.
When a participant withdraws from participation in the study, all applicable activities 
scheduled for the final study  visit (Visit 7[30 Day s after Visit 6])should be perfor med (at 
the time of withdrawal). Any AEs that are present at the time of withdrawal should be 
followed in accordance with the safet y requirements outlined in Section 8.4 .
[IP_ADDRESS] Withdrawal From Future Biomedical Resear ch
Participants may  withdraw their consent f
or future biomedical r esearch. Participants may  
withdraw consent at an y time by  [CONTACT_59554] [INVESTIGATOR_63472] . If 
medical records for the main study  are still available, the investigator will contact [CONTACT_778743] ([EMAIL_1250]). 
07X67T
PRODUCT: V114 63
PROTOCOL/AMENDMENT N O.: 022 -04 
V114 -022-04FINAL PROTOCOL 02-APR -2019
Subsequently ,the participant's consent for future biomedical r esearch will be withdrawn. A 
letter will be sent from the Sponsor to the investigator confirming the withdrawal. It is the 
responsibility  of the investigator to inform the participant of completion of withdrawal. An y 
analyses in progress at the time of request for withdrawal or alread y performed prior to the 
request being received by [CONTACT_528879]. No new analys es would be generated after the request is received.
In the event that the medical records for the main study  are no longer available (eg, if the 
investigator is no longer required b y regulatory authorities to retain the main study  records) 
or the specimens have been completel y anon ymized, there will no longer be a link between 
the participant’s personal information and their specimens. In this situation, the request for 
specimen withdrawal cannot be processed.
8.1.12 Participant Blinding/Unblindi ng
STUDY INTERVENT ION IDENT IFICATION INFORMAT ION IS TO BE UNMASKED 
ONLY IF NECESSARY FOR THE WELFARE OF THE PARTICIPANT. EVERY 
EFFORT SHOULD BE MADE NOT TO UNBLIND.
For emergency  situations where the investigator or medically  qualified designee (consistent 
with local requirements) needs to identify  the drug used by  a participant and /orthe dosage 
administered, he/she will contact [CONTACT_63529] t elephone and 
make a request for emergency  unblinding. As requested by  [CONTACT_2697] y 
qualified designee, the emergency  unblinding call center will provide the information to 
him/he r promptly  and report unblinding to the Sponsor. Prior to contact[CONTACT_126538] a participant’s treatment assignment, the 
investigator who is a qualified phy sician should make reasonable attempts to enter the 
intensity /toxicity  grade of the AEs observed, the relation to study  intervention, the reason 
thereof , etc., in the medical chart. If it is not possible to record this assessment in the chart 
prior to the unblinding, the unblinding should not be delay ed.
In the event that unblinding has occurred, the circumstances around the unblinding (eg, date, 
reason, and person performing the unblinding) must be documented promptly, and the 
Sponsor Clinical Director notified as soon as possible.
Participants whose tr eatment assignment has been unblinded by  [CONTACT_2697] y 
qualified designee and/or nonstudy  treating ph ysician should continue to be monitored in the 
study .Participants may  receive PNEUMOVAX™23 , or V114 or Prevnar 13™ for 
participants with c hronic GVHD, at Visit 6(12months after allo- HSCT ) after a benefit/risk 
assessment and consultation between the investigator/delegate and Sponsor
Additionally , the investigator or medically  qualified designee must go into the I RT sy stem 
and perform the unblind in the I RT sy stem to update drug disposition. In the event that the 
emergency  unblinding call center is not available for a given site in this study , the IRT 
system should be used for emergency  unblinding in the event that this is required for 
partic ipant safety .
07X67T
PRODUCT: V114 64
PROTOCOL/AMENDMENT N O.: 022 -04 
V114 -022-04FINAL PROTOCOL 02-APR -2019
8.1.13 Calibration of Equipme nt
The investigator or qualified designee has the responsibility  to ensure that any  device or 
instrument used for a clinical evaluation/test during a clinica l study  that provides information 
about inclusion/exclusion cri teria and/or safety  or efficacy  parameters shall be suitably  
calibrated and/or maintained to ensure that the data obtained is reliable and/or reproducible. 
Documentation of equipment calibration must be retained as source documentation at the 
study  site.
8.2 Immunogenicity Assessmen ts
Sera from participants will be used to measure vaccine -induced OPA and IgG for serot ypes 
included in V114 and Prevnar 13™. These endpoints will be tested for all blood draws. 
Blood collection, storage and shipment instructions for serum samples will be provided in the 
operations/laboratory  manual.
Measurement of serot ype-specific IgG will be measured using the PnECL  v2.[ADDRESS_1070154] disease in vivo. The OPA assay  isa useful tool for assessing the protective function 
of serot ype-specific antibodies and therefore the immunogenicit y of pneumococcal vaccine 
formulations.
8.2.1 Electrochemiluminescence (ECL)
MSD has developed and optimized a multiplex, ECL -based detection method for the 
quantitation of IgG serotype -specific antibodies to the [ADDRESS_1070155] prespecified acceptance criteria 
for each of the parame ters.
8.2.2 Multiplex Opsonophagocytic Assay (MOPA)
The MOPA, developed and published by  [CONTACT_63532] (Director of the United 
States World Health Organization pneumococcal serology reference laboratory and National 
Institutes of Health pneumococcal refere nce laboratories), is a multiplexed OPA assay  
07X67T
PRODUCT: V114 65
PROTOCOL/AMENDMENT N O.: [ADDRESS_1070156] a total of 16 serot ypes of pneumococci 
[Burton, Robe rt L. and Nahm, Moon H. 2006] . The OPA is an antibod y-mediate d killing 
assay  that measures the ability of human serum to kill S.pneumoniae serot ypes with the help 
of complement and phagocytic effector cells. The ability  of the assay  to simultaneously  test 4 
seroty pes/run reduces the amount of serum needed for testi ng. The assay readout is the 
opsonization index, which is the reciprocal of the highest dilution that gives ≥50% bacterial 
killing, as determined b y comparison to assay  background controls. [COMPANY_006] Sharp & Dohme 
Corp. has developed and optimized the MOPA in a high throughput micro -colony  platform. 
The MOPA assay  for all 15 V114 serot ypes has undergone validation. The validation study 
evaluated various performance parameters of the assay  including precision, relative 
accuracy /dilutional linearity , and specific ity. The validation results were evaluated against 
pre-specified acceptance criteria for each of the parameters.
8.3 Safety Assessments
Details regarding specific safet y procedures/assessments to be performed in this study  are 
provided. 
Planned time points for all safety assessments are provided in the SoA.
8.3.1 Physical Examinations
A complete ph ysical examination will be conducted by  [CONTACT_63534] (consistent with local requirements) as clinically  relevant for this patient popula tion 
before vaccination at Visit 2(Day 1).  A directed phy sical examination will be conducted b y 
an investigator or medically  qualified designee (consistent with local requirements) before 
vaccination at Visit 3 (Day 30), Visit 4 (Day  60), and Visit 6 ([ADDRESS_1070157]) . 
Investigators should pay  special attention to clinical signs related to previous illnesses.  A 
directed ph ysical examination includes obtaining vital signs (heart rate, respi[INVESTIGATOR_2842], 
blood pressure, bod y temperature) and a ph ysical examination focused on complaints based 
on medical history .In the source documents, investigators should docu ment phy sical exam 
data and the status of all active medical conditions. Note that temperature is the only vital 
sign to be collected in the InForm database for this trial.
A complete ph ysical examination includes but is not limited to the assessments of s ystemic 
assessment of general appearance, vital signs (heart rate, respi[INVESTIGATOR_697], blood pressure, 
body  temperature), ey es, throat, mouth, cardiovascular, respi[INVESTIGATOR_696] , gastrointestinal, skin, 
neurologic and ps ychiatric systems, and other organ systems as indicated.
8.3.[ADDRESS_1070158] consistent with local requirements (sensitive to at least 25 IU beta human 
chorionic gonadotropin [β-hCG ]) must be performed before vaccination at Visit 2 (Day 1), 
Visit 3 (Day  30), Visit 4 (day  60), and Visit 6 ([ADDRESS_1070159]) in WOCBP as 
described in Section 1.3. Pregnancy  tests can be repeated as needed based on local 
07X67T
PRODUCT: V114 66
PROTOCOL/AMENDMENT N O.: [ADDRESS_1070160] febrile illness (oral temperature ≥38.0°C [≥100. 4°F] or 
axillary  temperature ≥37.4°C [≥99.4°F]) occurring at or within [ADDRESS_1070161] be rescheduled.   Oral is the preferred method of obtaining participant’s 
temperature. Axillary  (underarm) is an acceptable method for pediatric participants but 
temperature needs to be confirmed b y oral measuremen t if fever is detected. If an axillary  
temperature is reported to be ≥37. 4°C (≥99.4°F), an oral temperature must be taken. 
The participant or the participant’s legally  acceptable representative will be asked to record 
body  temperature using their eVRC during the eVRC -specified postvaccination follow -up 
period (Section 8.3.4). Adult participants should be instructed to take their p ost vaccination 
body temperatures Day  [ADDRESS_1070162] vaccination 
temperatures for pediatri c participants <18 years of age should be taken Day  1 through Day 7 
following each vaccination by  [CONTACT_98901]’s legally  acceptable 
representative.  For pediatric participants, a t emperature measurement must be recorded in 
the eVRC i ffever is suspected during Day [ADDRESS_1070163] be recorded on the appropriate eCRF.
Adult participants will use the eVRC (Section 8.1.9) to document the following information:
•Oral bod y temperatures measured Day 1 (day of vaccination) through Day 5 
postvaccination;
•Solicited injection -site AEs (redness/ery thema, swelling, and tenderness/pain) Day  1 
through Day  5 postvaccination;
•Solicited sy stemic AEs (muscle pain/my algia, joint pain/arthralgia, headache, and 
tiredness/fatigue) Day  1 through Day  14 postvaccination;
07X67T
PRODUCT: V114 67
PROTOCOL/AMENDMENT N O.: 022 -04 
V114 -022-04FINAL PROTOCOL 02-APR -2019
•Any other injection -site or sy stemic AEs Day 1 through Day  14 postvaccination; and
•Concomitant medications and nonstudy  vaccinations Day  1 to Day 14 postvaccination.
Pediatric participants or the participant’s legally acceptable representative will use the eVRC 
(Section 8.1.9) to document the following information:
Pediatric participant s 3to <18years of age
•Body temperatures measured Day 1 (day  of vaccination) t hrough Day 7 postvaccination; 
Day [ADDRESS_1070164] vaccination if fever is suspected
•Solicited injection -site AEs (redness /erythema , swelling, tenderness /pain, and hard 
lump ) 
Day 1 through Day 14postvaccination
•Solicited sy stemic AEs (muscle pain /myalgia , joint pain /arthralgia , headache, 
tiredness /fatigue , and hives or welts ) Day 1 through Day 14postvaccination
•Any other inj ection- site or sy stemic AEs Day 1 through Day 14 p
ostvaccination
•Use of an y analgesic or antipy retic on the day  of vaccination.
•Concomitant medications and nonstudy  vaccinations Day 1 to Day 14 postvaccination .
8.3.5 Clinical Laboratory Assessments
•Refer to Appendix [ADDRESS_1070165] of clinical laboratory tests to be performed and to the 
SoA for the timing and frequency .
•All protocol -required laboratory  assessments, as defined in Appendix 2, must be 
conducted in accordance with the laboratory  manual and the SoA .
•If laboratory  values from nonprotocol specified lab oratory  assessments performed at the 
institution’s local laboratory  require a change in study  participant management or are 
considered clinically  significant by  [CONTACT_093] (eg, SAE or AE or dose 
modification), then the results must be recorded in the appropriate CRF (eg, SL AB).
•For an y laboratory  tests with values considered clinically  significantl y abnormal during 
participation in the study  or within [ADDRESS_1070166]: V114 68
PROTOCOL/AMENDMENT N O.: 022 -04 
V114 -022-04FINAL PROTOCOL 02-APR -2019
8.4 Adverse Events (AEs), Serious Adverse Events (SAEs), and Other Reportable 
Safety Events
The definitions of an AE or SAE, as well as the method of recording, evaluating, and 
assessing causalit y of AE and SAE and the procedures for completing and transmitting AE, 
SAE, and other reportable safety event reports can be found in Appendix 3.
Adverse events, SAEs, and other reportable safety events will be reported by  [CONTACT_171589]’s legally acceptable representative .
The investigator and an y designees are responsible for detecting, documenting, and reporting 
events that meet the definition of an AE or SAE as well as other reportable safet y events. 
Investigators remain responsible for following up AE, SAEs, and other reportable safety 
events for outcome according to Section 8.4.[ADDRESS_1070167] to seriousness, 
intensity /toxicity  and causality .
8.4.1 Time Period and Frequency for Collecting AE, SAE ,and Other Reportable 
Safety Event Informatio n
All AEs, SAEs, and other reportable safety events that occur after the consent form is signed 
but before allocation/randomization must be reported by  [CONTACT_63536] , or are the result of a pro tocol -specified 
intervention, including but not limited to washout or discontinuation of usual therap y, diet, 
placebo treatment, or a procedure.
All AEs, SAEs, and other reportable safety events must be reported b y the investigator from 
the day  of allocati on/randomization to the first vaccination and from the day of each 
vaccination through [ADDRESS_1070168] also 
be reported throughout the duration of the individual’s participation in the study, regardless 
ofwhether or not related to the Sponsor’s product .
Additionally , any SAE brought to the attention of an investigator at an y time outside of the 
time period specified in the previous paragraph also must be reported immediatel y to the 
Sponsor if the event is either:
A death that occurs prior to the participant completing the study .
OR
An SAE that is considered by  [CONTACT_19427] a qualified ph ysician to be vaccine 
related .
Investigators are not obligated to actively seek AE or SAE or other reportable sa fety events 
in former stud y participants. However, if the investigator learns of an y SAE, including a 
07X67T
PRODUCT: V114 69
PROTOCOL/AMENDMENT N O.: 022 -04 
V114 -022-04FINAL PROTOCOL 02-APR -2019
death, at an y time after a participant has been discharged from the study, and he/she 
considers the event to be reasonabl y related to the study interventi onor study  participation, 
the investigator must promptly  notify  the Sponsor.
All initial and follow -up AEs, SAEs, and other reportable safety  events will be recorded and 
reported to the Sponsor or designee within the time frames as indicated in Table 4 .
Table 4 Reporting Time Periods and Time Frames for A dverse Events and Other 
Reportable Safet y Events
Type of Event Reporting Time 
Period:
Consent to 
Randomization/ 
AllocationReporting Time 
Period:
Randomization/ 
Allocation 
through Protocol -
Specified Follow -
up PeriodReporting Time Period:
After the Protocol 
Specified Follow -up 
PeriodTimeframe 
to Report 
Event and 
Follow -up 
Information 
to 
SPONSOR:
Non-Serious Adverse 
Event (NSAE)Report if:
-due to protocol -
specified 
intervention
-causes exclusion
-participant is 
receiving placebo 
run-in or other 
run-in treatmentReport all Not required Per data entry 
guidelines
Serious Adverse Event 
(SAE)Report if:
-due to protocol -
specified 
intervention
-causes exclusion
-participant is 
receiving placebo 
run-in or other 
run-in treatmentReport all Report if:
-drug/vaccine related.
-any death until 
participant completion of 
study
(Follow  ongoing to 
outcome)Within 24 
hours of 
learning of 
event
Pregnancy/Lactation 
ExposureReport if:
-due to 
intervention
-causes exclusionReport all Previously reported –
Follow  to 
completion/termination; 
report outcomeWithin [ADDRESS_1070169] for this study. Not 
applicable
Cancer Report if:
-due to 
intervention
-causes exclusionReport all Not required Within 5 
calendar days 
of learning of 
event
Overdose Report if:
-receiving 
placebo run -in or 
other run -in 
medication Report all Not required Within [ADDRESS_1070170]: V114 70
PROTOCOL/AMENDMENT N O.: 022 -04 
V114 -022-04FINAL PROTOCOL 02-APR -2019
8.4.2 Method of Detecting AE s, SAE s,and Other Reportable Safety Events
Care will be taken not to introduce bias when detecting AE and/or SAE and other reportable 
safet y events. Open -ended and nonleading verbal questioning of the participant is the 
preferred method to inquire about AE occurrence.
8.4.3 Follow -up of AE, SAE ,and Other Reportable Safety Event Information
After the initial AE/SAE report, the investigator is required to proactivel y follow each 
participant at subsequent visits/contacts. All AE, SAE, and other reportable safet y events 
including pregnancy  and exposure during breastfeeding, cancer, and overdose will be 
followed until re solution, stabilization, until the event is otherwise explained, or the 
participant is lost to follow -up (as defined in Section 7.3). In addition, the investigator will 
make every  attempt to follow all nonserious AEs that occur in randomized participants f or 
outcome. Further information on follow -up procedures is given in Appendix 3.
8.4.4 Regulatory Reporting Requirements for SAE
Prompt notification (within 24 hours) by  [CONTACT_778744] y of participants and the 
safety of a stud y intervention under clinical investigation are met.
The Sponsor has a legal responsibility  to notify  both the local regulatory  authority  and other 
regulatory  agencies about the safet y of a stud y intervention under clinical investigation. All 
AEs will be reported to regulatory  authorities, IRB/IECs, and investigators in accordance 
with all applicable global laws and regul ations (ie, per ICH Topic E6 (R2 ) Guidelines for 
Good Clinical Pr actice [GCP] ).
Investigator safety  reports must be prepared for suspected unexpected serious adverse 
reactions (S[LOCATION_003]R s) according to local regulatory  requirements and Sponsor policy  and 
forwarded to investigators as necessary .
An investigator who receives an investigator safety report describing an SAE or other 
specific safet y information (eg, summary or listing of SAE) from the Sponsor will file it 
along with the I Band will notify  the IRB/IEC, if appropriate according to local requirements .
8.4.5 Pregnancy and Exposure During Breastfeeding
Although pregnancy  and infant exposure during breastfeeding are not considered AEs, an y 
pregnancy  or infant exposure during breastfeeding in a participant (spontaneously reported to 
the investigator or their designee) that occurs during the stud y are reportable to the Sponsor.
All reported pregnancies must be followed to the completion/termination of the pregnancy . 
Pregnancy  outcomes of spontaneous abortion, missed abortion, benign h ydatidiform mole, 
blighted ovum, fetal death, intrauterine death, miscarriage, and stillbirth must be reported as 
serious events (Important Medical Events). If the pregnancy continues to term, the outcome 
(health of infant) must also be reported.
07X67T
PRODUCT: V114 71
PROTOCOL/AMENDMENT N O.: 022 -04 
V114 -022-04FINAL PROTOCOL 02-APR -2019
8.4.6 Disease -related Events and/or Disease -related Outcomes Not Qualifying as 
AEs or SAEs
This is not applicable to this study .
8.4.[ADDRESS_1070171] (ECI s)
There are no events of clinical interest for this study.
8.4.[ADDRESS_1070172]
Throughout a participant’s participation in the study, new onset and/or worsening of GVHD
status since Day  1as well as relapse and progression of underl ying disease (ie, the disease for 
which allo -HSCT was performed [see inclusion c riterion 2 in Section 5.1]) will be recorded 
as specific events of interest . Specific events of interest are to be reported as non-serious or 
serious AEs as defined in Appendix 3. Standard reporting time frames for non-serious and 
serious AEs will apply  (see Table 4 in Section 8.4.1).
8.[ADDRESS_1070173] be reported by [CONTACT_19452] 5 calendar day s to the 
Sponsor either by [CONTACT_26365]. Electronic reporting procedures can be found in 
the electronic data collection (EDC )data entry  guidelines. Paper reporting procedures can be 
found in the Inves tigator Trial File Binder (or equivalent) .
8.6 Pharmacokinetics
PK parameters will not be evaluated in this study .
8.7 Pharmacodynamics
Pharmacod ynamic parameters will not be evaluated in this study .
8.8 Future Biomedical Research Sample Collection
If the participant or the participant’s legall y acceptable representative signs the future 
biomedical r esearch consent, the following specime ns will be obtained as part of future 
biomedical r esearch:
07X67T
PRODUCT: V114 72
PROTOCOL/AMENDMENT N O.: 022 -04 
V114 -022-04FINAL PROTOCOL 02-APR -2019
•DNA for future research
•Leftover stud y serum after completion of immunogeni city testing stored for future 
research
8.9 Planned Genetic Analysis Sample Collection
Planned genetic a nalysis samples will not be evaluated in this study .
8.10 Biomarkers
Biomarkers are not evaluated in this study .
8.11 Medical Resource Utilization and Health Economics
Medical Resource Utilization and Health Economics are not evaluated in this study .
8.12 Visit Requirements
Visit requirements are outlined in Section 1.3. Specific procedure -related details are provided 
in Section 8.
8.12.1 Screening
Screening procedures wi ll be conducted at Visit 1 as outlined in Section 1.3 .
8.12.2 Treatment Period/Vaccination Visit
Requirements during the treatment period are outlined in Section 1.3 .
8.12.3 Discontinued Participants Continuing to be Monitored in the Study
A participant may  discontinue from study  intervention (ie, vaccination) but continue to 
participate in subsequent protocol visits as outlined in Section 1.3, as long as the participant 
or the participant’s legally acceptable representative does not withdraw consent . 
Protocol -specified activities, including blood draws for immunogenicit y assessments and AE 
monitoring, should occur at these visits .
07X67T
PRODUCT: V114 73
PROTOCOL/AMENDMENT N O.: 022 -04 
V114 -022-04FINAL PROTOCOL 02-APR -2019
9 STATISTICAL ANALYSIS PLAN
This section outlines the statistical analysis strategy and procedures for the study . Changes to 
analyses made after the protocol has been finalized, but prior to unblinding, will be 
documented in a supplemental statistical analy sis plan and referenced in the Clinical Study  
Report (CSR) for the study . Post hoc exploratory  anal yses will be clearl y identified in the 
CSR. 
9.1 Statistical Analysis Plan Summary
Key elements of the statistical anal ysis plan are summarized below; the comprehensive plan 
is provided in Sections 9.2 through 9.12.
Study Design Overview A Phase 3, Randomized, Double -Blind, Active Com parator -Controlled, 
Multicenter Clinical Trial to Evaluate the Safety, Tolerability, and 
Immunogenicity of V114 in Recipi[INVESTIGATOR_778727] (PNEU -STEM)
Treatm ent Assignme nt Approximately 250 adult participants and approximately 50 pediatric 
participants ( 3years of age and older) w ill be randomized, with 
approximately 150 participants in each intervention group.  
Participants will be randomly assigned in a 1:1 ratio to V114 or 
Prevnar 13™, respectively. Randomization will be stratified into 
12groups based on (1)use of systemic steroids within 14days before
randomization (Day 1)(yes or no) and (2) age category (3to 
<18years,18 to 49 years and ≥50years) (3) haploidentical donor status 
(yes or no) as described in Section 6.3.2. 
Analysis Populations Immunogenicity : Per -Protocol (PP)
Safety: All Participants as Treated (APaT)
Prim ary Endpoint(s) Immunogenicity :
Serotype- specific IgG GMCs at 30 days follow ing the 3rddose of
V114 or Prevnar 13™ ( Day 90 )
Safety :Following any of the 3 doses of V114 and any of the 3 doses of
Prevnar 13™ for adults (≥18 years of age ):
Proportion of participants with solicited injection -site AEs 
(redness /erythema, swelling, tenderness /pain ) from Day 1 through 
Day 5 postvaccination
Proportion of participants with solicited systemic AEs (muscle 
pain/myalgia , joint pain /arthralgia , headache, and tiredness /fatigue )
from Day 1 through Day 
14 postvaccination
Proportion of participants with vaccine -related SAEs from Day [ADDRESS_1070174]
     Follow ing any of the 3 doses of V114 and any of the 3 doses of    
      Prevnar 13™ for pediatrics ( 3to <18 years of age):
Proportion of participants with solicited injection -site AEs 
(redness/erythema, swelling, tenderness/pain , and hard lump ) from
Day [ADDRESS_1070175]: V114 74
PROTOCOL/AMENDMENT N O.: 022 -04 
V114 -022-04FINAL PROTOCOL 02-APR -2019
Proportion of participants with solicited systemic AEs (muscle 
pain/myalgia, join t pain/arthralgia, headache, tiredness/fatigue, and 
hives and welts ) from Day 1 through Day 14 postvaccination
Proportion of participants with vaccine -related SAEs from Day [ADDRESS_1070176]
Key Secondary Endpoints Immunogenicity :
Serotype- specific OPA GMTs at 30 days following the 3rddose of
V114 or Prevnar 13™ (Day 90)
Safety : The follow ing analysis endpoints will be evaluated follow ing 
vaccination with PNEUMOVAX™23 and following the 4thdose of V114 
or Prevnar 13™ (separately) for adults (≥18 years of age ):
Proportion of participants with solicited injection -site AEs 
(redness /erythema, swelling, tenderness /pain ) from  Day 1 through 
Day 5postvaccination
Proportion of participants with solicited systemic AEs (muscle 
pain/myalgia ,joint pain /arthralgia , headache, and tiredness /fatigue )
from Day 1 through Day 14 postvaccination
Proportion of participants with vaccine -related SAEs from Month [ADDRESS_1070177] to 1 month postvaccination or the completion of the 
study. (from  Month [ADDRESS_1070178] or the 
completion of the study )
The follow ing analysis endpoints will be evaluated following vaccination 
with PNEUMOVAX™23 and following the 4thdose of V114 or Prevnar 
13™ (separately) for pediatrics ( 3 to <18 years of age) :
Proportion of participants with solicited injection -site AEs 
(redness/erythema, swelling, tenderness/pain , hard lump ) from 
Day 1 
through Day 14 postvaccination
Proportion of participants with solicited systemic AEs (muscle 
pain/myalgia , joint pain /arthralg ia, headache, tiredness /fatigue, hives 
and w elts)from Day 1 through Day 14postvaccination
Proportion of participants with vaccine -related SAEs from Month [ADDRESS_1070179] to 1 month postvaccination or the completion of the 
study. (from  Month [ADDRESS_1070180] or the 
completion of the study)
Statistical Methods for Key 
Immunogenicity AnalysesImmunogenicity analyses will be conducted for the adult and pediatric 
participants for each of the 15 pneumococcal serotypes in V114 
separately. To address the primary immunogenicity objective, estimation 
of the IgG GMCs at 30 days follow ing the 3rdvaccination with V114 or 
Prevnar 13™ (Day 90) will include descriptive summaries and 
within -group 95% CIs to be calculated for each vaccination group . A 
similar statistical approach w ill be used to evaluate the OPA responses at 
Day 90.
07X67T
PRODUCT: V114 75
PROTOCOL/AMENDMENT N O.: [ADDRESS_1070181] safety parameters , 95% within -group CIswill be 
provided.
Interim Analyses To support the periodic review of safety and tolerability data across the 
V114 Phase [ADDRESS_1070182] to 
enable a benefit -risk assessment.
Multiplicity No adjustment will be made for multiplicity.
Sample Size and Power Immunogenicity :
This study will randomize approximately 150participants into the V114 
group and 150participan ts into the Prevnar 13™ group. It is assumed 
that approximately 105participants per group will be evaluable for 
immunogenicity analyses at Day 90 (70% evaluability rate). There are no 
hypotheses to be evaluated, but Section 9.9.1 provides information about 
the expected variability of the IgG GMCs given the sample size . 
Safety : 
Section 9.9.2 provides information about the ability of this study to 
estimate the incidence of AEs within the V114 group. 
9.2 Responsibility for Analyses/In -house Blinding
The statistical anal ysis of the data obtained from this study  will be th e responsibility  of the 
Clinical Biostatistics department of the Sponsor.
This study  will be conducted as a double -blind study  under in -house blinding procedures. 
The official, final database will not be unblinded until medical/scientific review has been 
performed, protocol deviations have been identified, and data have been declared final and 
complete.
The Clinical Biostatistics department will generate the randomized allocation schedule(s) for 
study  intervention assignment. Randomization will be implement ed using an I RT.
Blinding issues related to the planned interim analyses are described in Section 9.7.
9.3 Hypotheses/Estimation
Objectives of the stud y are stated in Section 3. This is an estimation study  and no formal 
hypothesis testing will be performed.
07X67T
PRODUCT: V114 76
PROTOCOL/AMENDMENT N O.: 022 -04 
V114 -022-04FINAL PROTOCOL 02-APR -2019
9.4 Analysis Endpoints
Immunogenicit y and safety analy sisendpoints that will be summarized are listed below.
9.4.1 Immunogenicity Endpoints
For all participants (adult and pediatric) a description of immunogenicit y assessments is 
contained in Section 8.2.
The i mmune responses will be measured for each of the following serot ypes contained in 
V114: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, [ADDRESS_1070183]
dose of V114 andPrevnar 13™ (Day  90).
The secondary  immunogenicity  analysis endpoints include:
•Seroty pe-specific OPA GMTs at 30 day s following the 3rddose of V114 andPrevnar 
13™ (Day 90)
•Seroty pe-specific 
GMFR sand proportions of participants with a ≥4-fold rise from 
prevaccination ( Day 1)to 30 day s following the 3rddose of V114 and 
Prevnar 13™
(Day 90)for both IgG and OPA responses.
The exploratory  immunogenicity  analysis endpoints include:
Seroty pe-specific IgG GMCs and OPA GMTs at 30 days postva ccination with
PNEUMOVAX™23 (Month [ADDRESS_1070184])
Seroty pe-specific IgG GMCs and OPA GMTs at 30 day s postvaccination with a
4th
dose of V114 or Prevnar 13™ (Month [ADDRESS_1070185])
Seroty pe-specific GMFR sand proportions of participants with a ≥4-fold rise from 
prior to 
vaccination (Month [ADDRESS_1070186]) to 30 day s following 
PNEUMOVAX™23 (Month [ADDRESS_1070187] )for both IgG and OPA responses
Seroty pe-specific GMFRs and proportions of participants with a ≥4-fold rise from 
prior to vaccination (Month [ADDRESS_1070188]) to 30 day s following a 4thdose of 
V114 or Prevnar 13™ (Month [ADDRESS_1070189]) for both IgG and OPA responses 
9.4.2 Safety Endpoints
A description of safet y measures is contained in Sections 8.3 and 8.4. The anal ysis of safety  
results is described in Section 9.6.2.
Safety  and tolerability  will be assessed b y clinical review of all relevant parameters 
separately  foradults and pediatric participants, including adverse events and postvaccination 
temperature measurements following anyof the 3 dosesofV114 and Prevnar 13™ ,
07X67T
PRODUCT: V114 77
PROTOCOL/AMENDMENT N O.: 022 -04 
V114 -022-04FINAL PROTOCOL 02-APR -2019
following PNEUMOVAX™23 , and following the 4thdose of V114 or Prevnar 13™ 
(separatel y). 
The safet y analysis endpoints for adults (≥18 y ears of age ) include :
•Proportion of participants with solicited injection -site AEs (redness/ery thema, swelling, 
tenderness/pain) from Day 1 through Day  5 postvaccination
•Proportion of participants with solicited sy stemic AEs (muscle pain/m yalgia, joint 
pain/arthralgia, headache, and tiredness/fatigue) from Day 1 through Day 14 
postvaccination
•Proportion sof participants with the broad AE categories consisting of an y AE, a 
vaccine -related AE, a SAE, a death, an AE which is both vaccine -related and serious, and 
discontinuation due to an AE, and the proportion of participants who died
•Proportion of participants with maximum temperature measurements meeting the 
Brighton Collaboration cut points from Day 1 through Day  5 postvaccin ation
The safet y analysis endpoints for pediatrics 3to <18yearsof age include:
•Proportion of participan
ts with solicited injection -site AEs (redness/ery thema, swelling, 
tenderness/pain , and hard lump) from Day  1 through Day  14 postvaccination
•Proportion of participants with solicited sy stemic AEs (muscle pain/m yalgia, join t 
pain/arthralgia, headache, tiredn
ess/fatigue , and hives and welts ) from Day  1 through 
Day 14 postvaccination
•Proportions of participants with the broad AE categories consisting of an y AE, a 
vaccine -related AE, a SAE, a death, an AE which is both vaccine -related and serious, and 
discontinuation due to an AE, and the proportion of participants who died
•Proportion of participants with maximum temperature measurements meeting the 
Brighton Collaboration cut points from Day  1 through Day  7postvaccin ation
9.5 Analysis Populations
9.5.1 Immunogenicity Analysis Populations
The Per -Protocol (PP) population will serve as the primary  population for the anal ysis of 
immunogenicit y data in this study. The PP population consists of all randomized participants 
without deviations from the protocol that may  substa ntially  affect the results of the 
immunogenicit y endpoints. Potential deviations that may result in the exclusion of a 
participant from the PP population for all immunogenicity anal yses include the following:
07X67T
PRODUCT: V114 78
PROTOCOL/AMENDMENT N O.: 022 -04 
V114 -022-04FINAL PROTOCOL 02-APR -2019
•Failure to receive study  vaccine at Visit 2 (Da y 1), Visit 3 (Day 30), and Visit 4 (Day 60)
•Failure to receive correct clinical material as per randomization schedule (ie, participants 
who were cross- treated) at Visit 2 (Day  1), Visit 3 (Day  30), and Visit 4 (Day 60)
•Receipt of prohibited medication or prohibited vaccine prior to stud y vaccination at 
Visit 2 (Day  1), Visit 3 (Day  30), and Visit 4 (Day  60)
Additional potential deviations that may  result in the exclusion of a participant from the 
PPpopulation for specific immunogenicit y analyses (dependi ng on the time point) include:
•Failure to receive study  vaccine at Visit 6(Month [ADDRESS_1070190])
•Receipt 
of prohibited medication or prohibited vaccine prior to a blood sample collection
•Collection of blood sample outside of the pre -specified window ( as descr ibed in 
Section 1.3)
The final determination on protocol deviations, and th ereby [CONTACT_778745], will be made prior to the final unblinding of the database. Participants will be 
included in the vaccination group to which they  are randomized for the analy sis of 
immunogenicit y data using the PP population.
A supportive anal ysis using the Full Anal ysis Set (FAS) population will also be performed 
for the primary  immunogenicity  endpoints. The FAS population consists of all randomized 
participants who received at least [ADDRESS_1070191] 1serology  result. 
Participants will be included in the vaccination group to which they are randomized for the 
analysis of immunogenicity  data using the FAS population. 
9.5.2 Safety Analysis P opulations
Safety  anal yses will be conducted in the All Participants as Treated (APaT) population, 
which consists of all randomized participants who received at least 1dose of study  
vaccination. Participants will be included in the group corresponding to the study  vaccination 
they actuall y received for the anal ysis of safety  data using the APaT population . 
This will be 
the group to which they  are randomized except for participants who take incorrect study 
vaccination; such participants will be included in the group corresponding to the study  
vaccination actually  received. Safet y parameters for cross -treated subjects (received 
vaccination both from v114 and Prevnar13) will be summarized separatel y. At least 
1temperature measurement obtained subsequent to st udy intervention is required for 
inclusion in the analy ses of temperature.
07X67T
PRODUCT: V114 79
PROTOCOL/AMENDMENT N O.: 022 -04 
V114 -022-04FINAL PROTOCOL 02-APR -2019
9.6 Statistical Methods
Statistical testing and inference for immunogenicity  and safet y anal yses are described in 
Section 9.6.1 and Section 9.6.2, respectivel y. Section 9.6.3 describes how demographic and 
baseline characteristics will be summarized.
9.6.1 Statistical Methods for Immunogenicity Analyses
This section describes the statistical methods that address the primary and secondary 
immunogenicit y objectives. Methods related to exploratory objectives will be described in 
the supplemental s tatistical analysis plan.
Immunogenicit y anal yses will be conducted for each of the 15 pneumococcal serot ypes in 
V114 separatel y. To address the primary  immunogenicity  objective, evaluation of the IgG 
GMCs at 30 day s following the 3rddose of V114 andPrevnar 13™ (Day  90) will include 
descriptive summaries and within- group 95% CI s to be calculated for each vaccination 
group . Point estimates for the IgG GMCs will be calculated b y exponentiating the estimates 
of the mean of the natural log values. The within -group CIs will be derived by  [CONTACT_528885] s of the mean of the natural log values based on the t -distribution. 
A similar statistical approach will be used to evaluate the OPA responses at 30days 
following the 3rddose of V114 andPrevnar 13™ (Day  90). 
Descriptive statistics with point estimates and within -group 95% CIs will be provided for all 
other immunogenicit y endpoints. For the continuous endpoints, a similar statistical approach 
will be used as described above for the primary  endpoint . 
Point estimates will be calculated 
by [CONTACT_778746] -group 
CIs will be derived b y exponentiating the CIs of the mean of the natural l og values based on 
the t-distribution. For the dichotomous endpoints, the within- group CIs will be calculated 
based on the exact method proposed b y Clopper and Pearson [Clopper, C. J. and Pearson, E. 
S. 1934] .
Reverse Cumulative Distribution Curves for IgG concentrations and OPA titers 
will be 
graphicall y displayed b y seroty pe at Day  90. A detailed anal ysis strategy  for immunogenicit y 
endpoints is listed in Table 5.
07X67T
PRODUCT: V114 80
PROTOCOL/AMENDMENT N O.: 022 -04 
V114 -022-04FINAL PROTOCOL 02-APR -2019
Table 5 Analy sis Strategy  for Immunogenicit y Variables
Endpoint/Variable
(Description, Time Point)Prim ary vs. 
Supportive 
Approach†Statistical 
MethodAnalysis 
PopulationMissing 
Data 
Approach
Prim ary Endpoints
IgG GMCs at Day 90PDescriptive 
Statistics
(estimate, 95% CI)PPMissing data 
will not be 
imputedS FAS
Secondary Endpoints
OPA GMTs at Day 90 P Descriptive 
Statistics
(estimate, 95% CI)PP Missing data 
will not be 
imputed
GMFR and % sof participants with a ≥4-fold 
rise from Day 1 to Day 90 for both IgG and 
OPA responsesPDescriptive 
Statistics
(estimate, 95% CI)PPMissing data 
will not be 
imputed
† P=Primary approach; S=Supportive approach.
CI=Confidence Interval; FAS =Full Analysis Set; GMC = Geom etric Mean Concentration; GMT = Geometric 
Mean Titer; IgG =Immunoglobulin G; OPA =Opsonophagocytic Activity; PP =Per-Protocol.
To address the exploratory immunogenicit y objectives aiming to evaluate the IgGGMCs at 
30days following the 3rddose of V114 andPrevnar 13™ (Day  90)between vaccination 
groups , the serot ype-specific IgG GM Cs will be compared between vaccination groups 
through the estimation of serotype -specific IgG GMC ratios for each of the 15 seroty pes in 
V114. Estimation of the IgG GMC ratios and computation of the corresponding 95% CIs will 
be calculated using a constrained longitudinal data anal ysis (cLDA) method proposed by  
[CONTACT_165381] [L iang, K -Y and Zeger, S. L. 2000] . Details regarding the cLDA models 
will be included in the supplemental statistical analy sis plan .
9.6.2 Statistical Methods for Safety Analyses
Safety
 and tolerability  will be assessed b y clinical review of all relevant parameters 
separately  for adults and pediatric participants including AEs and postvaccination 
temperature measurements.
The anal ysis strategy  of safet y parameters is summarized in Table 6. The proportion of 
participants with solicited injection -site AEs (redness/ery thema, swelling, tenderness/pain 
from Day  1 to Day  5postvaccination for adult participants, and redness/ery thema, swelling, 
tenderness/pain, and hard lump from Day  1 to Day 14postvaccination for pediatric 
participants ) and solicited sy stemic AEs (muscle pain/my algia, joint pain/arthralgia, 
headache, and tiredness/fatigue from Day  1 to Day  14 postvaccination for adult participants ,
and muscle pain/my algia, join t pain/arthralgia, headache, tiredness/fatigue , and hives and 
07X67T
PRODUCT: V114 81
PROTOCOL/AMENDMENT N O.: 022 -04 
V114 -022-04FINAL PROTOCOL 02-APR -2019
welts for pediatric participants ) will be provided along with the corresponding within -group 
95% CI s (based on the exact binomial method proposed by [CONTACT_93325] [Clopper, C. 
J. and Pearson, E. S. 1934] ). In addition, the broad AE categories consisting of the proportion 
of participants wit h any AE, a vaccine -related AE, a SAE, an AE which is both vaccine -
related and serious, discontinuation due to an AE, and the proportion of participants who died 
will be summarized in the same manner separately  for adult and pediatric participants . The 
proportion of participants with maximum temperature measurements meeting the Brighton 
Collaboration cut points (from Day  1 through Day 5 postvaccination for adult participants,
and Day  1 through Day  7 for pediatric participants ) will also will be provided along with the 
corresponding within -group 95% CI s. Point estimates by  [CONTACT_778747] y parameters (specific AE terms and system organ class terms). 
The anal ysis of safet y parameters will be evaluated separately for adul t and pediatric 
participants at 3 separate time points: (1) following administration of any of the 3 doses of 
V114 andPrevnar 13™ (combined across each of the vaccinations), (2) following 
administration of PNEUMOVAX™23 (administered [ADDRESS_1070192]) , and 
(3)following administration of a 4thdose of V114 or Prevnar 13™ (administered [ADDRESS_1070193]) . Descriptive summaries of AEs following administration of any of the 
3doses of V114 or Prevnar 13™ will include NSAE within 14 day s of vaccination and 
SAEs /special events of interest occurring Day  [ADDRESS_1070194] (prior to 
vaccination with PNEUMOVAX™23 or a 4thdose of V114 or Prevnar 13™). Descriptive 
summaries of AEs following administration of PNEUMOVAX™ will include NSAEs within 
14 day s of vaccination and SAEs /special events of interest occurring Month [ADDRESS_1070195] (Day  1 relative to vaccination w ith PNEUMOVAX™23) through Month [ADDRESS_1070196] (Day 30 relative to vaccination with PNEUMOVAX™23). Descriptive 
summaries of AEs following administration of a 4thdose of V114 or Prevnar 13™ will 
include NSAEs within 14 day s of vaccination and SAEs /special events of interest occurring 
Month [ADDRESS_1070197] (Day  1 relative to vaccination with a 4thdose of V114 or 
Prevnar 13™) through Month [ADDRESS_1070198] (Day  30 relative to vaccination with a 4th
dose of V114 or Prevnar 13™).
The rate of SAEs, vaccine -related SAEs and death that occur throughout the entire stud y 
follow -up period will also be summarized per 1000 person -years of follow -up by  [CONTACT_46372]. 
In addition, the proportion of participants who 
havenew onset and/or worsening of GVHD as 
well as relapse and progression of the underl ying disease (ie, the disease for which the 
allo
-HSCT was performed [see inclusion c riterion 2 in Section 5.1]) during study 
participation will be summarized descriptivel y. Limited summaries may  also be generated 
following each of the 3 doses of vaccination of V114 or Prevnar 13™.
Safety  anal yses will be based on observed data (ie, no imputation of missing data).
07X67T
PRODUCT: V114 82
PROTOCOL/AMENDMENT N O.: 022 -04 
V114 -022-04FINAL PROTOCOL 02-APR -2019
Table 6 Analy sis Strategy for Safety  Parameters 
Safety Endpoint95% CI for Within -
Group ComparisonDescriptive Statistics
Injection -site redness /erythema (Days 1 to 5for 
adult participants and Day 1 to Day 14 for pediatric 
participants )†X X
Injection -site swelling (Days 1 to 5 for adult 
participants and Day 1 to Day 14 for pediatric 
participants )†X X
Injection -site tenderness /pain (Days 1 to 5 for adult 
participants and Day 1 to Day 14 for pediatric 
participants ) †X X
Injection -site hard lump/induration for pediatric 
participants (Days 1 to 14) †
Muscle pain /myalgia (Days 1 to 14)†X
XX
X
Joint pain /arthralgia (Days 1 to 14)†X X
Headache (Day s 1 to 14)†X X
Tiredness /fatigue (Days 1 to 14)†X X
Hives or welts/ urticarial for pediatric participants
(Day s 1 to 14)†
Any AE‡X
XX
X
Any vaccine -related AE‡X X
Any SAE‡X X
Any vaccine -related SAE‡X X
Discontinuation due to AE‡X X
Death‡X X
Maximum temperature measurements meeting the 
Brighton Collaboration cut points (Days 1 to 5 for 
adult participants and Day 1 to Day 7 for pediatric 
participants )X X
Specific AEs by[CONTACT_766086] X
†Includes solicited events only.
‡These endpoints are broad adverse event categories. For example, descriptive statistics for the safety endpoint 
of “Any AE” will provide the number and percentage of participants with at least 1AE.
AE=adverse event; CI = confidence interval; PT = prefer red term; SAE =serious adverse event; SOC =
System  Organ Class; X =results will be provided.
9.6.3 Demographic and Baseline Characteristics
The comparability  of the vaccination groups for each relevant demographic and baseline 
characteristic will be assessed b y the use of summary  tables . No statistical hy pothesis tests 
will be performed on these characteristics. The number and percentage of pa rticipants 
screened and randomized and the primary  reasons for screening failure and discontinuation 
will be display ed. Demographic variables (eg, age, race, and gender), baseline characteristics, 
07X67T
PRODUCT: V114 83
PROTOCOL/AMENDMENT N O.: [ADDRESS_1070199] to enable a benefit -
risk assessment.
Study  enrollment is likely  to be ongoing a t the time of any  interim analy ses. Blinding to 
intervention assignment will be maintained at all investigational sites. The results of interim 
analyses will not be shared with the investigators prior to the completion of the study. 
Participant -level unbli nding will be restricted to an external unblinded statistician performing 
the interim anal ysis.
The DMC will serve as the primary  reviewer of the results of the safet y interim anal yses and 
will make recommendations for discontinuation of the study or proto col modifications to an 
Executive Oversight Committee of the Sponsor (see Appendix 1 for details on the 
Committees Structure for this study ). If the DMC recommends modifications to the design of 
the protocol or discontinuation of the study, this Executive Oversite Committee (and 
potentially  other limited Sponsor personnel) may  be unblinded to results at the intervention 
level in order to act on these recommendations. The extent to which individuals are 
unblinded with respect to results of interim anal yses will be documented b y the unblinded 
statistician . Additional logistical details will be provided in the DMC Charter. 
Intervention- level results from the safety  interim analy sis will be provided by  [CONTACT_63540] . Prior to final study unblinding, the unblinded statistician will not be 
involved in any  discussions regarding modifications to the protocol, statistical methods, 
identification of protocol deviations, or data validation efforts after the interim analyses.
9.8 Multiplicity
Noadjustment will be made for multiplicity .
9.9 Sample Size and Power Calculations
9.9.1 Sample Size and Power for Immunogenicity Analyses
This is a descriptive study. This study  will randomize approximately  150 participants into 
the V114 group and 150participants into the Prevnar 13™ group . It is assumed that 
approximately  105participants per vaccination group will be evaluable for PP
immunogenicit y anal yses at Day  90 (based on a 70% evaluability  rate).
07X67T
PRODUCT: V114 84
PROTOCOL/AMENDMENT N O.: 022 -04 
V114 -022-04FINAL PROTOCOL 02-APR -2019
The width of the within- group 95% CIs for the seroty pe-specific IgG GMCs depend on the 
sample size, variability  of the natural log concentrations, and the magnitude of the IgG GMC. 
In Table 7, 95% CIs for various hy pothetical Day [ADDRESS_1070200] deviation estimates for the natural log titers are displayed.
Table 7 Within -Group 95% CI s for Vary ing Hy pothetical IgG GMCs and Vary ing 
Standard Deviations with 105Evaluable Participants in Each Vaccination Group
Standard 
Deviation of 
natural log titers†Serotype- specific IgG GMC†
1 5 10
1.0 (0.83, 1.21) (4.13, 6.05) (8.26, 12.10 )
1.5 (0.75, 1.33) (3.75, 6.66) (7.51, 13.32 )
2.0 (0.68, 1.47) (3.41, 7.33) (6.82, 14.66)
†The estimates of the standard deviation, GMT and GMC arerepresentative of those observed in 
V114 -006.
CI=Confidence Interval; GMC= Geometric Mean Concentration; IgG= Immunoglobulin G.
9.9.[ADDRESS_1070201] 1SAE in this study  depends on the 
number of participants vaccinated and the underlying percentage of participants with a SAE 
in the study  population. Calculations below assume that 100% of the randomized participants 
will be evaluable for safety  analy ses. 
For adult participant s, there is an 80% chance of observing at least 1SAE among 
125participants in the V114 group if the underl ying incidence of a SAE is 1.3% (1 of every  
77participants receiving the vaccine). There is a 50% chance of observing at least 1 SAE 
among 125participants in the V114 group if the underly ing incidence of a SAE is 0.6% (1 of 
every  182participants receiving the vaccine). If no SAEs are observed among the 
125participants in the V114 group, this stud y will provide 97.5% confidence that the 
underly ing percentage of participants with a SAE is < 2.9% (1 in every  35participants) in the 
V114 group . 
For pediatric participa nts, there is an 80% chance of observing at least 1 SAE among 
25participants in the V114 group if the underl ying incidence of a SAE is 6.2
% (1 of every  
16participants receiving the vaccine). There is a 50% chance of observing at least 1 SAE 
among 125 participants in the V114 group if the u nderly ing incidence of a SAE is 2.7% (1 of 
every  37 participants receiving the vaccine). If no SAEs are observed among the 
25participants in the V114 group, this stud y will provide 97.5% confidence that the 
underly ing percentage of participants with a SAE is <13.7% (1 in every  7participants) in the 
V114 group . 
07X67T
PRODUCT: V114 85
PROTOCOL/AMENDMENT N O.: 022 -04 
V114 -022-04FINAL PROTOCOL 02-APR -2019
9.10 Subgroup Analyses
Subgroup anal yses (e.g., use of s ystemic steroids within 14 day s before randomization
[Day 1], age category ) will be performed for the primary  immunogenicity  endpoints and /or
selected safet y endpoints (summary  of AEs and summary  of solicited AEs). Details of 
subgroup anal yses will be documented in the supplemental statistical anal ysis plan .
9.11 Compliance (Medication Adherence)
Compliance will not be calculated. However, t he numbe r and proportion of randomized 
participants receiving each vaccination will be summarized (Section 9.12).
9.[ADDRESS_1070202]: V114 86
PROTOCOL/AMENDMENT N O.: 022 -04 
V114 -022-04FINAL PROTOCOL 02-APR -2019
10 SUPPORTING DOCUMENTATION AND OPERATIONAL
CONSIDERATIONS
10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.[ADDRESS_1070203] for Clinical Trials
[COMPANY_006] Sharp and Dohme Corp., a subsidiary of [COMPANY_006] & Co., Inc. (MSD)
Code of Conduct for Interventional Clinical Trials
I. Introduction
A.Purpose
MSD, through its subsidiaries, conducts clinical trials worldwide to evaluate the safety and effectiveness of our 
products. As such, we are committed to designing, implementing, conducting, analyzing and reporting these trials 
in compliance with the highest ethical and scientific standards. Protection of participant s inclinical trials is the 
overriding concern in the design of clinical trials . In all cases, M SD clinical trials wi ll be conducted in compliance 
with local and/or national regulations (eg, International Council for Harmonisation Good Clinical Practice [ICH -
GCP]) and in accordance with the ethical principles that have their origin in the Declaration of Helsinki.
B.Scop e
Highest ethical and scientific standards shall be endorsed for all clinical interventional investigations sponsored by 
[CONTACT_19481] (parties) employed for their execution (eg, contract research organizations, 
collaborative research efforts). This Code is not intended to apply to trials that are observational in nature, or 
which are retrospective. Further, this Code does not apply to investigator -initiated trials , which are not under the 
full control of M SD.
II.Scientific Issues
A.Trial Conduct
1.Trial Design
Except for pi[INVESTIGATOR_19354], clinical trial protocols will be hypothesis -driven to assess safety, 
efficacy, and/or pharmacokinetic or pharmacodynamic indices of M SD or comparator products. 
Alternatively, M SDmay conduct ou tcomes research trials, trials to assess or validate various endpoint 
measures, or trials to determine patient preferences, etc.
The design (ie, participant population, duration, statistical power) must be adequate to address the specific
purpose of the tr ial. P articipants must meet protocol entry criteria to be enrolled in the trial. 
2.Site Selection
MSD selects investigative sites based on medical expert[INVESTIGATOR_18700], access to appropriate participants, adequacy of 
facilities and staff, previous performance in clinical trials, as well as budgetary considerations. Prior to trial 
initiation, sites are evaluated by M SD personnel to assess the ability to successfully conduct the trial.
3.Site Monitoring/Scientific Integrity
Investigative t rial sites are monitored to assess compliance with the trial protocol and general principles of 
Good Clinical Practice (GCP). MSD reviews clinical data for accuracy, completeness, and consistency. Data 
are verified versus source documentation according to standard operating procedure s. Per M SD policies and 
procedures, if fraud, scientific/research misc onduct, or serious GCP -noncompliance is suspected, the issues 
07X67T
PRODUCT: V114 87
PROTOCOL/AMENDMENT N O.: 022 -04 
V114 -022-04FINAL PROTOCOL 02-APR -2019
areinvestigated. When necessary, the clinical site will be closed, the responsible regulatory authorities and 
ethics review committees notified .
B. Publication and Authorship
Regardless of trial outcome, MSD commits to publish primary and secondary results o f its registered trials of 
marketed products in which treatment is assigned, according to the prespecified plans for data analysis. To the 
extent scientifically appropriate, M SDseeks to publish the results of other analyses it conducts that are important 
to patients, physicians, and payers. Some early phase or pi[INVESTIGATOR_26346] -generating rather 
than hypothesis testing , in such cases, publication of results may not be appropriate since the trial may be 
underpowered and the analyses complicated by [CONTACT_19482].
MSD’s policy on authorship is consistent with the re commendations published by [CONTACT_26399] (ICMJE). In summary, authorship should reflect significant contri bution to the design and 
conduct of the trial, performance or interpretation of the analysis, and/or writing of the manuscript. All named 
authors must be able to defend the trial results and conclusions. M SD funding of a trial will be acknowledged in 
publications.
III.Participant Protection
A. Ethics Committee Review (Institutiona Review Board [ IRB]/Independent Ethics Committee [ IEC])
All clinical trials will be reviewed and approved by [CONTACT_2717]/IEC before being initiated at each site. Significant 
changes or revisions to the protocol will be approved by [CONTACT_63543], except 
changes required urgently to prot ect participant safety that may be enacted in anticipation of ethics committee 
approval. For each site, the ethics committee and M SDwill approve the participant informed consent form.
B. Safety
The guiding principle in decision -making in clinical trials i s that participant welfare is of primary importance. 
Potential participants will be informed of the risks and benefits of, as well as alternatives to, trial participation. At 
a minimum, trial designs will take into account the local stand ard of care.
All p articipation in M SD clinical trials is voluntary. Participants enter the trial only after informed consent is 
obtained . Participants may withdraw from a n MSD trial at any time, without any influence on their access to, or 
receipt of, medical care that may otherwise be available to them.
C. Confidentiality
MSD is committed to safeguarding participant confidentiality, to the greatest extent possible. Unless required by 
[CONTACT_2371], only the investigator, Sponsor (or representative), ethics committee, and/or regulator y authorities will have 
access to confidential medical records t hat might identify the participant by [CONTACT_2300].
D. Genomic Research
Genomic research will only be conducted in accordance with a protocol and informed consent authorized by [CONTACT_63544] c ommittee.
IV. Financial Considerations
A. Paym ents to Investigators
Clinical trials are time -and labor -intensive. It is M SD’s policy to compensate investigators (or the sponsoring 
institution) in a fair manner for the work performed in support of M SD trials. M SD does not pay incentives to 
enroll participants in its trials. However, when enrollment is particularly challenging, additional payments may be 
made to compensate for the time spent in extra recruiting efforts.
07X67T
PRODUCT: V114 88
PROTOCOL/AMENDMENT N O.: 022 -04 
V114 -022-04FINAL PROTOCOL 02-APR -2019
MSD does not pay for participant referrals. Howeve r, MSDmay compensate referring physicians for time spent 
on chart review to identify potentially eligible participants.
B.Clinical Research Funding
Informed consent forms will disclose that the trial is sponsored by M SDand that the investigator or spons oring 
institution is being paid or provided a grant for performing the trial. However, the local ethics committee may 
wish to alter the wording of the disclosure statement to be consistent with financial practices at that institution. As 
noted above, all publications resulting from M SD trials will indicate M SD as a source of funding.
C. Funding for Travel and Other Requests
Funding of travel by [CONTACT_19488] (eg, to scientific meetings, investigator meetings, etc.) will be 
consistent with local guidelines and practices .
V. Investigator Commit ment
Investigators will be expected to review M SD’s Code of Conduct as an appendix to the trial protocol, and in signing the 
protocol, agree to support these ethical and scientific standards.
10.1.2 Financial Disclosure
Financial Disclosure requirements are outlined in the US Food and Drug Administration 
Regulations, Financial Disclosure b y Clinical I nvestigators (21 CFR Part 54). I t is the 
Sponsor's responsibility  to determine, based on these regulations, whet her a request for 
Financial Disclosure information is required. It is the investigator's/subinvestigator's 
responsibility  to comply  with any  such request.
The investigator/subinvestigator(s) agree, if requested by  [CONTACT_19489] 21 
CFR Part 54, to provide his/her financial interests in and/or arrangements with the Sponsor to 
allow for the submission of complete and accurate certification and disclosure statements. 
The investigator/subinvestigator(s) further agree to provide this information on a 
Certification/Disclosure Form, commonly  known as a financial disclosure form, provided by  
[CONTACT_1034]. The investigator/subinvestigator(s) also consent to the transmission of this 
information to the Sponsor in the [LOCATION_002] for these purposes. This may  involve the 
transmission of information to countries that do not have laws protecting personal data.
10.1.3 Data Protection
Participants will be assigned a unique identifier by [CONTACT_1034]. An y participant records or 
datasets that are transferred to the Sp onsor will contain the identifier only; participant names 
or an y information that would make the participant identifiable will not be transferred.
The participant must be informed that his/her personal study -related data will be used by  [CONTACT_778748]. The level of disclosure must also be 
explained to the participant. 
The participant must be informed that his/her medical records may  be examined by  [CONTACT_778749] S ponsor, by  
[CONTACT_6667]/IEC members, and b y inspectors from regulatory authorities.
07X67T
PRODUCT: V114 89
PROTOCOL/AMENDMENT N O.: 022 -04 
V114 -022-04FINAL PROTOCOL 02-APR -2019
[IP_ADDRESS] Confidentiality of Data
By [CONTACT_12570], the investigator affirms to the Sponsor that information furnished to 
the investigator by [CONTACT_1034] w ill be maintained in confidence, and such information will 
be divulged to the IRB, IEC,or similar or expert committee; affiliated institution and 
employ ees, only  under an appropriate understanding of confidentialit y with such board or 
committee, affiliated institution and employ ees. Data generated b y this study will be 
considered confidenti al by  [CONTACT_093], except to the extent that it is included in a 
publication as provided in the Publications section of this protocol.
[IP_ADDRESS] Confidentiality of Participant Records
By [CONTACT_12570], the investigator agrees that the Sponsor (or Sponso r representative), 
IRB/IEC, or regulatory  authority  representatives may  consult and/or cop y study  documents to 
verify  worksheet/ CRF report form data. By  [CONTACT_17317], the participant agrees 
to this process. If stud y documents will be photocopie d during the process of verify ing 
worksheet/ CRF information, the participant will be identified b y unique code only; full 
names/initials will be masked prior to transmission to the Sponsor.
By [CONTACT_12570], the investigator agrees to treat all par ticipant data used and 
disclosed in connection with this study  in accordance with all applicable privacy  laws, rules 
and regulations.
[IP_ADDRESS] Confidentiality of IRB/IEC Information
The Sponsor is required to record the name [CONTACT_19525]/IEC that reviews and 
approves this study . The Sponsor is also required to document that each IRB/IEC meets 
regulatory  and ICH GCP requirements b y requesting and maintaining records of the names 
and qualifications of the IRB/IEC members and to make these records available for 
regulatory  agency  review upon request b y those agencies.
10.1.4 Committees Structure
[IP_ADDRESS] Scientific Advisory Committee
This study  was developed in collaboration with a Scientific Advisory  Committee (SAC). The 
SAC is comprise d of both Sponsor and non -Sponsor scientific experts who provide input 
with respect to study  design, interpretation of study  results, and subsequent peer -reviewed 
scientific publications.
[IP_ADDRESS] Executive Oversight Committee
The Executive Oversight Committee (EOC) is comprise d  of members of Sponsor Senior 
Management. The EOC will receive and decide upon any  recommendations made by  [CONTACT_63547] .
07X67T
PRODUCT: V114 90
PROTOCOL/AMENDMENT N O.: 022 -04 
V114 -022-04FINAL PROTOCOL 02-APR -2019
[IP_ADDRESS] External D ata Monitoring Committee
To supplement the routine study monitoring outlined in this protocol, an external DMC will 
moni tor the interim data from this study. The voting members of the committee are external 
to the Sponsor. The members of the DMC must not be involved with the study in an y other 
way (eg, they  cannot be study  investigators) and must have no competing interests that could 
affect their roles with respect to the study .
The DMC will make recommendations to the EOC regarding steps to ensure both participant 
safet y and the continued ethical integrity of the study. Also, the DMC will review interim 
study  results, cons ider the overall risk and benefit to study participants (Section 9.7) and 
recommend to the EOC whether the stud y should continue in accordance with the protocol.
Specific details regarding composition, responsibilities, and governance, including the roles 
and responsibilities of the various members and the Sponsor protocol team ; meeting 
facilitation; the study  governance structure; and requirements for and proper documentation 
of DMC reports, minutes, and recommendations will be described in the DMC charter that is 
reviewed and approved by [CONTACT_63548].
10.1.[ADDRESS_1070204] (FDAA A) of 2007 
and the European Medicines Agency (EMA) clinical trial Directive 2001/20/EC, the Sponsor 
of the study  is solel y responsible for determining whether the stud yand its results are subject
to the requirements for submission to http://www.clinicaltr ials.gov, 
www.clinicaltrialsregister.eu or other local registries. MSD, as Sponsor of this study , will 
review this protocol and submit the information necessary  to fulfill these requirements. MSD 
entries are not limited to FDAAA or the EMA clinical trial d irective mandated trials. 
Information posted will allow participants to identify  potentiall y appropriate studies for their 
disease conditions and pursue participation b y calling a central contact [CONTACT_778750] s and study  site contact [CONTACT_3031].
07X67T
PRODUCT: V114 91
PROTOCOL/AMENDMENT N O.: [ADDRESS_1070205] the study  in an efficient and 
diligent manner and in conformance with this protoc ol; generally accepted standards of G CP
(eg, International Conference on Harmonization of Technical Requirements for Registration 
of Pharmaceuticals for Human Use GCP : Consolidated Guideline and other generally  
accepted standards of good clinical practice); and all applicable federal, state and local laws, 
rules and regulations relating to the conduct of the clinical study. The Code of Conduct, a 
collection of goals and considerations that govern the ethical and scientific conduct of 
clinical investigations sponsored b y MSD, is provided i n this appendix under the Code of 
Conduct for Clinical Studies.
The investigator agrees not to seek reimbursement from participants, their insurance 
providers, or from government programs for procedures included as part of the study  
reimbursed to the investigator b y the Sponsor.
The investigator will promptly  inform the Sponsor of an y regulatory authority inspection 
conducted for this study .
The investigator agrees to provide the Sponsor with relevant information fro m inspection 
observations/findings to allow the Sponsor to assist in responding to an y citations resulting 
from regulatory  authority inspection and will provide the Sponsor with a copy  of the 
proposed response for consultation before submission to the regulatory  authority . 
Persons debarred from conducting or working on clinical studies by  [CONTACT_63550]’s studies. The investigator 
will immediately  disclose in writing to the Sponsor i f any person who is involved in 
conducting the study  is debarred or if any  proceeding for debarment is pending or, to the best 
of the investigator’s knowledge, threatened.
10.1.8 Data Quality Assurance
All participant data relating to the stud y will be recorded o n printed or electronic CRF unless 
transmitted to the Sponsor or designee electronically (eg, laboratory data). The investigator 
or qualified designee is responsible for verify ing that data entries are accurate and correct by  
[CONTACT_55896] y or electronically  signing the CRF.
Detailed information regarding Data Management procedures for this protocol will be 
provided separatel y.
The investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF.
07X67T
PRODUCT: V114 92
PROTOCOL/AMENDMENT N O.: [ADDRESS_1070206] permit study -related monitoring, audits, IRB/IEC review, and 
regulatory  agency  inspections and provide direct access to source data documents.
Study  documentation will be promptly  and fully  disclosed to the Sponsor by [CONTACT_126564], 
copy ing, review, and audit at reasonable times b y representatives of the Sponsor or an y 
regulatory  authorities. The investigator agrees to promptly  take an y reasonable steps that are 
requested b y the Sponsor or any regulatory  authorit ies as a result of an audit or inspection to 
cure deficiencies in the stud y documentation and worksheets/CRFs .
The Sponsor or designee is responsible for the data management of this study  including 
quality checking of the data.
Study  monitors will perform ongoing source data review and verification to confirm that data 
entered into the CRF b y authorized site personnel are accurate, complete, and verifiable from 
source documents; that the safet y and righ ts of participants are being protected; and that the 
study  is being conducted in accordance with the currentl y approved protocol and an y other 
study  agreements, ICH GCP, and all applicable regulatory  requirements.
Records and documents, including signed IC F, pertaining to the conduct of this study  must 
be retained b y the investigator for 15 ye ars after study  completion unless local regulations or 
institutional policies require a longer retention period. No records may be destroyed during 
the retention period without the written approval of the Sponsor. No records may  be 
transferred to another location or part y without written notification to the Sponsor.
10.1.9 Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrit y of the data collected. Source documents are filed at the investigator’s site.
Data reported on the CRF or entered in the eCRF that are transcribed from source documents 
must be consistent with the source documents or the discrepancies must be explained. The 
investigator may  need to request previous medical records or transfer records, depending on 
the study . Also, current medical records must be available.
10.1.10 Study and Site Closure
The Sponsor or its designee may  stop the study  or study  site part icipation in the study  for 
medical, safety , regulatory , administrative, or other reasons consistent with applicable laws, 
regulations, and GCP.
In the event the Sponsor prematurel y terminates a particular stud y site, the Sponsor will 
promptly  notify  that s tudy site’s IRB/IEC.
07X67T
PRODUCT: V114 93
PROTOCOL/AMENDMENT N O.: 022 -04 
V114 -022-04FINAL PROTOCOL 02-APR -2019
10.2 Appendix 2: Clinical Laboratory Tests
•The tests detailed in Table 8will be performed according to local requirements .
•Protocol -specific require ments for inclusion or exclusion of participants are detailed in 
Section 5of the protocol.
•Additional tests may  be performed at an y time during the study as determined necessary 
by [CONTACT_43215].
Table 8 Protocol -Required Safet y Laboratory  Assessments
Laboratory 
AssessmentsParameters
Hem atology Platelet Count RBC Indices:
MCV
MCH
%ReticulocytesWBC count with 
Differential:
Neutrophils
Lymphocytes
Monocytes
Eosinophils
BasophilsRBC Count
Hem oglobin
Hem atocrit
Chemistry Blood Urea 
Nitrogen (BUN)Potassium Aspartate 
Aminotransferase
(AST)/ Serum 
Glutamic -
Oxaloacetic 
Transaminase 
(SGOT)Total bilirubin (and 
direct bilirubin, if 
total bilirubin is 
elevated above the 
upper limit of 
normal)
Albumin Bicarbonate Chloride Phosphorous
Creatinine Sodium Alanine 
Aminotransferase
(ALT)/ Serum 
Glutamic -Pyruvic 
Transaminase 
(SGPT)Total Protein
Glucose Calcium Alkaline 
phosphatase
Other Screening 
TestsSerum or urine β -hCG pregnancy test (as needed for WOCBP)
β-hCG = β human chorionic gonadotropin; WOCBP = w oman/women of childbearing potential.
The i nvestigator (or medically  qualified designee) must document their review of each 
laboratory  safet y report.
07X67T
PRODUCT: V114 94
PROTOCOL/AMENDMENT N O.: 022 -04 
V114 -022-04FINAL PROTOCOL 02-APR -2019
10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
10.3.1 Definition of AE
AE definition
•An AE is an y untoward medical occurrence in a clinical study participant, temporally 
associated with the use of study  intervention , whether or not considered related to the 
study  intervention.
•NOTE: An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) temporally  
associated with the use of a study  intervention.
•NOTE: For purposes of AE definition, study  intervention (also referred to as Sponsor’s 
product) includes an y pharmaceutical product, biological product, vaccine, device, 
diagnostic agent, or protocol specified procedure whether investigati onal (including 
placebo or active comparator product) or marketed, manufactured b y, licensed by, 
provided b y, or distributed by [CONTACT_63553].
Events meeting the AE definition
•Any abnormal laboratory test results (hematology , clin ical chemistry , or urinaly sis) or 
other safet y assessments (eg, ECG, radiological scans, vital signs measurements), 
including those that worsen from baseline, considered clinicall y significant in the medical 
and scientific judgment of the investigator.
•Exacerbation of a chronic or intermittent pre -existing condition including either an 
increase in frequency  and/or intensity  of the condition.
•New conditions detected or diagnosed after stud y intervention administration even 
though it may  have been present bef ore the start of the study .
•Signs, sy mptoms, or the clinical sequelae of a suspected drug -drug interaction.
•Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
intervention or a concomitant medication.
•For all reports of overd ose (whether accidental or intentional) with an associated AE, the 
AE term should reflect the clinical s ymptoms or abnormal test result. An overdose 
without any  associated clinical sy mptoms or abnormal laboratory  results is reported using 
the terminology  “accidental or intentional overdose without adverse effect.”
•Any new cancer or progression of existing cancer .
07X67T
PRODUCT: V114 95
PROTOCOL/AMENDMENT N O.: 022 -04 
V114 -022-04FINAL PROTOCOL 02-APR -2019
Events NOT meeting the AE d efinition
•Medical or surgical procedure (eg, endoscop y, appendectom y): the condition that leads to 
the procedure is the AE.
•Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
•Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present or 
detected at the start of the study  that do not worsen.
•Surgery  planned prior to informed consent to treat a pre- existing condition that has not 
worsened.
•Refe r to Section 8.4.[ADDRESS_1070207] medical occurrence that, at any dose:
a.Results in death
b.Is life -threatening
•The term “ life-threatening ”in the definition of “serious” refers to an event in which 
the participant was at risk of death at the time of the event. It does not refer to an 
event, which h ypothetically  might have caused death, if it were more severe.
c.Requires inpatient hospi[INVESTIGATOR_1081]
•Hospi[INVESTIGATOR_19357], regardless of length of stay, even 
if the hospi[INVESTIGATOR_2138] a precautionary  measure for continued observation. (Note: 
Hospi[INVESTIGATOR_19358] a pre -existing c ondition that has not 
worsened is not an SAE. A pre -existing condition is a clinical condition that is 
diagnosed prior to the use of an MSD product and is documented in the participant’s 
medical history .
d.Results in persistent or significant disability/inca pacity
•The term disability  means a substantial disruption of a person’s ability  to conduct 
normal life functions.
07X67T
PRODUCT: V114 96
PROTOCOL/AMENDMENT N O.: 022 -04 
V114 -022-04FINAL PROTOCOL 02-APR -2019
•This definition is not intended to include experiences of relativel y minor medical 
significance such as uncomplicated headache, nausea, vomiti ng, diarrhea, influenza, 
and accidental trauma (eg, sprained ankle) that may interfere with or prevent 
every day life functions but do not constitute a substantial disruption.
e.Is a congenital anomaly/birth defect
•In offspring of participant taking the produ ct regardless of time to diagnosis.
f.Other important medical events
•Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that may 
not be immediately  life-threatening or result in death or hospi[INVESTIGATOR_43193] 1 
of the other outcomes listed in the above definition. These events should usually be 
considered serious.
Examples of such events include invasive or malignant cancers, intensive treatment in 
an emergency  room or at home for allergic bronchospasm, blood dy scrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug dependency 
or drug abuse.
10.3.3 Additional Events Reported
Additional events that require r eporting
In addition to the above criteria, AEs meeting either of the below criteria, although not 
serious per ICH definition, are reportable to the Sponsor.
•Is a cancer
•Is associated with an overdose
10.3.4 Recording AE and SAE
AE and SAE r ecording
•When an AE/SAE occurs, it is the responsibility  of the investigator to review all 
documentation (eg, hospi[INVESTIGATOR_1088], laboratory , and diagnostics reports) related to 
the event.
•The investigator will record all relevant AE/SAE information on the AE 
CRFs /worksheets at each examination.
07X67T
PRODUCT: V114 97
PROTOCOL/AMENDMENT N O.: 022 -04 
V114 -022-04FINAL PROTOCOL 02-APR -2019
•It is not acceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s medical 
records to the Sponsor in lieu of completion of the AE C RF page.
•There may  be instances when copi[INVESTIGATOR_63475] b y 
the Sponsor. I n this case, all participant identifiers, with the exception of the participant 
number, will be blinded on the copi[INVESTIGATOR_63476].
•The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. I n such cases, the diagnosis (not the 
individual signs/sy mptoms) will be documented as the AE/ SAE.
Assessment of Intensity /Toxicity
•An event is defined as “serious” when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, not when it is rated as severe.
•The investigator will make an assessment of intensity  for each AE and SAE (and other 
reportable safet y event) reported during the stud y and assign it to 1 of the following 
categories:
-Mild: An event that is easily  tolerated b y the participant, causing minimal discomfort 
and not interfering with every day activiti es (for pediatric studies, awareness of 
symptoms, but easily  tolerated).
-Moderate: An event that causes sufficient discomfort to interfere with normal 
every day activities (for pediatric studies definitel y acting like something is wrong).
-Severe: An event t hat prevents normal every day activities. An AE that is assessed as 
severe should not be confused with an SAE. Severe is a category  utilized for rating 
the intensity  of an event; and both AE and SAE can be assessed as severe (for 
pediatric studies, extremel y distressed or unable to do usual activities).
•Injection- site redness/erythema or swelling from the day  of vaccination through Day  5 
(for adult participants) or Day  14 (for pediatric participants) postvaccination will be 
evaluated b y maximum size .
•The investigator will make an assessment of toxicity  for each AE and SAE (and other 
reportable event) reported during the stud y. 
Toxicity  is only  being assessed for adults 
18years of age and older . 
Atoxicity  grade will be assigned to injection -site AEs, specific 
systemic AEs, other s ystemic AEs, and vital sign (temperature) AEs as shown in the 
following tables. The toxicity  grading scales used in this study  are adapted from the 
“FDA Guidance for Industry : Toxicity  Grading Scale for Healthy Adult and Adole scent 
Volunteers Enrolled in Preventive Vaccine Clinical Trials, September 2007.”
07X67T
PRODUCT: V114 98
PROTOCOL/AMENDMENT N O.: 022 -04 
V114 -022-04FINAL PROTOCOL 02-APR -2019
Injection Site Reaction 
to Study 
Vaccine/PlaceboaGrade 1 Grade 2 Grade 3 Grade 4
Injection -site AEs occurring Days 1 through 5 following receipt of study vaccine/placebo
Pain/Tenderness Does not interfere 
with activityRepeated use of non -
narcotic pain reliever 
>24 hours or 
interferes with 
activityAny use of narcotic 
pain reliever or 
prevents daily 
activityERvisit or 
hospi[INVESTIGATOR_2666]/Redness Size measured as
BSize measured as
C or DSize measured as
E→Necrosis or 
exfoliative dermatitis 
or results in ER visit 
or hospi[INVESTIGATOR_63477]/Swelling Size measured as 
BSize measured as
C or DSize measured as
E→Necrosis or ER visit 
or hospi[INVESTIGATOR_63478] -
narcotic pain reliever 
>24 hours or 
interferes with 
activityAny use of narcotic 
pain reliever or 
prevents daily 
activityER visit or 
hospi[INVESTIGATOR_63479] -site reaction that begins ≥ 6 days after receipt of study vaccine/placebo
Pain/tenderness
Erythema/Redness
Induration/Swelling
OtherDoes not interfere 
with activityRepeated use of non -
narcotic pain reliever 
>24 hours or 
interferes with 
activityAny use of narcotic 
pain reliever or 
prevents daily 
activityER visit or 
hospi[INVESTIGATOR_63480]: AE=adverse event; ER=emergency room; eVRC=electronic vaccine report card; SAE=serious adverse event
a Based upon information provided by [CONTACT_63554]. Eryt hema/Redness and 
Induration /Swelling are specific injection -site AEs with size designations of letters A through E →, based upon a graphic in 
the eVRC. Size A is not assigned a toxicity grade; however, injection -site AEs that measure size A should be re ported as 
adverse experiences. If the participant has an ER visit or is hospi[INVESTIGATOR_63481] -site AE, that AE is to be assigned a 
toxicity grade of 4, regardless of the size measured.
Specific Systemic AE Toxicity Grading Scale
System ic (General)Mild 
(Grade 1)Moderate 
(Grade 2)Severe 
(Grade 3)Potentially Life 
Threatening
(Grade 4)
Headache No interference with 
activityRepeated use of non -
narcotic pain reliever 
>24hours or some 
interference with 
activitySignificant; any use of 
narcotic pain reliever 
or prevents daily 
activityER visit or 
hospi[INVESTIGATOR_63482]; prevents 
daily activityER visit or 
hospi[INVESTIGATOR_63483]; prevents 
daily activityER visit or 
hospi[INVESTIGATOR_63480]: AE=adverse event; ER= emergency room
07X67T
PRODUCT: V114 99
PROTOCOL/AMENDMENT N O.: 022 -04 
V114 -022-04FINAL PROTOCOL 02-APR -2019
Other Systemic AE Toxicity Grading Scale
System ic IllnessaMild 
(Grade 1)Moderate 
(Grade 2)Severe 
(Grade 3)Potentially Life 
Threatening
(Grade 4)b
Illness or clinical AE 
(as defined according 
to applicable 
regulations)No interference with 
activitySome interference with 
activity not requiring 
medical interventionPrevents daily activity 
and required medical 
interventionER visit or 
hospi[INVESTIGATOR_63480]: AE=adverse event; ER=emergency room; eVRC= electronic vaccine report card; SAE= serious adverse event
aBased upon information provided by [CONTACT_63555] -up period. For SAEs reported beyond the primary safety follow -up period, grading will be based upon the 
initial report and/or follow -up of the event.
bAEs resulting in death will be assessed as Grade 4
Vital Sign (Temperature) Toxicity Grading Scale
Vital SignsaMild 
(Grade 1)Moderate 
(Grade 2)Severe 
(Grade 3)Potentially Life 
Threatening
(Grade 4)
Fever (°C)b
(°F)b38.0 to 38.4
100.4 to 101.138.5 to 38.9
101.2 to 102.039.0 to 40.0
102.1 to 104.0>40.0
>104.[ADDRESS_1070208] for all vital sign requirements
bOral temperature; no recent hot or cold beverages or smokin g
Assessment of c ausality
•Did the Sponsor ’s product cause the AE?
•The determination of the likelihood that the Sponsor ’s product caused the AE will be 
provided b y an investigator who is a qualified physician. The investigator’s signed/dated 
initials on the source document or worksheet that supports the causalit y noted on the AE 
form, ensures that a medically  qualified assess ment of causalit y was done. This initia lled 
document must be retained for the required regulatory time frame. The criteria below are 
intended as reference guidelines to assist the investigator in assessing the likelihood of a 
relationship between the test product and the AE based upon the available information.
•The following components are to be used to assess the relationship between the 
Sponsor ’s product and the AE; the greater the correlation with the components and 
their respective elements (in number a nd/or intensity ), the more likel y the Sponsor ’s 
product caused the AE :
-Exposure: Is there evidence that the participant was actuall y exposed to the 
Sponsor ’s product such as: reliable history, acceptable compliance assessment (diary , 
etc.), seroconversion 
or identification of vaccine virus in bodily  specimen?
07X67T
PRODUCT: V114 100
PROTOCOL/AMENDMENT N O.: 022 -04 
V114 -022-04FINAL PROTOCOL 02-APR -2019
-Time Course: Did the AE follow in a reasonable temporal sequence from 
administration of the Sponsor ’s product? I s the time of onset of the AE compatible 
with a vaccine -induced effect?
-Likely Cause: Is the AE not reasonabl y explained by  [CONTACT_63556], other drug(s)/vaccine(s), or other host or environmental factors ?
-Rechallenge: Was the participant re -exposed to the Sponsor ’s product in the study ?
-If yes, did the AE recur or worsen?
-If yes, this is a positive rechallenge.
-If no, this is a negative rechallenge.
(Note: This criterion is not applicable if: (1) the initial AE resulted in death or permanent 
disability , or (2) the study  is a single -dose vaccine study ); or (3) Spons or’s product(s) is/are 
used only  1 time.)
NOTE: IF A RECHALLENGE IS PL ANNED FOR AN AE THAT WAS SERI OUS AND 
MAY HAVE BEEN CAUSED BY [CONTACT_26370] ’S PRODUCT, OR I F RE -EXPOSURE 
TO THE SPONSOR ’S PRODUCT POSES ADDITIONAL POTENTIAL SI GNIFICANT 
RISK TO THE PARTI CIPANT THEN THE RECHALLENGE MUST BE APPROVED I N 
ADVANCE BY [CONTACT_63557], AND IF REQUI RED, THE 
IRB/IEC .
-Consistency with study intervention profile: Is the clinical/pathological 
presentation of the AE consistent with previous knowledge regardi ng the Sponsor ’s 
product or drug class pharmacology  or toxicology?
-The assessment of relationship will be reported on the CRFs /worksheets by [CONTACT_26368] a qualified phy sician according to his/her best clinical judgment, 
including consideration of the above elements.
-Use the following scale of criteria as guidance (not all criteria must be present to be 
indicative of a Sponsor ’s product relationship).
-Yes, there is a reasonable possibility  of Sponsor ’s product relationship:
-There is evidence of e xposure to the Sponsor ’s product. The temporal sequence of the 
AE onset relative to the administration of the Sponsor ’s product is reasonable. The 
AE is more likely  explained by  [CONTACT_1034] ’s product than by  [CONTACT_5748].
-No, there is not a reasonable possibility  of Sponsor ’s product relationship:
-Participant did not receive the Sponsor ’s product OR temporal sequence of the AE 
onset relative to administration of the Sponsor ’s product is not reasonable OR the AE 
07X67T
PRODUCT: V114 101
PROTOCOL/AMENDMENT N O.: 022 -04 
V114 -022-04FINAL PROTOCOL 02-APR -2019
is more likely  explained by  [CONTACT_778751] n the Sponsor’s product. (Also entered 
for a participant with overdose without an associated AE.)
•For each AE/SAE, the investigator must document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causalit y.
•There ma y be situations in which an SAE has occurred and the investigator has minimal 
information to include in the initial report to the Sponsor. However, it is very important 
that the investigator always make an assessment of causalit y for every event before the
initial transmission of the SAE data to the Sponsor.
•The investigator may change his/her opi[INVESTIGATOR_19954] -up 
information and send an SAE follow -up report with the updated causality  assessment.
•The causality  assessment is 1 of the cr iteria used when determining regulatory  reporting 
requirements.
Follow -up of AE and SAE
•The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested b y Sponsor to
elucidate the nature and/or causalit y of the AE or SAE as fully as possible. This may 
include additional laboratory  tests or investigations, histopathological examinations, or 
consultation with other health care professionals.
•New or updated information will be recorded in the CRF.
•The investigator will submit any  updated SAE data to the Sponsor within 24 hours of 
receipt of the information.
10.3.5 Reporting of AE, SAE, and Other Reportable Safety Events to the Sponsor
AE, SAE, and o ther reportable safety e vent re
porting to Sponsor via electronic d ata 
collection t ool
•The primary  mechanism for reporting to the Sponsor will be the electronic data collection 
(EDC) tool.
•Electronic reporting procedures can be found in the EDC data entry guidelines (or 
equivalent).
•If the electronic s ystem is unavailable for more than [ADDRESS_1070209]: V114 102
PROTOCOL/AMENDMENT N O.: 022 -04 
V114 -022-04FINAL PROTOCOL 02-APR -2019
•Reference Section 8.4.1  for reporting time requirements.
•The site will enter the SAE data into the electronic sy stem as soon a s it becomes 
available.
•After the stud y is completed at a given site, the EDC tool will be taken off -line to prevent 
the entry  of new data or changes to existing data.
•If a site receives a report of a new SAE from a study participant or receives updated da ta 
on a previousl y reported SAE after the EDC tool has been taken off -line, then the site can 
report this information on a paper SAE form or by [CONTACT_756] (see next section).
•Contacts for SAE reporting can be found in the Investigator Stud y File Binder (or 
equivalent).
SAE reporting to the Sponsor via paper CRF
•If the EDC tool is not operational, facsimile transmission or secure e -mail of the SAE 
paper CRF is the preferred method to transmit this information to the Sponsor.
•In rare circumstances and in the a bsence of facsimile equipment, notification by  
[CONTACT_9337] a cop y of the SAE data collection tool sent by [CONTACT_19515].
•Initial notification via telephone does not replace the need for the investigator to 
complete and sign the SAE CRF pages within the designated reporting time frames.
•Contacts and instructions for SAE reporting and paper reporting procedures can be found 
in the Investigator Study  File Binder (or equivalent).
07X67T
PRODUCT: V114 103
PROTOCOL/AMENDMENT N O.: 022 -04 
V114 -022-04FINAL PROTOCOL 02-APR -2019
10.4 Appendix 4: Medical Device Incidents: Definit ion and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
Not applicable
07X67T
PRODUCT: V114 104
PROTOCOL/AMENDMENT N O.: 022 -04 
V114 -022-04FINAL PROTOCOL 02-APR -2019
10.5 Appendix 5: Contraceptive Guidance and Pregnancy Testing
10.5.1 Definitions
Wome n of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming postmenopausal 
unless permanentl y sterile.
Women in the following categories are not considered WOCBP:
•Premenarchal
•Premenopausal female with 1 of the following:
- Documented h ysterectomy
-Documented bilateral salpi[INVESTIGATOR_1656]
-Documented bilateral oophorectom y
Note: Documentation can come from the site personnel’s review of the participant’s medical 
records, medical examination, or medical history  interview.
•Postmenopausal female
-A postmenopausal state is defined as no menses for 12 months without a n alternative 
medical cause .
•A high follicle stimulating hormone (FSH) level in the postmenopausal range may be 
used to confirm a postmenopausal state in women not using hormonal contraception or 
hormone replacement therap y (HRT). However, in the absence o f [ADDRESS_1070210]: V114 105
PROTOCOL/AMENDMENT N O.: 022 -04 
V114 -022-04FINAL PROTOCOL 02-APR -2019
Table 9 Contraceptive Methods
Acceptable Contraceptive Methods
Failure rate of >1% per year when used consistently and correctly.
●Male or female condom with or without spermicide
●Cervical cap, diaphragm or sponge with spermicide
Highly Effective Contraceptive Methods That Are User Dependenta
Failure rate of <1% per year when used consistently and correctly.
●Com bined (estrogen -and progestogen -containing) hormonal contraceptionb
○Oral
○Intravaginal
○Transdermal
○Injectable
●Progestogen only hormonal contraceptionb,c
○Oral
○Injectable
Highly Effective Methods That Have Low User Dependency
Failure rate of <1% per year when used consistently and correctly.
●Progestogen -only contraceptive implantb
●Intrauterine hormone -releasing system (IUS)b
●Intrauterine device (IUD)
●Bilateral tubal occlusion
●Vasectomized partner
A vasectomized partner is a highly effective contraception method provided that the partner is the sole 
male sexual partner of the WOCBP and the absence of sperm has been confirmed. If not, an additional 
highly effective method of contraception should be used.
●Sexual abstinence
Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual
intercourse during the entire period of risk associated with the study intervention. The reliability of 
sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and 
usual lifestyle of the participant.
Notes:
Use should be consistent with local regulations regarding the use of contraceptive methods for participants of 
clinical studies.
aTypi[INVESTIGATOR_63485] -use failure rates (ie, when used consistently and 
correctly).
bIf locally required , in accordance with Clinical Trial Facilitation Group guidelines, acceptable hormonal 
contraceptives are limited to those which inhibit ovulation.
10.5.[ADDRESS_1070211]: V114 106
PROTOCOL/AMENDMENT N O.: 022 -04 
V114 -022-04FINAL PROTOCOL 02-APR -2019
10.6 Appendix 6: Collection and Management of Specimens for Future Biomedical 
Research
1. Definitions
Biomarker: A biological molecu le found in blood, other body fluids, or tissues that is
a sign of a normal or abnormal process or of a condition or disease. A biomarker may
be used to see how well the body responds to a treatment for a disease or condition . 
Pharmacogenomics: The invest igation of variations of DNA and RNA characteristics 
as related to drug/vaccine response.2
Pharmacogenetics: A subset of pharmacogenomics, pharmacogenetics is the influence 
of variations in DNA sequence on drug/vaccine response.2
DNA: Deox yribonucleic acid .
RNA: Ribonucleic acid.
2. Scope of Future Biomedical Research
The specimens consented and/or collected in this study  as outlined in Section 8. 8will be 
used in various experiments to understand:
•The biology  of how drugs/vaccines work
•Biomarkers responsible for how a drug/vaccine enters and is removed b y the body
•Other pathway s drugs/vaccines may  interact with
•The biology  of disease
The specimen(s) may  be used for future assay  development and/or drug/vaccine 
development.
It is now well recognized that informa tion obtained from study ing and testing clinical 
specimens offers unique opportunities to enhance our understanding of how individuals 
respond to drugs/vaccines, enhance our understanding of human disease and ultimately  
improve public health through develo pment of novel treatments targeted to populations 
with the greatest need. All specimens will be used by [CONTACT_63558].
07X67T
PRODUCT: V114 107
PROTOCOL/AMENDMENT N O.: 022 -04 
V114 -022-04FINAL PROTOCOL 02-APR -2019
3. Summary of Procedures for Future Biomedical Research .
Participants for Enrollment
All participants enrolled in the clinical study will be considered for enrollment in the 
future biomedical research substudy
Informed Consent
Informed consent for specimens (ie, DNA, RNA, protein, etc.) will be obtained 
during screening for protocol enrollment from all participants or legal guardians at a 
study  visit by  [CONTACT_63559] d esignate. Informed consent for future 
biomedical r esearch should be presented to the participants on the visit designated in 
the SoA. If delay ed, present consent at next possible Participant Visit. Consent forms 
signed b y the participant will be kept at the clinical study site under secure storage for 
regulatory  reasons.
A template of each stud y site’s approved informed consent will be stored in the 
Sponsor’s clini cal document repository .
eCRF Documentation for Future Biomedical Research Specimens
Documentat ion of participant consent for future biomedical research will be captured 
in the eCRFs . Any specimens for which such an informed consent cannot be verified 
willbe destroy ed.
Future Biomedical Research Specimen(s)
Collection of specimens for future biomedical r esearch will be performed as outlined 
in the SoA. I n general, if additional blood specimens are being collected for future 
biomedical r esearch, these will usually  be obtained at a time when the participant is 
having blood drawn for other study  purposes.
4. Confidential Participant Information for Future Biomedical Research
In order to optimize the resea rch that can be conducted with future biomedical r esearch 
specimens, it is critical to link participant' clinical information with future test results. I n 
fact little or no research can be conducted without connecting the clinical study data to 
the specimen. The clinical data allow specific analyses to be conducte d. Knowing 
participant characteristics like gender, age, medical history and treatment outcomes are 
critical to understanding clinical context of anal ytical results.
To maintain privacy  of information collect ed from specimens obtained for future 
biomedical research, the Sponsor has developed secure policies and procedures. All 
specimens will be single -coded per ICH E15 guidelines as described below.
07X67T
PRODUCT: V114 108
PROTOCOL/AMENDMENT N O.: 022 -04 
V114 -022-04FINAL PROTOCOL 02-APR -2019
At the clinical study  site, unique codes will be placed on the future biomedical r esearch 
specimens. This cod e is a random number which does not contain an y personally 
identify ing information embedded within it. The link (or key ) between participant 
identifiers and this unique code will be held at the study  site. No personal identifiers will 
appear on the specime n tube.
5. Biorepository Specimen Usage
Specimens obtained for the Sponsor will be used for anal yses using good scientific 
practices. Anal yses utilizing the future biomedical r esearch specimens may  be performed 
by [CONTACT_1034], or an additional third party  (eg, a university  investigator) designated by 
[CONTACT_1034]. The investigator conducting the anal ysis will follow the Sponsor’s privacy 
and confidentialit y requirements. An y contracted third part y anal yses will conform to the 
specific scope o f anal ysis outlined in this substudy . Future biomedical r esearch 
specimens remaining with the third part y after specific anal ysis is performed will be 
reported to the Sponsor.
6. Withdrawal From Future Biomedical Research
Participants may  withdraw their consent for future biome dical r esearch and ask that thei r 
biospecimens not be used for future biomedical r esearch. Participants may withdraw 
consent at an y time b y contact[CONTACT_154478] [INVESTIGATOR_63472]. If medical 
records for the main study are still available, the investigator will contact [CONTACT_90095] ([EMAIL_1250]). 
Subsequently , the participant's specimens will be flagged in the biorepository  and 
restricted to main stud y use only . If specimens were collec ted from study participants 
specificall y for future biomedical r esearch, these specimens will be removed from the 
biorepository  and destroyed. Documentation will be sent to the investigator confirming 
withdrawal and/or destruction, if applicable. It is the responsibility  of the investigator to 
inform the participant of completion of the withdrawal and/or destruction, if applicable. 
Any anal yses in progress at the time of request for withdrawal/destruction or alread y 
performed prior to the request being rece ived b y the Sponsor will continue to be used as 
part of the overall research study  data and results. No new analy ses would be generated 
after the request is received.
In the event that the medical records for the main study  are no longer available (eg, if the 
investigator is no longer required b y regulatory authorities to retain the main study 
records) or the specimens have been completel y anonymized, there will no longer be a 
link between the participant’s personal information and their specimens. In this situation, 
the request for withdrawal of consent and/or destruction cannot be processed.
7. Retention of Specimens
Future biomedical r esearch specimens will be stored in the biorepository  for potential 
analysis for up to [ADDRESS_1070212]: V114 109
PROTOCOL/AMENDMENT N O.: [ADDRESS_1070213] results are accessible only to the 
authorized Sponsor representatives and the designated study administrator research 
personnel and/or collaborators. Database user authentication is highl y secure, and is 
accomplished using network securit y policies and practices based on international 
standards to protec t against unauthorized access.
9. Reporting of Future Biomedical Research Data to Participants
No information obtained from exploratory  laboratory  studies will be reported to the 
participant, famil y, or physicians. Principle reasons not to inform or return results to the 
participant include: Lack of relevance to participant health, limitations of predictive 
capability , and concerns regarding misinterpretation.
If important research findings are discovered, the Sponsor may publish results, present 
results in national meetings, and make results accessible on a public website in order to 
rapi[INVESTIGATOR_252314]. Participants will not be 
identified by  [CONTACT_63561].
10. Future Biomedical Research Study Population
Every  effort will be made to recruit all participants diagnosed and treated o n Sponsor 
clinical studies for f uture biomedical r esearch.
11. Risks Versus Benefits of Future Biomedical Researc h
For future biomedical research, risks to the participant have been minimized and are 
described in the Future Biomedical Research informed consent.
The Sponsor has developed strict security, policies, and procedures to address participant 
data privacy  concerns. Data privacy  risks are largely  limited to rare situations involving 
possible breach of confidentiality . In this highl y unlikely  situation, there is risk that the 
information, like all medical information, may  be misused.
07X67T
PRODUCT: V114 110
PROTOCOL/AMENDMENT N O.: 022 -04 
V114 -022-04FINAL PROTOCOL 02-APR -2019
12. Questions
Any questions rela ted to the future biomedical research should be e mailed directly  to 
[EMAIL_1250].
13. References
National Cancer Institute [Internet]: Available from 
https://www.cancer.gov/publications/dictionaries/cancer -terms?cdrid=[ZIP_CODE]
International Conference on Harmonization [Internet] : E15: Definitions for Genomic 
Biomarkers, Pharmacogenomics, Pharmacogenetics, Genomic Data and Sample 
Coding Categories. Available from 
http://www.ich.org/products/guidelines/efficacy /efficacy -single/article/defin itions-
for-genomic -biomarkers- pharmacogenomics -pharmacogenetics -genomic -data-and-
sample -cod.html
Industry  Pharmacogenomics Working Group [Internet]: Understanding the I ntent, 
Scope and Public Health Benefits of Exploratory  Biomarker Research: A Guide for 
IRBs/IECs and Investigational Site Staff. Available at http://i- pwg.org/ 
Industry  Pharmacogenomics Working Group [Internet]: Pharmacogenomics 
Informational Brochure for I RBs/IECs and Investigational Site Staff. Available at 
http://i- pwg.org/
07X67T
PRODUCT: V114 111
PROTOCOL/AMENDMENT N O.: 022 -04 
V114 -022-04FINAL PROTOCOL 02-APR -2019
10.7 Appendix 7: Co untry-s pecific Requirements
10.7.[ADDRESS_1070214] from Swed ish Health Authority
[IP_ADDRESS] Benefit/Risk Assessment
Prior to the evaluation of V114 in humans, preclinical animal studies were conducted in rats, 
mice, rabbits, and non -human primates, and stud y results showed that the vaccine was 
immunogenic and displayed an acceptable safety profile. V114 contains similar components 
as the licensed vaccines Preve nar™ and Prev enar13™ which comprise a subset of 
respectivel y 7 and 13 of the 15 PnPs conj ugated to the CRM 197carrier protein found in V114, 
as well as Aluminum Phosphate Adjuvant ( APA ). The safe ty profiles for Prev enar™ and 
Prevenar13™ can be found in the respective product labeling . Two different formulations of 
V114 were studied in 8 Phase 1
and Phase 2 clinical studies involving 4,140 subjects 
comprising of 2,960 chi ldren (90 toddlers ,12to 18 months of age and 2,870 infants , 6to 
12weeks of age) who received a 4- dose regimen of study  vaccine given at 2, 4, 6, and 12 to 
15months of age and 1, 810 adults (180 y oung adults 18 to 49 years of age and 1,630 adults 
≥50years of age) who received a single dose of the study  vaccine . A total of 2,685 subjects 
(1,950 children and 735 adults) received a t least 1 dose of V114. 
Both n onadjuvanted V11 4 and APA -adjuvanted V114 were evaluated in early  Phase 1 
(single dose in toddlers and y oung adults 18-49 years of age ) and Phase 2 (4 -dose regimen in 
infants) clinical studies . The 2 vaccines display ed acceptable safet y profiles comparable to 
Prevenar™ an d Prevenar 13™ . In 1adult Pha se 2clinical study  comparing the safet y and 
immunogenicit y of V114 to Prevenar 13™ and PNEUMOVAX™ 23, the safet y profile of 
V114 was also shown to be comparable to PNEUMOVAX ™23. Following vaccination with 
V114, the most freque ntly reported adverse events were those solicited in the clinical study
and included injection- site pain/tenderness (72% in infants and 60% in adults) , redness (59% 
in infants and 14% in adults), and swelling (49% in infants and 20% in adults) . Most 
freque ntly reported s ystemic adverse e vents wer ethose solicited in the studies ; muscle pain 
(29%), fatigue (25%), headache (17%) , and joint pain (17%) were commonly  reported 
among adults while irritability (86%), drowsiness (72%), decreased appetite (57%) were 
commonly  reported in infants following an y vaccination . Vaccine -induced immune responses 
were directed to all 15 serotypes included in V114 and r ecipi[INVESTIGATOR_778728] V114 
vaccine general lytende dto exhibit higher sero type-specific IgG GMCs and OPA GMTs for 
the majority of the sero types included in V114, justify ing the inclusion of APA in the vaccine 
formulation in order to provide optimal antibody  responses . Although the antibody responses 
measured in adults vaccinated with V114 were comparable to t hose measured in recipi[INVESTIGATOR_778729]13™ f or most shared serot ypes, antibody responses measured in infants vaccinated 
with V114 were generally lower than those vaccinated with Prev enar13™ for some shared 
serotypes at [ADDRESS_1070215]: V114 112
PROTOCOL/AMENDMENT N O.: 022 -04 
V114 -022-04FINAL PROTOCOL 02-APR -2019
TheSponsor conducted additional clinical studies to optimize the vaccine formulation and 
assess its tolerabilit y, safe ty, and immunogenicity profiles. As part of the formulation 
optimization, 2formulations of V114 (Formulation A and Formulation B) were tested 
clinically in several Phase 1/2 clinical studies involving a small number (20 to 50 subjects per
arm) of young adults (18 to 49 years of age) and infants (V114- 004 and V114 -005), as we ll 
aslarger number (125 to 230 subjects p er arm) of pneumococcal vaccin e-naïve adults 
50years of age and older (V114 -006) and adults 65 years of age or older with prior history
(at least 1 year prior to study  entry )of vaccination with PNEUMOVAX™ 23 (V114- 007). 
Both V114 formulations displa yed anacceptable safe ty profile and induced comparable 
levels of antibodies to Prev enar13™ for the shared sero types. V114 also induced higher 
antibodies to sero types 22F and 33F, which are not included in Prev enar13™ and h ave 
emerged recent ly as important causes of pneumococcal disease in both children and adults.
Results from these studies identified a formulation (Formulation B) with improved clinical 
performance in both infants and older adults. A pediatric Phase 2 stud y(V11 4-008) involving 
1,050 infants (350 per arm) is ongoing to confirm the p erformance of Formulation B 
observed in V114 -005. Following vaccination with V114 Formulation B, the most frequentl y 
reported adverse events were those solicited in the clinical study and included injection -site 
pain/tenderness ( 64% in infants and 60% in adults), redness ( 38% in infants and 11% in 
adults), and swelling ( 20% in infants and 16% in adults). Most frequentl y reported s ystemic 
adverse events were those solicited in the studies; muscle pain ( 18%), fatigue ( 17%), 
headache ( 12%), and joint pain ( 7%) were commonly  reported among adults ,while 
irritability (82%) , drowsiness (60%) , decreased appetite ( 32%) were commonly  reported in 
infants following an y vaccination.
Several studies have evaluated the safet y and immunogenicity of pneumococcal vaccines in 
adult and pediatric recipi[INVESTIGATOR_571082] [Meisel, R., et al 2007] [Kumar, D., et al 
2007] [Pao, M., et al 2008] [Okinaka, K., et al 2017] [Cor donnier, C., et al 2009] 
[Cordonnier, C., et al 2010] [Cordonnier, C., et al 2015] .The number of doses and nature of 
the pneumococcal vaccines administered varied between studies altho ugh most recent studies 
consisted of the sequential administration of 3 -4 doses of pneumococcal conjugate vaccine 
(Prev enar™or Prev enar13™) followed b y a dose of PNEUMOVAX™ 23. Results from 
these studies showed that pneumococcal vaccination was associated with an in creased 
frequency  of local and systemic reactions associated with repeated dosing; the majority of 
reported adverse events (AEs) were those solicited in the study , including injection site 
(pain/tenderness, redness, and swelling) AEs and systemi c (fever, headache, fatigue, muscle 
pain, and joint pain) AEs. These events were transient (average of 5 day s for local AEs and 7 
days for systemic AEs) . Moreover, A Es associated with withdraw alfrom the study were 
generall y due to underl ying disease and n one of the [ADDRESS_1070216] recipi[INVESTIGATOR_778730] 13 ™ followed by  [CONTACT_63506] ™23 [European Medicines Agency  2014] .
Previous studies comparing the safet y and immunogenicity o f the investigational V114 to 
Prevenar 13™ and/or PNEUMOVAX™ 23 did not show a difference in the frequency  and 
severit y of AEs reported following vaccination [Ermlich, S. J., et al 2018] .The comparable 
07X67T
PRODUCT: V114 113
PROTOCOL/AMENDMENT N O.: 022 -04 
V114 -022-04FINAL PROTOCOL 02-APR -2019
safet y and immunogenici ty profiles of V114 to Prevenar 13™ and PNEUMOVAX™[ADDRESS_1070217] recipi[INVESTIGATOR_840]. Although V114 induc es 
antibody  respons es to 2 more serot ypes (22F and 33F) than Prevenar 13™, i t cannot be 
guaranteed that participants in V114 clinical studies will directly  benefit from intervention 
during participation, as clinical studies are designed to provide informat ion about the safet y 
and effectiveness of an investigational vaccine.
In conclusion, the investigational V114 vaccine has comparable safet y and immu nogenicit y 
profiles to Prevenar 13™ and PNEUMOVAX™ 23, [ADDRESS_1070218] recipi[INVESTIGATOR_778731] 13™ and PNEUMOVAX™ 23 by [CONTACT_778752]/agencies, the benefit/risk for vaccinating HSCT recipi[INVESTIGATOR_89278] V114 is favorable 
as it is anticipated that V114 will provide health benefits comparable to these licensed 
vaccines [Lopez, A., et al 2017] .The safet y profile of the investigational V114 vaccine is 
closely  monitored on a continuing basis by  [CONTACT_4617].
[IP_ADDRESS] Ethics Committee Review [Institutional Review Board (IRB)/Independent 
Ethics Committee (IEC)]
Thefollowing statement will replace the Participant Protection Section III , Part A of 
Appendix 1, Code of Conduct for Clinical Trials:
The protocol, protocol amendments, I CF, Investigator Brochure, and other relevant 
documents must be submitted to and approved b y the applicable Competent Authority  and 
IRB/IEC before the study is initiated in accordance with EU Directive 2001/20/EC, Article 
10 (a) and/or local requirements.
Any amendments to the protocol will require IRB/I EC and Competent Authority  approval 
before implementation of changes made to the study design, except for changes necessary to 
eliminate an immediate hazard to study  participants [2001/20/EC, Article 10 (b)].
07X67T
PRODUCT: V114 114
PROTOCOL/AMENDMENT N O.: 022 -04 
V114 -022-04FINAL PROTOCOL 02-APR -2019
10.8 Appendix 8: Abbreviations
Abbreviation Expanded Term
AE adverse event 
CRF Case Report Form 
DMC Data Monitoring Committee 
DNA deoxyribonucleic acid 
ECG electrocardiogram 
ECL Electrochemiluminescence
eCRF electronic Case Report Form
EDC electronic data collection 
EMA European Medicines Agency
FDAAA Food and Drug Administration Amendments Act
EU European Union
eVRC Electronic Vaccination Report Card
FAS Full Analysis Set
FSH Follicle stimulating hormone 
GCP Good Clinical Practice 
HRT hormone replacement therapy
GMC Geom etric Mean Concentration
GMFR Geom etric Mean Fold Rise
GMT Geom etric Mean Titer
IB Investigator’s Brochure 
ICF Informed Consent Form 
ICH International Conference on Harmonization
IEC Independent Ethics Committee
IgG Immunoglobulin G
IMP Investigational Medicinal Product
IPD Invasive Pneumococcal Disease
IRB Institutional Review Board 
IUD intrauterine device
IUS intrauterine hormone -releasing system
IVRS/IWRS Interactive Voice Response System/Integrated Web Response System
MOPA Multiplexed Opsonophagocytic Assay
MRL [COMPANY_006] Research Laboratories
NIMP Non-Investigational Medicinal Product 
NSAE Non-Serious Adverse Event 
PnECL Pneumococcal Electrochemiluminescence
PP Per-Protocol
PPV23 PNEUMOVAX™23
RNA ribonucleic acid
SAE serious adverse event 
SoA schedule of activities
S[LOCATION_003]R suspected unexpected serious adverse reaction
WOCBP woman/ women of childbearing potential 
07X67T
PRODUCT: V114 115
PROTOCOL/AMENDMENT N O.: 022 -04 
V114 -022-04FINAL PROTOCOL 02-APR -2019
11 REFERENCES
[Anttila, M., et al 1999] Anttila M, Voutilainen M, Jäntti V, Eskola J, 
Käyhty H. Contribution of serot ype-specific 
IgG concentration, IgG subclasses and relative 
antibody  avidit y to opsonophagocytic activity 
against Streptococcus pneumoniae. Clin Exp 
Immunol 1999;118(3):402- 7.03QY70
[Bonten, M. J., et al 2015] Bonten MJ, Huijts SM, Bolkenbaas M, Webber 
C, Patterson S, Ga ult S, et al. Poly saccharide 
conjugate vaccine against pneumococcal 
pneumonia in adults. N Engl J Med. 2015 Mar 
19;372(12):1114 -25.04NFHD
[Burton, Robert L . and Nahm, 
Moon H. 2006]Burton RL, Nahm MH. Development and 
validation of a fourfold multiplexed 
opsonization assay  (MOPA4) for 
pneumococcal antibodies. Clin Vaccine 
Immunol 2006;13(9):1004- 9.03QT2R
[Castiglia P. 2014] Castiglia P. Recommendations for 
pneumococcal immunization outside routine 
childhood immunization programs in Western 
Europe. Adv Th er. 2014Oct;31(10):1011 -44.04P7L W
[Centers for Disease Control 
and Prevention (CDC) 2013]Centers for Disease Control and Prevention 
(CDC). Use of 13 -valent pneumococcal 
conjugate vaccine and 23 -valent pneumococcal 
polysaccharide vaccine among children a ged 6 -
18 years with immunocompromising 
conditions: recommendations of the Advisory  
Committee on I mmunization Practices (ACIP). 
MMWR Morb Mortal Wkly  Rep. 2013 Jun 
28;62(25):521- 4.043QRD
[Centers for Disease Control 
and Prevention 2008]Centers for Diseas e Control and Prevention 
(CDC). Invasive pneumococcal disease in 
children 5 years after conjugate vaccine 
introduction- eight states,1998 -2005. MMWR 
Morb Mortal Wkly  Rep. 2008 Feb 
15;57(6):[ADDRESS_1070219]: V114 116
PROTOCOL/AMENDMENT N O.: 022 -04 
V114 -022-04FINAL PROTOCOL 02-APR -2019
[Centers for Disease Control 
and Prevention 2010]Centers for Disease Control and Prevention. 
Prevention of Pneumococcal Disease Among 
Infants and Children -Use of 13- Valent 
Pneumococcal Conjugate Vaccine and 23-
Valent Pneumococcal Poly saccharide Vaccine; 
Recommendations of the Advisory  Committee 
on Immuniz ation Practices (ACI P). MMWR 
2010;59(RR -11):1- 19.03RSB6
[Centers for Disease Control 
and Prevention 2010]Centers for Disease Control and Prevention. 
Updated recommendations for prevention of 
invasive pneumococcal disease among adults 
using the 23- valent pneumococcal 
polysaccharide vaccine (PPSV23). MMWR 
2010;59(34):1102 -6.03RCFX
[Centers for Disease Control 
and Prevention 2015]Centers for Disease Control and Prevention. 
Epi[INVESTIGATOR_528850] -
preventable diseases. 13th ed. Hamborsk y J,
Kroger A, Wolfe S, editors. Washington (DC): 
Department of Health and Human Services 
(HHS); c2015. Chapter 6, Vaccine 
administration; p. 79 -106.0508PV
[Clopper, C. J. and Pearson, 
E. S. 1934]Clopper CJ, Pearson ES. The use of confidence 
or fiducial limits illustrated in the case of the 
binomial. Biometrika 1934;26(4):404- 13.03Q0L W
[Cordonnier, C., et al 2009] Cordonnier C, Labopin M, Chesnel V, Ribaud 
P, De La Camara R, Martino R, et al. 
Randomized study  of early  versus late 
immunization with pneumoco ccal conjugate 
vaccine after allogeneic stem cell 
transplantation. Clin I nfect Dis. 2009 May  
15;48:1392- 401.04XH3N
[Cordonnier, C., et al 2010] Cordonnier C, Labopin M, Chesnel V, Ribaud 
P, Camara Rde L, Martino R, et al. I mmune 
response to the 23 -valent polysaccharide 
pneumococcal vaccine after the 7- valent 
conjugate vaccine in allogeneic stem cell 
transplant recipi[INVESTIGATOR_840]: results from the EBMT 
IDWP01 trial. Vaccine. 2010;28:[ADDRESS_1070220]: V114 117
PROTOCOL/AMENDMENT N O.: 022 -04 
V114 -022-04FINAL PROTOCOL 02-APR -2019
[Cordonnier, C., et al 2015] Cordonnier C, L jungman P, Juergens C, 
Maertens J, Selleslag D, Sundarai yer V. et al. 
Immunogenicit y, safet y, and tolerability of 13 -
valent pneumococcal conjugate vaccine 
followed b y 23-valent pneumococcal 
polysaccharide vaccine in recipi[INVESTIGATOR_778732] ≥2 y ears: an open -label study . Clin Infect 
Dis. 2015 Aug 1;61(3):313 -23.04R2B3
[Engelhard, D., et al 2002] Engelhard D, Cordonnier C, Shaw PJ, Parkalli 
T, Guenther C, Martino R, et al. Earl y and late 
invasive pneumococcal infection following 
stem cell transplantation: a European Bone 
Marrow Transplantation survey . Br J 
Haematol. 2002 May ;117(2):444 -50.04NKF9
[Ermlich, S. J., et al 2018] Ermlich SJ, Andrews CP, Folkerth S, Rupp R, 
Greenberg D, McFetridge RD, et al. Safet y and 
immunogenicit y of 15 -valen t pneumococcal 
conjugate vaccine in pneumococcal vaccine -
naive adults >=50 years of age. Vaccine. In 
press 2018.04YNVX
[European Centre for Disease 
Prevention and Control 2016]European Centre for Disease Prevention and 
Control. Annual Epi[INVESTIGATOR_778733] 2016 
–Invasive pneumococcal disease. [I nternet]. 
Stockholm: ECDC; 2016. Available from: 
http://ecdc.europa.eu/en/healthtopi[INVESTIGATOR_1102]/pneumoc
occal_infection/Pages/Annual -
epi[INVESTIGATOR_904] -report -2016.aspx.04LP3M
[European Medicines Agency  
2014]European Medi cines Agency . Assessment 
report: Prevenar 13: international non-
proprietary  name: [CONTACT_778755] (13 -valent, 
adsorbed). London: European Medicines 
Agency  (EMA); 2014. 42 p. 
EMA/CHMP/495981/2014.0508FK
07X67T
PRODUCT: V114 118
PROTOCOL/AMENDMENT N O.: 022 -04 
V114 -022-04FINAL PROTOCOL 02-APR -2019
[Farrell, D. J, et al 2007] Farrell DJ, Klugman KP, Pi[INVESTIGATOR_63489] M. 
Increased antimicrobial resistance among 
nonvaccine serot ypes of Streptococcus 
pneumoniae in the pediatric population after 
the introduction of [ADDRESS_1070221] D is 
J. 2007 Feb;26(2):123 -8.04KWD9
[Giebink, G. S., et al 1986] Giebink GS, Warkentin PI , Ramsay  NKC, 
Kersey  JH. Titers of antibody  to pneumococci 
in allogeneic bone marrow transplant recipi[INVESTIGATOR_778734]. J Infect Dis 
1986;154(4):590 -6.03PPS7
[Guevara, M., et al 2016] Guevara M, Barricarte A, Torroba L, Herranz 
M, Gil -Setas A, Gil F, et al. Direct, indirect 
and total effects of 13 -valent pneumococcal 
conjugate vaccination on invasive 
pneumococcal disease in children in Navarra, 
Spain, 2001 to 2014: cohort and case -control 
study . Euro Surveill. 2016;21(14).04KSQ3
[Hicks, L . A., et al 2007] Hicks LA, Harrison LH, Flannery B, Hadler 
JL, Schaffner W, Craig AS, et al. Incidence of 
Pneumococcal Disease Due to Non-
Pneumococcal Conjugate Vaccine (PCV7) 
Seroty pes in the [LOCATION_002] during the Era 
of Widespread PCV7 Vaccination, [ADDRESS_1070222] Dis 2007;196:1346 -54.03QT0G
[Jagasia, M. H., et al 2015] Jagasia MH, Greinix HT, Arora M, Williams 
KM, Wolff D, Cowe n EW, et al. National 
Institutes of Health consensus development 
project on criteria for clinical trials in chronic 
graft -versus- host disease: I . The 2014 
Diagnosis and Staging Working Group report. 
Biol Blood Marrow Transplant. 2015;21:[ADDRESS_1070223] on criteria for 
clinical trials in chronic GVD steering 
committee; p. 401.e1.04XGD8
07X67T
PRODUCT: V114 119
PROTOCOL/AMENDMENT N O.: 022 -04 
V114 -022-04FINAL PROTOCOL 02-APR -2019
[Jokinen, J., et al 2015] Jokinen J, Rinta -Kokko H, Siira L , Palmu AA, 
Virtanen MJ, Nohy nek H, et al. I mpact of ten -
valent pneumococcal conjugate vaccination on 
invasive pneumococcal disease in Finnish 
children a population- based study . PLoS One. 
2015 Mar 17;10(3):e0120290.04KW7F
[Kaufman, R. M., et al 2015] Kaufman RM, Djulbegovic B, Gernsheimer T, 
Kleinman S, Tinmouth AT, Capocelli KE, et 
al. Platelet transfusion: a clinical practice 
guideline from the AABB. Ann Intern Med. 
2015 Feb 3;162(3):205 -13. Current author 
addresses and Appendix tables 1 -8; 7 p.04X2MR
[Kobay ashi, M., et al 2015] Kobay ashi M, Bennett NM, Gierke R, 
Almendares O, Moore MR, Whitney  CG, et al. 
Intervals Between PCV13 and PPSV23 
Vaccines: Recommendations of the Advisory  
Committee on I mmunization Practices (ACIP). 
MMWR Morb Mortal Wkly  Rep. 2015 Sep 
4;64(34):944 -7.04P7L H
[Kumar, D., et al 2007] Kumar D, Chen MH, Welsh B, Siegal D, 
Cobos I , Messner HA, et al. A randomized, 
double -blind trial of pneumococcal vaccination 
in adult allogeneic stem cell transplant donors 
and recipi[INVESTIGATOR_840]. Clin Infect Dis. 2007 Dec 
15;45:1576- 82.0508FN
[Lepoutre, A., et al 2015] Lepoutre A, Varon E, Georges S, Dorleans F, 
Janoir C, Gutmann L , et al. I mpact of the 
pneumococcal conjugate vaccines on invasive 
pneumococcal disease in [LOCATION_009], 2001 -2012. 
Vaccine. 2015 Jan 3;33(2):359 -66.04KW88
[Lexau, C. A., et al 2005 ] Lexau CA, Ly nfield R, Danila R, Pi[INVESTIGATOR_63466] T, 
Facklam R, Farley  MM, et al. Changing 
epi[INVESTIGATOR_624751]. 
JAMA 2005;294(16):[ADDRESS_1070224]: V114 120
PROTOCOL/AMENDMENT N O.: 022 -04 
V114 -022-04FINAL PROTOCOL 02-APR -2019
[Liang, K -Y an d Zeger, S. L . 
2000]Liang K -Y, Zeger SL. Longitudinal data 
analysis of continuous and discrete responses 
for pre -post designs. Sanky ha: The Indian 
Journal of Statistics 2000;62(Series B, Part 
1):134- 48.00V5V6
[Lopez, A., et al 2017] Lopez A, Mariette X, Bachelez H, Belot A, 
Bonnotte B, Hachulla E, et al. Vaccination 
recommendations for the adult 
immunosuppressed patient: a sy stematic 
review and comprehensive field s ynopsis. J 
Autoimmun. 2017;80:10 -27.0508N0
[Martinelli, D., et al 2014] Martinelli D, Pe dalino B, Cappelli MG, Caputi 
G, Sallustio A, Fortunato F, et al Towards the 
13-valent pneumococcal conjugate universal 
vaccination: effectiveness in the transition era 
between PCV7 and PCV13 in I taly, 2010 -
2013. Hum Vaccin Immunother. 
2014;10(1):33- 9.04KW8B
[Meisel, R., et al 2007] Meisel R, Kuy pers L, Dirksen U, Schubert R, 
Gruhn B, Strauss G, et al. Pneumococcal 
conjugate vaccine provides earl y protective 
antibody  responses in children after related and 
unrelated allogeneic hematopoietic stem cell 
transplantation. Blood. 2007 Mar 
15;109(6):2322- 6.0508GZ
[Metlay , J. P., et al 2006] Metlay  JP, Fishman NO, Joffe M, Edelstein 
PH. I mpact of pediatric vaccination with 
pneumococcal conjugate vaccine on the risk of 
bacteremic pneumococcal pneumonia in adults.
Vaccine 2006;24:468- 75.03RC46
[Moore, M. R., et al 2015] Moore MR, L ink-Gelles R, Schaffner W, 
Lynfield R, Lexau C, Bennett NM, et al. Effect 
of use of 13 -valent pneumococcal conjugate 
vaccine in children on invasive pneumococcal 
disease in children and adults in the [LOCATION_003]: 
analysis of multisite, population -based 
surveillance. Lancet Infect Dis. 2015 Feb 3. 
[Epub ahead of print].043MRP
07X67T
PRODUCT: V114 121
PROTOCOL/AMENDMENT N O.: 022 -04 
V114 -022-04FINAL PROTOCOL 02-APR -2019
[Okinaka, K., et al 2017] Okinaka K, Akeda Y, Kurosawa S, Fuji S, 
Tajima K, Oishi K, et al. Pneumococcal 
polysaccharide vaccination in allogeneic 
hematopoietic stem cell transplantation 
recipi[INVESTIGATOR_840]: a prospective single -center stud y. 
Microbes Infect. 2017;19:553- 9.0508G6
[Palmu, A. A., et al 2015] Palmu AA, Kilpi [CONTACT_58465], Rinta -Kokko H, 
Nohy nek H, Toropainen M, Nuorti JP, et al. 
Pneumococcal conjugate vaccine and clinicall y 
suspected invasive pneumococcal disease. 
Pediatrics. 2015 Jul;136(1):e22 -7.04KVRL
[Pao, M., et al 2008] Pao M, Papadopoulos EB, Chou J, Glenn H, 
Castro- Malaspi[INVESTIGATOR_28947] H, Jakubowski AA, et al. 
Response to pneum ococcal (PNCRM7) and 
Haemophilus influenzae conjugate vaccines 
(HIB) in pediatric and adult recipi[INVESTIGATOR_778735] 
(alloHCT). Biol Blood Marrow Transplant. 
2008;14:1022- 30. Erratum in: Biol Blood 
Marrow Transplant. 2008 Nov;14(11):1319.0508JL
[Pi[INVESTIGATOR_63466], Tamara, et al 
2010]Pi[INVESTIGATOR_63466] T, Lexau C, Farley MM, Hadler J, 
Harrison LH, Bennett NM, et al. Sustained 
reductions in invasive pneumococcal disease in 
the era of conjugate vaccine. J I nfect Dis 
2010;201(1):32- 41.03R5S4
[Romero -Steiner, S., et al 
1997]Romero- Steiner S, L ibutti D, Pais LB, Dy kes J, 
Anderson P, Whitin JC, et al. Standardization 
of an opsonophagocy tic assay  for the 
measurement of functional antibody  activity  
against streptococcus pneumoniae using 
differentiated HL -60 cells. Clin Diagn Lab 
Immunol 1997;4(4):415- 22.03NWQ5
[Rubin, L . G., et al 2014] Rubin L G, Levin MJ, L jungman P, Davies EG, 
Avery  R, Tombly n M, et al. [ADDRESS_1070225] Dis. 
2014 Feb;58(3):e44 -100. Erratum in: Clin 
Infect Dis. 2014 Jul 1;59(1):144.045XYX
07X67T
PRODUCT: V114 122
PROTOCOL/AMENDMENT N O.: 022 -04 
V114 -022-04FINAL PROTOCOL 02-APR -2019
[Ruckinger, S., et al 2009] Ruckinger S, van der Linden M, Reinert RR, 
von Kries R, Burckhardt F, Siedler A. 
Reduction in the incidence of invasive 
pneumococcal disease after general vaccination 
with 7- valent pneumococcal conjugate vaccine 
in German y. Vaccine 2009;27:4136 -41.03QYQQ
[Tombly n, M., et al 2009] Tombly n M, Chiller T, Einsele H, Gress R, 
Sepkowitz K, Storek J, et al. Guidelines for 
preven ting infectious complications among 
hematopoietic cell transplantation recipi[INVESTIGATOR_840]: a 
global perspective. Biol Blood Marrow 
Transplant 2009;15:1143 -238.03W7R4
[Tombly n, Marcie, et al 
2009]Tombly n M, Chiller T, Einsele H, Gress R, 
Sepkowitz K, Storek J, e t al. Guidelines for 
preventing infectious complications among 
hematopoietic cell transplantation recipi[INVESTIGATOR_840]: A 
global perspective. Biol Blood Marrow 
Transplant 2009;15(10):1143.03R3X3
[Tomczy k, S., et al 2014] Tomczy k S, Bennett NM, Stoecker C, Gierke 
R, Moore MR, Whitney  CG, et al. Use of 13 -
valent pneumococcal conjugate vaccine and 
23-valent pneumococcal poly saccharide 
vaccine among adults aged is greater than or 
equal to 65 y ears: recommendations of the 
Advisory  Committee on Immunization 
Practices (AC IP). MMWR Morb Mortal Wkly  
Rep. 2014 Sep 19;63(37):822- 5.040XNF
[U.S. Food and Drug 
Administration 2009]U.S. Food and Drug Administration (CDER, 
CBER, CDRH). Guidance for industry  patient -
reported outcome measures: use in medical 
product development to support labeling claims 
[Internet]. Washington: U.S. Department of 
Health and Human Services; 2009. Available 
from: 
https://www.fda.gov/downloads/drugs/guidanc
es/ucm193282.pdf04MG9J
07X67T
PRODUCT: V114 123
PROTOCOL/AMENDMENT N O.: 022 -04 
V114 -022-04FINAL PROTOCOL 02-APR -2019
[Wagenvoort, G. H., et al 
2016]Wagenvoort GH, Knol MJ, de Melker HE, 
Vlaminckx BJ, van der Ende A, Rozenbaum  
MH, et al.  Risk and outcomes of invasive 
pneumococcal disease in adults with 
underly ing conditions in the post -PCV7 era, 
The Netherlands. Vaccine. 2016 Jan 
12;34(3):334 -40.04KTDB
[Waight, P. A., et al 2015] Waight PA, Andrews NJ, Ladhani SN, 
Sheppard CL, Slack MP, Miller E. Effect of the 
13-valent pneumococcal conjugate vaccine on 
invasive pneumococcal disease in England and 
Wales 4 y ears after its introduction: an 
observational cohort study. Lancet Infect Dis. 
2015 May;15(5):535 -43.04KTF2
[Weiss, S., et al 2015] Weiss S, Falkenhorst G, van der Linden M, 
Imohl M, von Kries R. Impact of 10 -  and 13-
valent pneumococcal conjugate vaccines on 
incidence of invasive pneumococcal disease in 
children aged under 16 years in German y, 2009 
to 2012. Euro Surveill. 2015 Mar 
12;20(10):[ZIP_CODE].04KTFC
[Whitney , Cynthia G., et al 
2003]Whitney  CG, Farley  MM, Hadler J, Harrison 
LH, Bennett NM, Ly nfield R, et al. Decline in 
invasive pneumococcal disease after the 
introduction of prote in-polysaccharide 
conjugate vaccine. N Engl J Med 
2003;348(18):1737 -46.03QT0D
[Youssef, S., et al 2007] Youssef S, Rodriguez G, Rolston KV, 
Champlin RE, Raad II, Safdar A. 
Streptococcus pneumoniae infections in 47 
hematopoietic stem cell transplantation 
recipi[INVESTIGATOR_840]: clinical characteristics of infections 
and vaccine -breakthrough infections, 1989-
2005. Medicine (Baltimore). 2007 
Mar;86(2):69 -77.04NKDK
07X67T